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Symposium on 'Intestinal
carcinogenesis'
The role of heredity in intestinal carcinogenesis
B.C. Morson
St. Mark's Hospital, London, UK.
There is no evidence, per se, that colorectal cancer
is inherited. On the other hand, there are
indications that a genetic factor is involved in. the
appearance of the principal precursor lesion, the
adenoma.
In familial polyposis coli, which is inherited as a
dominant Mendelian character, the colorectal
mucosa is covered by thousands of adenomas. It is
important to decide what differences, if any, exist
between the adenomas of polyposis and those
occurring in non-polyposis patients. One obvious
difference is that of number. Whereas in polyposis
the average number of adenomas is measured in
thousands there are usually fewer than twenty
adenomas in non-polyposis patients. The figure of
100 adenomas is a practical one to use as a division
between the two groups of patients. No differences
have been detected in the clinical and histological
characteristics of the adenomas occurring in the
two groups and the resulting cancers show similar
characteristics. The question therefore arises
whether the adenomas in non-polyposis patients
also have a genetic origin.
A family history has been elicited in 26% of
colorectal cancer patients (Lovett, Br. J. Surgery,
63, 13, 1976). The majority had only one affected
relative but 8% were two case families and 10%
had three or more affected relatives. The average
number of adenomas per patient (who also had
cancer) increased with the number of affected
family members. In contrast to polyposis coli the
carcinomas in cancer families are accompanied by
only small numbers of precursor adenomas,
although on average significantly more than the
numbers seen in association with sporadic colo-
rectal cancer.
Woolf et al. (Cancer, 8, 403, 1955) showed that
the prevalence of adenomas in close relatives of
colorectal cancer cases was 45% compared with
only 5% in spouses.
In addition to adenomas determined by an
autosomal dominant gene i.e. polyposis coli, there
is the possibility that isolated adenomas could be
produced by an autosomal recessive gene (Veale,
Intestinal Polyposis, Eugenics Lab. Memoirs, Series
40, 1965, CUP). Only a tiny proportion of human
colorectal cancers are the consequence of autosomal
dominant genetic disease, and an autosomal
recessive gene could be far more important in terms
of the numbers of cases for which it is responsible.
In a population uniformly exposed to environ-
mental agents the level of exposure to such agents
might determine the incidence of bowel cancer, but
genetic factors might determine which members of
the population actually develop the disease.
All indications are that the factors causing
adenomas differ from those causing the progression
to carcinoma. Moreover, the factors causing the
initial formation of an adenoma appear to differ
from those which cause the adenoma to grow in
size and to progress to carcinoma. Thus there are
both genetic and environmental factors in the
causation of adenomas and the genetic factors
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render some persons more susceptible than others
to the environmental factors. A postulated
mechanism for the aetiology of the adenoma-
carcinoma sequence which integrates both genetic
and environmental factors has been proposed
(Morson et al., Cancer Surveys, 2, 451, 1983).
Proliferation abnormalities in adenomas
E. Friedman & M. Lipkin
Memorial Sloan-Kettering Cancer Center,
Laboratory ofGastrointestinal Cancer Research and
Gastroenterology Service, New York City, New York
10021, USA.
Proliferative abnormalities define preneoplastic
states in human colon, oesophagus, and stomach,
as defined by an enlarged proliferative compart-
ment using [3H]-thymidine labelling as a marker.
This abnormality is preserved in colonic adenomas
which have an increased proliferative compartment,
but have also lost some directional control over cell
migration. Adenomas of the simple tubular class
placed into tissue culture respond by mitogenesis to
synthetic tumour promoters of the phorbol ester
class. Similar responses occurred to diacylglycerols,
which are found within the colon, bind to the TPA
receptor, and thus can be considered endogenous
tumour promoters. Normal colonic epithelial cells
in tissue culture do not respond to tumour pro-
moters by proliferation. More advanced adenomas
of the villous class and carcinomas respond to
synthetic and endogenous tumour promoters by
secretion of a urokinase-type plasminogen activator.
Intestinal carcinogenesis: The role of diet
K.W. Heaton
University Department ofMedicine, Bristol Royal
Infirmary, Bristol BS2 8HW, UK.
Geographical differences in colorectal cancer
mortality point strongly to the life-style of 'western'
countries. Popular theories blame high fat intake,
low fibre intake and high cholesterol intake but the
evidence for each is conflicting and incomplete.
Several mechanisms exist whereby dietary fibre and
undigested starch could be protective.
Case control studies can explain why, within a
community, some people contract a disease and
others do not. With colorectal cancer, case-control
studies have given inconsistent results. Possible
reasons include: (i) imprecise methodology for
assessing dietary intake; (ii) failure to measure
possibly important dietary factors, such as dietary
fibre and refined sugar; (iii) loose matching of cases
and controls, and (iv) inclusion of cancer patients
whose dietary intake had changed as a result of
their symptoms, e.g. anorexia, vomiting, weight
loss. We have carried out a case-control study
which was designed to avoid the last 3 problems.
Despite imprecise methodology (the dietary history
method using a food frequency questionnaire) we
were able to show that, compared with healthy
controls, 50 cancer patients ate a diet providing
16% excess calories (P<O.OO1). The excess came
chiefly from fat and carbohydrate, and the biggest
difference (41%) was in the intake of refined (fibre-
depleted) sugar. Indeed, half the excess calories
were attributable to sugar itself or to fat eaten in
combination with sugar.
Extensive animal experiments have shown that a
20-30% decrease in calorie intake inhibits carcino-
genesis. We have found that a 23-28% fall in
calorie intake occurs unconsciously and without
hunger when volunteers switch from a diet contain-
ing 1lOg sucrose to one containing 5-1Og (Gut, 24,
2, 1983; 25, 269, 1984).
Dietary practices which inflate calorie intake and,
specifically, the use of sucrose should be considered
as increasing the risk ofcolorectal cancer.
Intestinal carcinogenesis: Inflammation
J.E. Lennard-Jones
Academic Unit ofGastroenterology, The London
Hospital Medical College, London, UK.
Two conditions predispose to malignancy in the
small intestine; gluten-sensitive enteropathy and
Crohn's disease. The former is perhaps not truly an
'inflammation' but there are many chronic inflam-
matory cells in the lamina propria and there is an
increased rate of epithelial turnover. The com-
monest malignancy observed in coeliac disease is
a lymphoma, derived from T cells, but adeno-
carcinoma also occurs. Crohn's disease of the small
intestine is occassionally complicated by carcinoma,
usually in long-standing disease, and occasionally in
a segment of inflammation bypassed at operation.
The commonest, and clinically most important,
inflammatory disorder predisposing to carcinoma is
ulcerative colitis. The tumours tend to occur at a
younger age than in the general population and
may be multi-focal. The presence of carcinoma is
usually associated with a patchy dysplastic change
elsewhere in the large intestine. Dysplasia can bePROCEEDINGS OF BACR 27TH AGM 139
recognised in flat mucosa but often there is a
proliferative component leading to a villous con-
figuration, mucosal nodularity or the formation of
a broad-based polyp. The occurrence of dysplasia
enables a presumed pre-cancerous phase to be
recognised on endoscopic biopsy, though when
high-grade dysplasia is found a co-existing carci-
noma is often present elsewhere in the colon. The
risk of carcinoma in ulcerative colitis can be de-
fined and it is greatest in patients with inflam-
mation affecting most or all of the mucosa with a
clinical history of at least 10 years. A cancer
surveillance programme is being evaluated in this
high risk group ofpatients.
There is an increased incidence of carcinoma in
colonic Crohn's disease, in which dysplastic changes
can also occur, but the risk at present does not
appear great enough to warrant regular surveil-
lance. The chronic anal lesions of Crohn's disease
may also become the site of carcinoma.
There is a major carcinoma risk at the anasto-
motic site of ureteric implantation into the colon.
An association between schistosomiasis and colonic
carcinoma has been reported. Other inflammations
such as diverticulitis do not appear to be associated
with a neoplastic risk.
Hyperplasia, the common thread
R.C.N. Williamson
University Department ofSurgery, Bristol Royal
Infirmary, Bristol BS2 8HW, UK.
Active cell proliferation is a prerequisite for the
initiation of carcinogenesis and is likely to be
important in tumour promotion. Hyperproliferative
lesions can be identified in premalignant colorectal
mucosa, e.g. in familial polyposis and in rodents
exposed to chemical carcinogens. Diet affects cyto-
kinetics throughout the intestinal tract either by a
direct trophic stimulus or by altering bile acids and
bacteria, which themselves influence cell turnover.
Thus obesity could enhance the risk of colorectal
cancer because hyperphagia increases the number of
cells with a potential for malignant transformation.
Crypt cell hyperplasia is also a feature of ulcerative
protocolitis, which is undoubtedly premalignant. By
measuring crypt cell production rate in cultured
rectal biopsies we have found increased replication
not only in active colitis but also in quiescent
disease. Likewise, irradiation markedly disturbs in-
testinal cell turnover and there is an increased risk
of rectal cancer developing many years after pelvic
irradiation.
The impact of increased and decreased cell pro-
liferation on colorectal neoplasia has been studied
in rats receiving intestinal carcinogens (Williamson
& Rainey, Scand. J. Gastroenterol., 19, Suppl. 104,
57, 1984). Resection of either proximal or distal
small intestine leads to colonic hyperplasia and
increased numbers of tumours in animals receiving
azoxymethane or dimethylhydrazine. Intestinal by-
pass generally has the same effect. Indeed, the
trebling of colorectal tumour yields in rats receiving
85-95% jejunoileal bypass is disquieting in view of
the large numbers of patients who have had this
operation performed for morbid obesity. Partial
colectomy only promotes carcinogenesis at the site
of anastomosis, possibly because its adaptive effects
are slight. The finding that a diverting colostomy
protects against tumour development is consistent
with the hypothesis linking hyperplasia and neo-
plasia, since defunctioned colon undergoes atrophy.
When instilled repeatedly per rectum, the secondary
bile salt sodium deoxycholate causes both local
hyperplasia and a sharp increase in susceptibility to
cancer. The same substance delivered into an
isolated loop of colon (Thiry-Vella fistula) is unable
to affect either the hypoplasia of defunction or the
concomitant resistance to a systemic carcinogen.
Reintroducing faeces into the Thiry-Vella fistula
largely reverses these effects.
The prevalence of suture-line cancers is a
consistent feature of these experiments. Intestinal
anastomoses remain at increased risk of carcino-
genesis even when fashioned up to 12 weeks before
the first injection of carcinogen. Our recent data
suggest that the anastomosis remains a focus of
increased proliferative activity throughout this
period. Perhaps some instances of 'recurrence' at
the intestinal anastomosis in patients surviving
colectomy reflect metachronous carcinogenesis in
an area of long-standing hyperplasia.
Symposium on 'Epithelial Cancers:
Experimental and Clinical Approaches'
Gastric cancer; cause, precancer and early cancer
N.J.McC. Mortensen
University Department ofSurgery, Bristol, UK.
Genetic factors may be implicated in only a small
proportion of gastric cancer patients. Migrant
studies and a worldwide decline in incidence suggest
that environmental factors are more important.
Dietary nitrosamines, hypochlorhydria, duodeno-140 PROCEEDINGS OF BACR 27TH AGM
gastric influx and histological changes in gastric
mucosa combine to result in a gastric cancer.
Patients who have previously had a partial gas-
trectomy for peptic ulcer are at increased risk of
developing carcinoma some 20 years or so after
their original surgery. They provide a unique
human model for the study of the evolution of
invasive cancer. After a gastrectomy the intragastric
acidity falls, the remnant becomes colonised by
bacteria, there are increased levels of nitrosamines
and bile acid levels are high from free influx. We
have studied a group of 63 partial gastrectomy
patients 20 years after surgery by repeated endo-
scopy and biospy over 6 years (Mortensen et al.,
Br. J. Surg., 71, 363, 1984) carefully grading histo-
logical changes for intestinal metaplasia chronic
atrophic gastritis, and dysplasia. Although 20%
had moderate or severe dysplasia, no patients have
so far developed invasive cancer. Histological
changes correlate with reflux, intragastric bile acids
and nitrite levels (Thomas et al., Scand. J.
Gastroenterol., 19, Suppl. 92, 195, 1984). Similar
histological changes have been described in per-
nicious amaemia patients, another high risk group.
Whilst these changes may be premalignant they
progress very slowly and the precise mechanisms of
carcinogenesis are still not known.
In Japan 30% of all gastric cancer cases are early
gastric cancers EGC with an 80-100% 5 year
survival. Until recently the incidence of EGC in this
country was low. We reviewed 35 cases diagnosed
between 1965 and 1985. Twice the number were
seen in the second decade compared with the first
suggesting a rising incidence probably as a con-
sequence of improved diagnostic surveillance. Life
table survival curves give an age adjusted 5 year
survival of 92% in these patients (Houghton et al.,
Br. Med. J., 291, 305, 1985).
An increasing understanding of the natural
history of premalignant histological lesions in the
stomach together with more frequent diagnosis of
EGC will result in an improved prognosis for
gastric cancer.
Surgical and adjuvant treatment for gastric cancer
J.L. Craven
York District Hospital, York, UK.
There exists a wide and poorly understood
variation in the results of treatment of gastric
cancer with particularly larger differences in the
outcome of therapy seeming to exist between Japan
and the rest of the world. There is little evidence to
support the view that these differences in the result
of treatment are due to undefined differences in the
biological behaviour of the tumour. Comparisons
of early gastric cancer between Japan and the
Western world reveal many areas of similarity. It
appears that much of the Japanese success in
treatment lies in their methodological approach in
which macroscopic staging at laparotomy, precisely
defined surgical techniques and microscopic staging
of the resected tumour permit comparison between
surgeons, hospitals and regions, Miwa's data (Garn,
22, 61, 1979) provides validification of their macro-
scopic and microscopic staging techniques.
The commonest cause of death after resection of
gastric cancer is recurrent disease within the gastric
bed and it is clear that an effective method of loco-
regional control would have very great survival
benefit. The application of total gastrectomy de
principe to the resection of gastric cancer has not
been tested by a controlled trial, but it does appear
that there will be many patients whose treatments
fail, even when the surgical regime is optimum and
these treatment failures have suggested a role for
adjuvant chemotherapy. Though single chemothera-
peutic agents have been shown to have some effect
upon the tumour, none of the adjuvant trials, either
with single or combination agents, have been
shown to have any survival benefit. This should not
give rise to too much pessimism. We may have
been expecting too much. Surgical treatment and
operative staging have not been standardised in any
of the studies and benefit from adjuvant chemo-
therapy will be felt only by those at risk of re-
currence. Single agent response rates are rarely
more than 25% and the beneficial anti-tumour
effect will be diluted by any excess of patients
whose resections alone have not been curative.
Much remains to be learnt of the effect of modify-
ing the combinations, their dosages and duration of
treatment.
Radiation has only been used infrequently as a
treatment for gastric cancer, but it has been shown
to have therapeutic potential in a small proportion
of patients and some benefit also occurs in ad-
vanced disease when used with chemotherapy.
Gunderson's reoperation data show that most of
the local recurrences can be encompassed by a
conventional radiotherapy portal and suggest a
logical role for radiotherapy as an adjunct to
surgery (Gunderson & Sosin, Int. J. Radiol. Oncol.
Biol. Phys., 8, 1, 1982). In an attempt to improve
its efficiency the use of chemotherapy in com-
bination has been tried with some modest success.
Radiosensitisers have been investigated, but none
without toxic side effects has yet been identified.
Intraoperative radiotherapy (IORT) was first used
by Abe and his encouraging, but uncontrolled
results have stimulated considerable interest in
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modality are now proceeding (Abe & Takahashi,
Int. J. Radiat. Oncol. Biol. Phys., 7, 863, 1981).
In the West, benefits in the treatment of gastric
cancer will most quickly follow the application of
defined surgical procedures applied after careful
macroscopic staging and validated by careful
pathological staging. Until those prerequisites are
met, it is fruitless to explore the benefit of what
may be necessary adjuncts to surgical treatment.
The dilemma of treatment
R.A. Malt
Department ofSurgery, Harvard Medical School,
Boston, Massachusetts 02114, USA.
(By title only)
Ovarian cancer - Studies with monoclonal antibodies
Aetiology of pancreatic cancer
K.G. Wormsley
Ninewells Hospital, Ninewells, Dundee DDJ 9SY,
UK.
Epidemiological analyses of the geographic and
demographic aspects of pancreatic cancer (including
geographic distribution, population group incidence
rates, migrant incidence rates and changes with
time) indicate that environmental carcinogens play
an important aetiological role in pancreatic carcino-
genesis (Wormsley, Ital. J. Gastroenterol., 17, 102,
1985). Unfortunately, until recently, satisfactory
direct techniques for identifying such pancreas-
specific carcinogens were not available. Additional
indirect information about the pathogenesis of pan-
creatic cancer has been obtained from study of
associated or predisposing diseases and from
analysis of the dietary habits of affected individuals.
More important and related pointers to the causes
of pancreatic cancer have been derived from animal
experiments (Longnecker et al., Int. Rev. Expie.
Pathol., 26, 177, 1984). For example, it has been
possible to identify chemicals with apparently
pancreas-specific activity as genotoxic carcinogens.
These agents often require metabolic conversion by
the pancreatic acinar cells before reacting with
DNA. Even more interestingly, it has been possible
to show that dietary modulation greatly sensitises
the rat pancreas to the carcinogenic effects of some
of the genotoxic chemicals (McGuinness et al.,
Environ. Health Perspect., 56, 205, 1984). The
dietary sensitisation, with raw soya flour, seems to
be dependent on the stimulation of pancreatic
growth. The dietarily 'sensitised' pancreas provides
an excellent model for the prospective screening of
environemntal carcinogens; for analysing the pro-
cesses involved in pancreatic carcinogenesis; and for
testing new therapeutic agents. These findings also
have implications for man, since the human pan-
creas seems functionally similar to the pancreas of
rats.
G.M. Stirrat
Department ofObstetrics & Gynaecology, University
ofBristol, UK.
(By title only)
Chemotherapy of ovarian cancer
J.G. McVie
The Netherlands Cancer Institute, Antoni van
Leeuwenhoekhuis, Amsterdam, The Netherlands.
There are four milestones in the recent history of
chemotherapy in ovarian cancer. First was the
realisation that median survival of 10 months with
single alkylating agents could be more than doubled
by addition of other agents, such as hexamethyl-
melamine, 5-fluorouracil, doxorubicin. Coupled with
the claims that combination chemotherapy was
superior to single agent came the increased aware-
ness that response criteria differed widely from
series to series and that reliance on clinical obser-
vations alone was totally inadequate. Thus the
complete remission pathologically proven became
the standard for reporting of results.
A third improvement was the realisation that
cisplatin was the single most active agent and the
fourth was that there was a clear dose response
relationship for cis-platin not only in clonogenic
assay systems in the lab but also in patients. A
large randomised trial has now shown clear superi-
ority not only in response rate but also in median
survival and long term survival between a platinum
containing regimen versus a non-platinum contain-
ing regimen (CHAP versus Hexacaf). The first
really long term results for platinum regimes are
now being reported and in selected cases a 20% 7
years' disease free survival has been achieved. The
latest controversy in this area has been the question
of the use of drugs in addition to platinum versus
platinum in high dose as a single agent. The latter142 PROCEEDINGS OF BACR 27TH AGM
is one of the most toxic regimes ever used. This has
led to the development of analogues of the drug
which are less toxic and carboplatin seems to be a
good candidate. This drug is already in a far
advanced stage of development and up until now
head on comparative studies in ovarian cancer of
carboplatin with cis-platin show little difference in
antitumour effect. There is almost no nephro-
toxicity from carboplatin and it does not require
aggressive in-patient hydration schemes; neuro-
toxicity seems to be a problem only in patients
previously treated with cis-platin.
Reassessment of i.p. cis-platin is now underway,
intended to increase the dose of drug reacting with
the i.p. tumour with a lower concentration in
distant organs. This approach has been particularly
successful in small volume 'minimal residual
disease' resistant to i.v. cis-platin. In our own series
we have achieved 30% pathologically proven com-
plete remissions in such patients, whereas with
conventional therapy we have yet to see a response
after failure of 6 months of i.v. cis-platin. Toxicity
is not negligible and neurotoxicity remains the dose
limiting toxicity. Nephrotoxicity and myelosuppres-
sion can to some extent be averted by concomitant
i.v. sodiumthiosulphate (STS) which neutralises
some of the cis-platin absorbed from the peritoneal
space. Howell and colleagues have developed this
idea further and have given STS with i.v. cis-platin.
There remains considerable controversy in this area
due to the theoretical likelihood of rescuing tumour
from the effect of cis-platin by complete neutral-
isation. It must be said, however, that there are
occasional reports of anti-tumour effect and toxicity
does seem to be slightly less. It is to be hoped that
a combination of new analogues of cis-platin and
alkylating agents, maximal debulking surgery, and,
when appropriate, local i.p. therapy that the
complete remission rate currently achieved at 30%
will eventually reach 50% accompanied by tolerable
toxicity for the patient.
Bladder cancer: Late promotional stages in relation
to causes and control
R.M. Hicks
School ofPathology, Middlesex Hospital Medical
School, Riding House Street, London WIP 7LD,
UK.
Human bladder cancer presents in two distinct
forms, with differing developmental pathways, be-
haviour patterns and associated mortalities. A
minority of cases,
- 10%, at first presentation have
rapidly invasive, solid transitional cell carcinoma
(TCC) which can arise over a wide front below flat
carcinoma-in-situ of the urothelium. Most patients,
however, present with recurrent, well-differentiated
papillary tumours which may not become invasive
for many years. Both disease patterns can now be
reproduced experimentally in rodent models.
There is good evidence that the papillary form of
TCC develops step-wise, by a process analagous to
multi-stage carcinogenesis in the mouse skin. The
rate at which each papillary tumour develops from
an initiated preneoplastic urothelial cell is critically
affected by late stage promoting or enhancing
factors which, though they may not be initiating
carcinogens per se, increase the incidence (age-
related prevalence) of human TCC. This suggests
that anti-promoting agents might reduce the
bladder cancer incidence in 'at risk' populations.
We have demonstrated that certain retinoids,
known to be anti-promoters in the mouse skin
carcinogenesis model, do indeed delay the develop-
ment and thus reduce the incidence of papillary
TCC in the N-butyl-N-(4-hydoxybutyl)nitrosamine
(BBN)-treated F344 rat bladder cancer model. By
contrast, the BBN-treated B6D2F1 hybrid mouse
develops both papillary TCC and a high incidence
of poorly differentiated solid invasive TCCs. The
latter do not appear to develop by the same multi-
stage mechanism, involving promotion and clonal
expansion of promoted cells, as do the papillary
tumours. Moreover in this model, retinoid treat-
ment does not reduce the incidence of the rapidly
growing solid cancers.
Our data suggest that there is scope for
improving the management of the patient with
papillary TCC by delaying or preventing re-
currences with agents which block the post-
initiation stages of cancer development; further
development work is necessary to design less toxic
and more effective anti-promoting agents. The data
do not suggest that anti-promoting agents such as
retinoids can be used therapeutically to treat either
flat invasive TCC or papillary tumours which are
growing autonomously; the latter are biologically
'late' tumours which have already passed through
the promotional stages of carcinogenesis.
A multidisciplinary approach in the diagnosis and
treatment of bladder cancer
A.T.K. Cockett
Department of Urology, University ofRochester,
NY, USA.
Since 1976, porcine sensitised lymph node cells -
tumour immune cells - have been employed byPROCEEDINGS OF BACR 27TH AGM 143
our group to treat selected cases of infiltrative
transitional cell bladder cancer. The continued
monitoring of patients with recurrent bladder
tumour has necessitated the refinement ofdiagnostic
techniques in order to stage beforehand the extent
of tumour involvement, and to evaluate the response
following treatment.
Downstaging of bladder tumour has provided a
new opportunity to employ a second protocol to
treat superficial, multifocal bladder tumours. Our
presentation will also include early results (2 years)
of treatment with the combination of Bacillus
Calmette Guerin (BCG) and Interleukin 2.
Ambulatory screening of all bladder tumour
patients now involves our Department of Pathology
who use Multidimensional Slit-scan lasers for de-
tection of bladder ca,ncer. Correlation of our pre-
liminary results in the 15 patients treated with BCG
and IL2 are excellent and will be briefly discussed.
Accurate staging of bladder cancer has provided
a continuing challenge to the urologist. We modi-
fied the technique for CAT scanning of the urinary
bladder in all cancer patients entering both of our
treatment protocols. Our diagnostic and cytopatho-
logic results will be correlated with the patients'
therapeutic responses.
Abstracts of members' proferred papers
A mouse monoclonal antibody against spontaneous
rat mammary carcinoma Sp4
E.W. Pascoe, R.A. Robins, M.R. Price
& R.W. Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, Nottingham NG7 2RD, UK.
Monoclonal antibody (MoAb) 226 was raised
against Sp4, a spontaneous rat mammary carci-
noma of WAB/Not strain origin to attempt to
provide a syngeneic animal/tumour system for the
experimental application of MoAb mediated
targeting.
BALB/c mice were immunised with cultured Sp4
cells and immune spleen cells fused with mouse
P3NS-I myeloma cell line. Resulting hybridoma
supernatants were screened using an ELISA. The
MoAb was tested by flow cytometry against a
number of tumour lines including other spon-
taneous mammary carcinomas and binding proved
to be specific for Sp4. This was subsequently con-
firmed using an immunoperoxidase technique on
frozen sections of WAB/Not tumours and normal
tissues. The only cross reaction observed was
against some luminal element found in sections of
normal gut. Biochemical characterisation of the
MoAb 226 defined antigen by SDS PAGE analysis
of 1251I-labelled immunoprecipitate showed it to be
a single chain glycoprotein with an apparent mol.
wt of 94kD containing some sialic acid. The MoAb
was isotyped as IgGl and has been successfully
purified using Protein A Sepharose column
chromatography.
An immunohistochemical study of ovarian carcinomas
F. Macdonald', R. Bird', H. Stokes', B. Russell'
& J. Crocker2
'Surgical Immunology Unit, Queen Elizabeth
Hospital and 2Department ofHistopathology, East
Birmingham Hospital, Birmingham, UK.
The immunohistochemical characterisation of
ovarian tumours of the major pathological types
has been carried out to determine if any antibody
or mixture of antibodies is of value either in the
histochemical diagnosis or in the localisation or
therapy of these tumours.
Tumour types studied included tumours of epi-
thelial origin (serous, mucinous) germ cell tumours
(teratomas, dysgerminomas) and tumours arising
from gonadal stroma (granulosa cell, thecoma) as
well as undifferentiated and benign tumours and
normal ovarian tissue. Between 1 and 7 blocks were
obtained from each tumour. Antibodies investigated
were anti-CEA (11-285-14), HMFG1, HMFG2,
CA125 and CA19-9. Tumour sections were labelled
by the indirect immunoperoxidase or avidin biotin
techniques. No single antibody or pattern of anti-
bodies was specific for any histological type of
tumour. Undifferentiated tumours were unreactive
with all. HMFG1 reacted with the majority of
tumours, both malignant and benign but is also
cross reactive with normal tissues. As in previous
studies anti-CEA antibodies were reactive primarily
with mucinous tumours (70%). CA19-9 reacted
strongly with mucinous tumours (80%) and serous
tumours (88%) whereas CA125 reacted mainly with
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serous tumours (65%). The less frequently diag-
nosed forms of ovarian tumours showed no par-
ticular pattern of reactivity although the number of
patients available for study was small.
CA19-9 and CA125 were frequently found to be
complementary to one another. Subsequent FACS
analysis with these antibodies on an ovarian cell
line suggests that the production of the antigens
recognised by these antibodies is cell-cycle related.
The use of the two antibodies together appears to
be a useful combination for immunolocalisation of
ovarian tumours.
Expression of Leu 7 antigen on human small cell
lung cancer cells
F.G. Hay', S.G. Allan2 & R.C.F. Leonard'
' University Department ofClinical Oncology and
2Imperial Cancer Research Fund Medical Oncology
Unit, Western General Hospital, Edinburgh, UK.
Two recent articles (Bunn et al., Blood, 65, 764,
1985; Cole et al. Cancer Res., 45, 4285, 1985) have
reported the expression of Leu 7 antigen on small
cell lung cancer (SCLC) cultured cell lines and
paraffin embedded tissues from SCLC patients. The
latter workers, finding low expression in human
tissues, speculated that the Leu 7 expression seen in
cell lines was compatible with Leu 7 being a
differentiation antigen. However, neither group ex-
amined the activity of Leu 7 antibody with freshly
obtained tumour cells from SCLC patients. We
have studied the expression of Leu 7 antigen in
human SCLC tumour cells in cell lines and freshly
obtained aspirates from patients. Four SCLC cell
lines were assesssed by flow cytometry and by PAP
immunohistochemistry for Leu 7 expression (Becton
Dickinson, HNK1). All 4 cell lines gave positive
results by both methods. The expression of Leu 7
antigen in fresh, aspirated tumour cells was
measured on air dried, acetone/methanol fixed pre-
parations obtained from pleural effusions (4), bone
marrow (5), lymph node aspirates (6) and disaggre-
gated solid tissue biopsies (6) using a PAP method.
We also reviewed formalin fixed, paraffin em-
bedded tissue sections. Of the freshly obtained
tumour samples, 18/21 (86%) expressed Leu 7
activity, in contrast only 2/27 (7%) of fixed tissues
were positive. Heterogeneity of staining was ob-
served with 25-90% of tumour cells expressing the
antigen. We conclude therefore that fresh SCLC
tumour cells do exhibit strong Leu 7 expression and
that reactivity is similar in both in vitro (cell line)
and in vivo. Reduced activity in paraffin embedded
samples may reflect processing effects not counter-
acted by prolonged antibody exposure or by
enzyme pretreatment.
Epithelial and neural antigens in human small cell
lung cancer (HSCLC)
F.G. Hay & R.C.F. Leonard
University Department ofClinical Oncology,
Western General Hospital, Edinburgh, UK.
Despite intensive treatment-orientated clinical
research, the origin and lineage of HSCLC remains
uncertain. Important information has been obtained
from HSCLC-derived cell lines that points to the
heterogeneity of the tumour cells (in terms of
biochemistry, immunological phenotype and genetic
character) as well as suggesting a relationship be-
tween certain of the cell line characteristics and
clinical behaviour. We have studied freshly ob-
tained tumour cells and cell lines using a library of
lineage-associated monoclonal antibody (MoAb)
markers to compare in vivo tissue with cell lines
with the aim of characterising HSCLC. The data
(Table) were obtained by applying mouse anti-
human MoAbs to air dried, acetone/methanol fixed
preparations of cultured cell lines, freshly aspirated
cells or disaggregated biopsies, followed by
immunoperoxidase staining (PAP).
Epithelial
MoAB HMFG1 HMFG2 AUAI
Fresh tumour cells 17/20 21/21 12/12
Cultured tumour
cells 4/4 4/4 3/4
Cytokeratin Neural
MoAb CAM 5.2 LE6J 534F8 UJ13A
Fresh tumour cells 11/11 21/21 21/21 8/10
Cultured tumour
cells 3/4 3/4 4/4 4/4
We found that the majority of cell lines and fresh
tumour tissues expressed epithelial and neural anti-
gens simultaneously and there was also co-
expression of low mol. wt cytokeratins.
These results support the hypotheses that dual
lineages are present or that the progenitor cells
differentiate along 2 different pathways in HSCLC.PROCEEDINGS OF BACR 27TH AGM 145
The reactivity pattern of the anti-epithelial and
neural antibodies encourages us to use them in the
detection of marrow involvement by SCLC with
consequent therapeutic implications.
The use of monoclonal antibodies to T cells and
leucocyte common antigen in the identification of
large cell lymphomas in formalin fixed, paraffin
embedded material
D.B. Jones', P. Beverley2 & D.H. Wright'
The distribution of DD9-E7 in non-pancreatic
carcinomas
Eadie Heyderman', Sandra Larkin',
R.J. Whittaker', J. Hermon-Taylor2
& Anne Grant2
'Department ofHistopathology, UMDS, St. Thomas
Hospital, London SE] 7EH and 2Department of
Surgery, St. George's Hospital, London SW17 ORE,
UK.
The monoclonal antibody DD9-E7, raised by im-
munisation of BALB/c mice with a GER pancreatic
adenocarcinoma xenograft, has previously been
shown by us to react with all 22 adenocarcinomas
of the exocrine pancreas, and with a variety of
other normal and neoplastic tissues, including poly-
morphs and macrophages. One hundred and
eighteen non-pancreatic tumours were selected from
our surgical files and an indirect immunoperoxidase
technique was used to see whether DD9-E7 might
be a useful addition to a panel of antibodies used
for the identification of the site of origin of a
metastasis from an occult primary carcinoma.
Positive staining was seen in 9/10 bronchial adeno-
carcinomas, 5/10 breast tumours, 8/10 gastric carci-
nomas, 12/12 colorectal, 2/5 endometrial, 5/6
cervical adenocarcinomas, 5/5 mucinous and 0/5
serous papillary adenocarcinomas of the ovary,
7/10 salivary gland adenocarcinomas, and in
occasional cells in 3/5 papillary and in 2/5 follicular
carcinomas of the thyroid. Two of 10 prostatic
carcinomas were positive only in foci of squamous
metaplasia, and only keratotic foci were positive in
25 primary skin carcinomas. It would appear that
DD9-E7 could be used to distinguish metastatic
pancreatic carcinomas from deposits of breast,
serous ovarian, endometrial, thyroid and prostatic
carcinoma (although thyroglobulin and prostatic
acid phosphatase are more specific markers for
thyroid and prostatic tumours), but not from
bronchial adenocarcinomas. Pancreatic tumours are
often only focally positive for CEA, unlike colo-
rectal and most gastric carcinomas, so the use of
DD9-E7, together with a CEA antibody, could be
of value in the differential diagnosis of metastases
from these sites.
' University Department ofPathology, General
Hospital, Southampton S09 4XY and 2ICRF
Tumour Immunology Unit, University College
Hospital, London, UK.
Monoclonal antibodies to leucocyte sub-
populations have enhanced our ability to charac-
terise lymphoma. However, most monoclonal anti-
bodies react only with cells in frozen section and
are, therefore, only applicable where adequate fresh
biopsies can be obtained. Further, whilst cell
surface antigens are frequently expressed strongly
on reactive populations, large cell lymphomas often
express antigen weakly and cell lineage deter-
mination can be difficult even with enhanced stain-
ing. In this presentation we report the results of a
study of 40 cases of fixed large cell lymphoma
using the monoclonal antibodies UCHL1 and PD7.
The former is raised to a T cell clone and the latter
identifies leucocyte common antigen. Enhanced
staining, using biotin-streptavidin large complex
was employed throughout. The bulk of the cases
had a diagnosis of T cell lymphoma on morpho-
logical grounds and, in some cases, frozen section
staining confirmed this diagnosis. Weak staining
with PD7 was frequently seen in cases where the
UCHL1 staining was strong, suggesting that leuco-
cyte common antigen expression on large cell
lymphoma may be weak. This observation has
diagnostic implications. In 10 cases of Hodgkin's
disease, UCHL1 did not stain the tumour cell
population. In conclusion, our data suggest that the
antibody UCHL1 is a useful adjunct to leucocyte
common antigen in the diagnosis of large cell
lymphoma in paraffin section.
Differential expression of MHC D-region sub-locus
products on human colorectal cancers: An
immunohistological study
A.K. Ghosh & M. Moore
Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester M20 9BX, UK.
The MHC status of tissue from 28 primary gastro-
intestinal (GI) neoplasms (colorectal 26; stomach
2), villous adenomata (VA 2) and inflammatory146 PROCEEDINGS OF BACR 27TH AGM
bowel disease (IBD 3) was evaluated using a panel
of monoclonal antibodies (McAbs) by cryostat
immunocytochemistry. With 2 exceptions, all the
carcinomas (cas) and the VA were uniformly
positive with anti-Class I (monomorphic deter-
minant) McAbs, although staining of 2 further
cases was weak. A more complex pattern of re-
activity encountered using a panel of Class II
McAbs, directed against the DP, DQ and DR
monomorphic determinants. Normal GI glandular
and luminal epithelium was consistently Class II
negative but 19 out of 28 (68%) neoplasms were
positive, the proportions of stained epithelial cells
ranging from 5 to 90%. Expression of Class II
products tended to be non-coordinate: DR was the
predominant specificity (19/19+) followed by DP
(13/19+) and DQ (5/19+). The epithelia of 3
samples of IBD were positive for all 3 D-region
products, as was one VA. Further analysis with a
panel of anti-leucocyte McAbs revealed a numerical
superiority of stromal T cells over those in epi-
thelium. In the stroma T cells of helper-inducer
phenotype (Th+i) pre-dominated over those of
cytotoxic-suppressor phenotype (Tc+s) (ratio=2.2
for Class II +ve tumours; 3.1 for Class II -ve). In
tumour epithelium the corresponding ratios were
0.8 and 0.7. Few intratumour T cells expressed the
IL-2 (Tac) receptor. There was thus no correlation
between MHC status and the extent or phenotype
of infiltrating T cells and a similar lack of corre-
lation was observed for macrophages. Possible
mechanisms for the induction of Class II molecules
on inflamed and neoplastic epithelia will be dis-
cussed and an analysis of the relationship between
MHC status, mononuclear cell infiltration, patho-
logical parameters and clinical course will be
presented.
Expression of MHC products and tumour-associated
antigens (TAA) before and after treatment of
malignant melanoma with IFN-y
T. Cerny', A.K. Ghosh3, A. Street3, J. Wagstaff',
N. Thatcher', M. Harris2 & M. Moore3
Departments of 'Medical Oncology, 2Pathology and
3Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester M20 9BX, UK.
IFN-y is an effective inducer of MHC Class II
expression in cell lines of malignant melanoma. To
investigate the possibility that IFN-y may increase
MHC Class I and II and melanoma TAA in vivo
we conducted immunohistochemical analyses of
biopsies from 6 patients with metastatic disease.
(Clinical Stage II and III.) Biopsies of skin or soft
tissue metastases were taken before and after a
variable duration of IFN-y treatment (50h up to 8
weeks; only 1 follow-up biopsy in one patient).
Subcutaneous injections of IFN-y (rDNA IFN-y
Schering 36850) were given 3 times a week and
single doses were in the range 3mgm 2 to
5mgm-2 (6-10 x106UIFN-y). The maximum
tolerated dose was 5mgm-2. For immunostaining,
3 anti-melanoma (Sorin Biomedica Clones 225.28S,
763.24T and 376.96S) and several anti-MHC mono-
clonals were used. Before IFN-y treatment, all
melanomas were Class I positive and all were Class
II negative. After treatment Class I expression was
neither enhanced nor Class II expression induced in
any tissue sample regardless of biopsy time or dose
of IFN-y. TAA expression was similarly unchanged.
However, in one case from which a primary culture
was established, IFN-y (500Uml-1) clearly in-
creased MHC Class II expression. The possibility
that in vivo IFN-y induces quantitative changes in
the expression of MHC products and TAA cannot
be excluded on the basis of the qualitative immuno-
cytochemical technique. However the ease with
which Class II products are routinely detected on
cultured melanoma cells and epithelial cancers
suggests, among other factors, that there is no
detectable induction of these antigens in vivo. So
far, none of the patients has responded to IFN-y
treatment.
Specificity of monoclonal antibodies against gamma
glutamyl transpeptidase
M.M. Manson & J.A. Green
MRC Toxicology Unit, Woodmansterne Road,
Carshalton, Surrey SM5 4EF, UK.
Gamma glutamyl transpeptidase (GGT), an enzyme
present in many normal epithelial cells, is also
induced in some preneoplastic and neoplastic
lesions during chemical carcinogenesis. We have
raised monoclonal antibodies against GGT from rat
Kidney. BALB/c mice were immunised with papain
cleaved, affinity purified enzyme (Cook & Peters,
Bioclin., Biophys. Acta., 828, 205, 1985) and
hybridoma cultures screened by solid phase ELISA
with streptavidin peroxidase complex for detection.
Five monoclonals were identified which immuno-
precipitated GGT from solubilised rat kidney brush
border membranes, but not from plasma
membranes of aflatoxin B,-induced hepatoma as
shown by histochemical staining of protein blots
from non-denaturing gels. Immunohistochemistry
with alkaline phosphatase conjugated second anti-
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in acetone fixed sections of adult rat kidney and 2
more reacted weakly if sections were pretreated
with 0.1% protease to unmask antigenic sites. The
antibodies do not recognise GGT in foetal or
neonatal kidney and react only with the enzyme in
2yr old kidney. A number of dimethylnitrosamine
induced kidney tumours were examined (material
provided by Dr. H.E. Driver). Neither epithelial
tumours (weakly positive for GGT activity) nor
mesenchymal tumours were immunoreactive but
many GGT+ve ducts trapped within the tumours
were immunoreactive. Of 3 monoclonals more fully
characterised, none cross-reacted with other rat
tissues including hepatoma, nor with mouse, guinea
pig or marmoset kidney. The specificity of these
monoclonals for normal adult rat kidney isozymes
of GGT suggests the possibility of raising others
against isozymes in preneoplastic and neoplastic
lesions or to those found in human serum during
various disease states, which would greatly enhance
the diagnostic value of GGT.
Interferon-y production by clones derived from human
peripheral blood Tcells and NK cells
S.E. Christmas', A. Meager2 & M. Moore'
'Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester M20 9BX and
2National Institutefor Biological Standards and
Control, London NW3 6RB, UK.
A variety of different cell types including natural
killer (NK) cells has been reported to be capable of
producing interferon-y (IFN-y). It has recently been
appreciated that NK cells, as well as having cyto-
lytic activity towards certain tumour lines, may
have a wider immunoregulatory role and that this
may be their primary function in vivo. The pro-
duction of IFNs represents an aspect that is readily
amenable to investigation in vitro. We have de-
veloped a technique of cloning human NK cells
obtained from the peripheral blood of normal
donors (Eur. J. Immunol., 15, 448, 1985). Lympho-
cytes treated with the B73.1 (Leu 11) monoclonal
antibody, which recognises all peripheral NK cells,
are sorted into B73.1 + and B73.1 - (T cell) fractions
using a FACS IV. Cells are then cloned by limiting
dilution in a feeder system incorporating allogenic
mononuclear cells, a B lymphoblastoid cell line,
interleukin 2 (IL-2) and PHA. Cloned cells are then
incubated at 106 cellsml-1 in 2.5Mgml-1 PHA for
48h and the supernatants assayed for IFNs using
antiviral and immunoradiometric assays. While
freshly isolated B73.1+ and B73.1- cells both pro-
duced significant amounts of IFN-y, most B73.1+
derived clones produced low amounts of IFN-y
under these conditions. Those which secreted higher
amounts of IFN-y had acquired the pan-T cell
marker OKT-3 during culture. Both OKT-4+ and
OKT-8+ T cell clones produced IFN-y. The results
suggest that most NK cells capable of proliferating
in IL-2 are either unable to or lose the ability to
produce IFN-y and that those which can produce
IFN-y show a T cell-like phenotype.
Specificity of cell destruction at the tumour site
during the rejection of syngeneic immunogenic rat
tumours
S. Kay, R.A. Robins, E.W. Pascoe
& R.W. Baldwin.
Cancer Research Campaign Laboratories, University
ofNottingham, Nottingham NG7 2RD, UK.
The nature of the effector cell pivotal in the tumour
rejection response is still under debate. A specific
cytotoxic T cell is a likely candidate for killing in
virally-induced tumour systems, but the T helper
cell, initiating a delayed type hypersensitivity re-
action recruiting non-specific effector cells, has also
been demonstrated.
This study was designed to investigate the speci-
ficity of the rejection response at the tumour site.
Sp4 and Mc7 are immunogenic tumours which can
induce tumour-specific immune responses. These
tumours were injected into naive, Mc7 immune,
and Sp4 immune rats, as mixed cell suspensions, at
number sufficient to allow the growth of either
tumour. The growing tumour was labelled with
anti-Sp4 monoclonal antibody, and analysed by
FACS. The antibody labelling in the Mc7-immune
animals identified the tumour as Sp4, whilst in the
Sp4-immune animals, it was negative, indicating
Mc7. Thus only the tumour against which the
animal was immunised, was rejected.
Depletion of T cells from human bone marrow using
monoclonal antibodies and rabbit complement: A
quantitative and functional analysis
A.Z.S. Rohatiner1, R. Gelber2, S.F. Schlossman2,
& J. Ritz2
'ICRF Department ofMedical Oncology, St.
Bartholomew's Hospital, London ECJ, UK and
2Dana Farber Cancer Institute & Harvard School of
Public Health, Boston, USA.
Graft versus host disease (GVHD) remains the148 PROCEEDINGS OF BACR 27TH AGM
principal complication of allogenic bone marrow
transplantation. In animal models mature T
lymphocytes have been shown to be reponsible for
GVHD and in vitro treatment of donor bone
marrow (BM) using T cell specific monoclonal
antibodies and complement is being investigated as
a means of preventing GVHD. Anti-T12, anti-Ti1
and rabbit complement were used to remove T
lymphocytes from normal BM. The efficacy of
depletion was investigated by immunofluorescence
and by in vitro culture of residual cells using non-
specific mitogens or allogenic B cells as the prolifer-
ative stimulus in the presence of IL-2. Immuno-
fluorescence analysis showed complete depletion of
T12 + and Ti + cells after treatment with the
respective antibodies and with the combination.
Nevertheless, culture of treated BM with either
PHA or Con-A and conditioned medium contain-
ing IL-2 resulted in the proliferation of mature T
cells (T3+, T4+ or T8+, Tll+). Stimulation of
treated BM with allogenic cells (Laz 388) resulted
in the growth of a population with natural killer
(NK) cell phenotype (T3-, Tll+, NKH1+)
which was found to be strongly cytotoxic against
K562 cells. A clonogenic assay was used to quanti-
tate the efficacy of target cell depletion. Three
incubations with either anti-T12 or anti-Tll plus
complement resulted in depletion of 1-2 logs of
cells. Treatment with both antibodies concurrently
resulted in elimination of 2-3 logs of target cells. It
remains to be established whether such combi-
nations will be necessary in the clinical setting.
The effects of MG+ + or EDTA on the subcellular
distribution of unoccupied oestrogen receptor in
breast cancer cells
J. Nelson', R. Clarke', G.R. Dickson2,
H.W. van den Berg3 & R.F. Murphy'
Departments of 'Biochemistry, 2Anatomy and
3Therapeutics and Pharmacology, Queen's University
ofBelfast, Northern Ireland, UK.
The unoccupied oestrogen receptor (ER), formerly
regarded as cytoplasmic now appears to be nuclear
(Clark, TIBS, 9, 207, 1984). EDTA, used to
optimize cytoplasmic ER levels in homogenates
damages cell membranes. Mg' + preserves sub-
cellular integrity. We have examined ER distri-
bution and nuclear integrity in the presence or
absence of divalent cations. Cells disrupted in hypo-
tonic Mg"+ or EDTA-Tris buffering were centri-
fuged at 2,500g. Supernatants were centrifuged at
100,000g to prepare cytosol which had low ER
levels. Semi-pure nuclei were prepared by pelleting
at 100,000g through 41% and 44% sucrose. Plasma
membranes remained on top of the 41% barrier.
Lactate dehydrogenase was not a contaminant of
particulate fractions. With Mg"+, 5'-nucleotidase
and ER were distributed between plasma
membranes and semi-pure nuclei. With EDTA,
most ER activity was with the nuclei. These were
extensively disrupted. Plasma membranes had no
ER. Mg-prepared nuclei purified by pelleting
through 1.8M sucrose were microscopically (EM)
intact but had no nucleotidase or ER. Thus,
nuclear ER appears to be an artifact caused by
contamination with plasma membranes.
Breast tumour activated oestrogen receptor:
Distribution according to disease stage and
recurrence
M.J. Hershman', J.O. White2, N.A. Habib',
M.G. Elder2, J.G. Azzopardi3 & C.B. Wood'
Departments of'Surgery, 2Gynaecology and
3Pathology, Royal Postgraduate Medical School,
London, UK.
Human breast cancer cytosol oestrogen receptors
exist in activated and non-activated states as as-
sessed by their ability to bind to the artificial
nuclear matrix (dT)-cellulose. This may distinguish
receptors with high affinity for nuclear receptor
sites in vivo. Oestrogen receptor status and acti-
vation were determined in 53 patients with benign
breast disease and 131 patients with breast cancer,
followed for a median of 27 months. Non-activated
oestrogen receptor positive tumours occurred sig-
nificantly (P<0.05) and more frequently in stage
IV disease compared with stages 1-111. No differ-
ence in tumour recurrence was found between
oestrogen receptor positive (ER+ve) tumours and
oestrogen receptor negative (ER-ve) tumours.
However, the incidence of disease recurrence was
significantly higher in non-activated (53.8%) com-
pared with activated (17.8%) ER+ve groups
(P<0.05). Patients with non-activated ER+ve
tumours had similar recurrence rates to ER-ve
patients. These data suggest that oestrogen receptor
activation is a more reliable prognostic indicator
than total oestrogen receptor status.PROCEEDINGS OF BACR 27TH AGM 149
Interferon-at increases oestrogen receptor expression
in the ZR-75-1 human breast cancer cell line.
H.W. van den Berg, W. Leahey & M. Lynch
Department of Therapeutics and Pharmacology, The
Queen's University ofBelfast, Northern Ireland, UK.
There is some evidence that interferon (IFN) may
increase the expression of oestrogen receptor (ER)
in target tissues, including breast carcinoma
(Pouillart et al., Eur. J. Cancer Clin. Oncol., 18,
929, 1982). If this were confirmed it might be
expected that IFN would increase the sensitivity of
breast carcinoma cells to the anti-oestrogen
tamoxifen (TAM). We have previously shown that
growth inhibitory concentrations of IFN and TAM
are additive rather than synergistic in their effects
on ZR-75-1 human breast cancer cells (Br. J.
Cancer, 52, 428, 1985). In this study we have
examined the ability of IFN to modulate ER
expression in this cell line.
Human recombinant IFN-a (10-1,000 Uml-1)
increased ER levels are measured in a whole cell
binding assay and this effect was inversely propor-
tional to dose. Specific binding at a single sub-
saturating ligand concentration (InM 3H-oestradiol),
was increased up to 10-fold by a 2-day pre-exposure
of cells to 1OUml-m IFN-a. This concentration
of IFN alone had no effect on cell proliferation.
IFN-a induced increases in specific binding of
oestradiol by ZR-75-1 cells was observed maximally
when cells were treated at a low cell plating density -
a factor which also increases the anti-proliferative
effects of higher concentrations of the agent.
Despite marked increases in detectable ER fol-
lowing IFN-a treatment, preliminary experiments
have failed to show enhanced sensitivity of ZR-75-1
cells to TAM following pre-treatment with IFN-x.
Effect ofvincristine (VCR) on oestrogen receptor
(ER) expression and the antiproliferative effects of
tamoxifen (TAM) in MCF-7 breast cancer cells
R. Clarke1, M. Cremin', J. Nelson1,
H.W. van den Berg2 & R.F. Murphy'
Departments of 1Biochemistry and 2Therapeutics &
Pharmacology, The Queen's University ofBelfast,
Northern Ireland, UK.
We have previously reported that VCR reduced ER
expression in MCF-7 cells and have now examined
the time course of this event. Since TAM is be-
lieved to exert its effects through interaction with
ER, we have also investigated the influence of VCR
on the antiproliferative effects of TAM. Following
exposure to 0.5nm or nMVCR, ER levels were
reduced to 30% and 0% respectively but returned
to or exceeded that of untreated cells within 72h of
removal of the drug. VCR (0.5nM) reduced the rate
of cell proliferation by 20%. TAM (2uM) reduced
cell proliferation by 50%. Pretreatment of cells with
0.5nM VCR did not influence their subsequent
response to TAM. VCR (1 nM) abolished ER levels
and induced a similar reduction in cell proliferation
as 2gM TAM. Exposure of cells to 1 nm VCR
followed by 2/M TAM was no more cytotoxic than
either drug alone. Since VCR and TAM have
different mechanisms of action an additive effect
might have been expected. Thus, VCR may be
reducing the antiproliferative effects of TAM or
vice versa.
Tumour cell DNA content in carcinoma of the
breast; response to endocrine therapy and effect of
tamoxifen
A.D. Baildam" 4, J. Zaloudik2, M. Moore2,
D.M. Barnes4, A. Howell3 & R.A. Sellwood1
Departments of'Surgery, 3Medical Oncology,
4Clinical Research and 2Paterson Laboratories,
Christie Hospital, Manchester M20 9BX, UK.
The relationship between DNA content of primary
breast tumour cells and subsequent response to
endocrine therapy was studied in 137 patients with
advanced disease. All were treated with tamoxifen
or ovarian ablation as first line systemic therapy,
and were evaluable for response according to UICC
criteria. DNA characterisation by flow cytometry
was used on tumour samples from paraffin em-
bedded fixed material according to the method of
Hedley et al. (J. Histochem. Cytochem., 31, 1333,
1983). Grouped according to DNA indices (DI),
response rates (CR+PR+SD) were respectively;
DI 1.0 27/53 (51%), DI 1.2-1.7 12/27 (44%), DI
1.8-1.9 16/19 (85%), DI 2.0 18/27 (67%) and
DI>2.1 3/10 (27%). The near-tetraploid group (DI
1.8-2.0) had the highest proportion of ER+
tumours (38/45, 87%, P<0.01).
The effect of tamoxifen upon DNA content was
assessed in a separate group of 77 patients with
primary breast tumours; all had two biopsies with a
median interval of 8 days, and 40 of them received
tamoxifen during this period. The most consistent
effect of tamoxifen was an abolition or reduction in
magnitude of >50% in a near tetraploid peak in
those tumours with DI 1.8-2.0 in the first biopsy150 PROCEEDINGS OF BACR 27TH AGM
(15/21 72%) compared with those not receiving
tamoxifen (3/16 18%), (P<0.01).
These data suggest that tamoxifen preferentially
affects tumours exhibiting a near tetraploid DNA
content, and that this may be related to endocrine
response.
Inhibition of neutrophil oxidase activation by
tamoxifen
K. Horgan, Eryl Cooke, M.B. Hallett
& L.E. Hughes
Department ofSurgery, University of Wales College
ofMedicine, Heath Park, CardiffCF4 4XN, UK.
Tamoxifen has recently been demonstrated to in-
hibit rat brain protein kinase C (PKC) in vitro (O.
Brian et al., Cancer Res., 45, 2462, 1985). PKC has
an established role in tumour promotion, cell
surface signal transduction and also activates the
oxidase mechanism in neutrophils. We have utilised
the neutrophil as an experimental model to assess
the effect of tamoxifen on PKC activity in intact
human cells.
Neutrophils from 6 healthy volunteers were sep-
arated through Ficoll-Hypaque centrifugation and
stimulated by phorbol-14-myristate-13 acetate
(PMA). Neutrophil oxidase activity was markedly
stimulated as assessed by both oxygen consumption
and oxygen radical production. These parameters
were measured by a Clark electrode and luminol
dependent chemiluminescence respectively. Tamoxi-
fen inhibited the stimulation in all six samples,
IC50=6.1±1.6pM (X_±s.e.). Measurement of intra-
cellular ATP and application of the trypan blue
exclusion test showed no significant difference
before and after tamoxifen. Other PKC stimulators,
mezerein and oleoyl acetyl glycerol were also in-
hibited by tamoxifen.
These experiments indicate tamoxifen inhibits
PKC in vivo. This inhibition may be central to its
antitumour action.
The use of a 75Se uptake assay to measure the
sensitivity of prostatic carcinoma cells to hormones
M. Ferro1, D. Heinemann2, P.J.B. Smith'
& M.O. Symes2
Departments of 1Urology and 2Surgery, Bristol
Royal Infirmary, and University ofBristol, Bristol,
UK.
Specimens of tumour tissue were obtained by trans-
urethral resection from 24 patients with prostatic
carcinoma. The tumour was disaggregated using
collagenase+DNAase and a relatively pure sus-
pension of carcinoma cells were separated from the
mixed cell suspension by centrifugation on a linear
density gradient of Nycodenz (Nyegaard & Co.,
AS, Oslo), (Umpleby et al., Br. J. Surg., 71, 659,
1984). The carcinoma cells were confirmed as being
of prostatic origin by staining with prostate specific
antibody using the immunoperoxidase technique.
Aliquots of carcinoma cells, 105, were cultured for
24h with increasing concentrations of either diethyl
stilboestrol (DES) or testosterone. The cells were
then washed free of hormone and resuspended in
2ml of methionine-free MEM with 2pCiml-1 of
75Se (as selenomethionine) added. After a further
48h incubation protein synthesis by the carcinoma
cells was estimated as the incorporated radio-
activity in the cell pellet. The percentage inhibition
or increase in 7'Se incorporation on exposure to
hormones was estimated with reference to control
aliquots of cells not exposed to hormones. DES at
pgmln-I inhibited protein synthesis in 15/24 cases
-29.5±21.3% (range -5 to -85%) and caused
stimulation in 9 of 24 tumours +22.9+27.2%
(range +4 to +85%). However, at 10gmlP- DES
was inhibitory in 22 of 23 patients -65.1 +20.9%
(range -9 to -96%). Testosterone stimulated
protein synthesis in 11/16 cases at lugmlP ,
+64.4±72.3% (range +14 to +222%) and in
13/18 cases 10pgml-1+64.4% (range +4 to
+256%).
Inhibition of protein synthesis by DES and its
stimulation by testosterone may indicate tumour
sensitivity to hormone therapy in vivo.
Tissue plasminogen activator and urokinase in human
colorectal cancer
J.S.K. Gelister1, S. Ishaql, M. Mahmoud2,
P.J. Gaffney2 & P.B. Boulos1
1Department ofSurgery, University College London,
and 2National Institutefor Biological Standards and
Control, London, UK.
Plasminogen activators, tPA and uPA are impli-
cated in tumour invasion and metastasis. UPA has
been associated with colorectal cancer but not with
normal colonic mucosa. However, there have been
no equivalent studies of human tPA. Samples of
tumour centre and edge (TC, TE) and of adjacent
and distant mucosa (AM, DM) were assayed for
fibrinolytic activity (FA) and for specific uPA and
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Results
Carcinoma
TC (n=30) TE (n =15)
FAmm2 263 (58-544) 254 (81-366)
tPAIUml1 0.8 (0.2-3.5) 1.2 (0.1-2.3)
uPAIUml 0.7 (0.2-4.2) 1.0 (0.4-1.5)
Normal mucosa
AM(n= 15) DM(n=30)
FAmm2 379 (176-422) 395 (255-644)
tPAIUml1 2.2 (1.0-4.3) 4.1 (1.5-16)
uPAIUml-' 0.2 (0.2-0.9) 0.2 (0.1-0.8)
In carcinomas, uPA was elevated (P<0.001);
however, tPA and fibrinolytic activity were
diminished (P<0.001) compared to normal mucosa.
There were no differences between tumour centre or
edge, but adjacent had less tPA than distant
mucosa (P<0.001) though was still higher than in
carcinoma (P<0.001).
This study demonstrates for the first time that
tPA production is diminished in colorectal cancer
and confirms previous reports of elevated uPA. The
capacity of colorectal cancers to release plasmin is
therefore less restricted compared to normal
mucosa, as the activation of plasminogen by uPA
(unlike tPA) is fibrin independent, and this may be
relevant to tumour invasion.
Enhanced plasminogen activator (PA) activity in
experimental colon neoplasia
J.S.K. Gelister', M.R. Lewin', F. Savage',
J. Garcia-Frade2, P.J. Gaffney2 & P.B. Boulos'
1Department ofSurgery, University College, London,
and 2National Institutefor Biological Standards and
Control, London, UK.
PAs exist in two well defined forms, tissue (tPA)
and urokinase (uPA). Abberant PA production is
implicated in malignant transformation and has
therefore been studied in experimental colonic neo-
plasia. Ten Wistar rats received dimethylhydrazine
(DMH, 40mgkg'-, s.c. weekly x 5) and 10 served
as controls. All 20 were sacrificed at 20 weeks,
when duplicate, weighed explants of macroscopi-
cally normal left colon from all rats and 12 polyps
from tumour bearing rats were established in tissue
culture. After 24h culture supernatnants were
assayed for total PA, tPA and uPA activity using
fibrin plates, a bioimmunoassay (using anti-human
tPA) and a simple amidolytic assay respectively.
Results
Control Colon DMH Colon
(n=10) (n=10)
Total PA (IUml-') 0.22 (0.01-1.52) 0.05 (0.00-1.11)
tPA (IUml ') 0.00 (0.00-0.08) 0.00 (0.00)
urPA (IUml) 0.32 (0.14-0.40) 0.33 (0.17-0.61)
Polyps
(n = 12)
Total PA (IUml-') 6.69 (0.13-70.5)
tPA (IUmlP) 0.28 (0.20-2.75)
tPA (IUml 1) 0.86 (0.12-14.1)
Polyps had significantly increased PA activity
(P<0.001), uPA activity (P<0.005) and tPA
activity (P<0.001) compared to normal mucosa
which did not differ in control and DMH treated
rats. This study shows that experimental colonic
polyps have an increased capacity to produce uPA
and tPA. These enzymes have been associated with
basement membrane destruction and may therefore
play a role in the adenoma-carcinoma sequence.
Carcinoma of breast contains increased, uninhibited
levels of urokinase
G. Layer1, S. Cederholm-Williams3,
S. Houlbrook3, P. Gaffney2, M. Mahmoud2,
M. Pattison' & K. Burnand'
'Department ofSurgery, St. Thomas' Hospital,
London SE], 2National Institute ofBiological
Standards and Control, London NW3, and 3Nuffield
Department ofObstetrics & Gynaecology, Oxford,
UK.
Malignant tumours express different levels of tissue
fibrinolytic activity compared with benign tissues
and these may determine metastatic spread. We
have investigated the fibrinolytic enzymes: tissue
plasminogen activator (tPA) and urokinase (UK)
produced by 26 breast carcinomas and 13 benign
breast biopsies. Extracts of tumour, 'normal' sur-
rounding breast and benign biopsies were prepared
by cryodestruction and analysed for protein content
(Bradford test) and fibrinolytic activity on fibrin
plates. UK and tPA were estimated by immuno-
assay (ELISA) and functional bioimmunoassay
(BIA) using chromogenic substrates. The enzymes
were characterised by fibrin overlay zymography
(incorporating antibodies) after SDS-PAG electro-
phoresis.152 PROCEEDINGS OF BACR 27TH AGM
Protein Fibrin
content plates
Breast tissues mgml-1' uml-1
Benign 0.56 0.14
+s.e. 0.07 0.02
Malignant 0.86 0.32
+s.e. 0.06 0.04
t tests t=3.20 t=3.40
P<0.002 P<0.001
ELISA immunoassay
tPA UK Total
Breast tissues iuml-1 iuml-1 iuml-1
Benign 2.41 0.20 2.62
+s.e. 0.47 0.03 0.47
Malignant 3.89 0.81 4.74
+s.e. 0.69 0.26 0.68
t tests t= 1.77 t=2.37 t=2.58
P<0.081 P<0.022 P<0.012
BIA immunoassay
tPA UK Total
Breast tissues iuml-1 iuml-1 iuml-
Benign 3.89 0.36 4.36
+s.e. 0.78 0.16 0.86
Malignant 5.64 1.60 7.23
+s.e. 0.93 0.37 0.94
t tests t= 1.44 t=3.10 t=2.26
P=0.156 P<0.003 P<0.027
Zymography
tPA % UK %
Breast tissues total total
Benign+s.e. 71 3
Malignant+s.e. 87 27
t tests X2=3.46 x2=6.58
P>0.05 P<0.02
Tumour extracts had significantly elevated
protein and fibrinolytic activity. UK and tPA
measured by ELISA and BIA correlated (r=0.794,
n=89, P<<0.001) suggesting absence of inhibition.
No inhibitors were shown by zymography and UK
was almost exclusively confined to malignant
extracts.
These results suggest invasive breast carcinoma is
associated with a significantly increased and un-
inhibited production of tissue urokinase.
A specific binding site for two-chain human urokinase
on human breast cancer cell membranes
G.K. Needham1, A.L. Harris2, G.V. Sherbet2
& J.R. Farndon1
Department of'Surgery and 2Cancer Research Unit,
University ofNewcastle upon Tyne, Newcastle upon
Tyne, UK.
Plasminogen Activators (PA) are associated with
tissue remodelling and cell migration and occur in
larger amounts in malignant tissues than in their
normal counterparts. PAs are closely associated
with the cell membrane fraction. We have shown
EGF receptors on breast cancers are associated
with a poor prognostic subgroup and it is known
that EGF can stimulate PA secretion. The inactive
'A' chain of urokinase has amino acid sequence
homology with EGF.
A study has been made of binding of two-chain-
human-urokinase (mol. wt 54,000) to human breast
cancer membrane preparations. High affinity
receptors were demonstrated with a Kd of
5x1011- to 3xIO-10. Nine out of 20 tumours
showed specific binding. Nonspecific binding
ranged from 5% to 15% of totals. Assay of intrin-
sic membrane PA showed lower levels in tumours
which bound urokinase than in those which did
not.
Binding of urokinase is mediated by the inactive
'A' chain since no competition for binding sites was
observed when 125I-labelled two-chain-urokinase
was incubated with membrane in the presence of
excess single-chain-urokinase whereas amount of
ligand bound was reduced by >50% when excess
two-chain-urokinase was used even when the active
site was inhibited by PMSF. No interaction was
seen with two-chain tissue PA or EGF.
These results show that the active site of
urokinase may be presented to the tumour stroma
via specific binding sites on breast cancer cell
membranes,
Alterations in host fibrinolysis affect the growth and
spread of a spontaneously-metastasising murine
tumour.
G.T. Layer, M. Pattison & K.G. Burnand
Department ofSurgery, St. Thomas' Hospital,
London SE] 7EH, UK.
Streptokinase has improved survival after colo-
rectal cancer resection. We investigated altering
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carcinoma (3LL) in C57B1 mice. Fibrinolysis was
estimated by euglobulin clot lysis time (ECLT).
Urokinase, stanozolol and s-aminocaproic acid
(EACA) were given to groups of 10 mice; ECLT at
sacrifice was altered in all groups. Changes ob-
served were in directions opposite to those found in
man.
Results
EACA Urokinase
ECLT 90mgday- 250iuday-
Controls mean+s.e.min 30.6+4.5 30.6+4.5
Treatment 17.3+3.7 73.5+8.2
Mann-Whitney U test P<0.032 P<0.003
Stanozolol Stanozolol
ECLT 0.125mgwk-1 0.5mgwk-'
Controls mean+s.e.min 18.2+0.8 18.2+0.8
Treatment 28.9.0+3.4 37.0+2.5
Mann-Whitney U test P<0.039 P<0.004
Stanozolol
ECLT 2.5mgwk - I
Controls mean+s.e.min 30.6+4.5
Treatment 205.0+33.8
Mann-Whitney U test P<0.004
Results
EACA Urokinase
Primary tumour weight 90mgday- 1 250iuday-
Controls mean+s.e.mg 1152+138 1152+138
Treatment 1179+207 2527 +332
Mann-Whitney U test P<0.734 P<0.005
Stanozolol Stanozolol
Primary tumour weight 0.125mgwk-1 0.5mgwk-I
Controls mean+s.e.mg 1152+138 2986+661
Treatment 2572+332 5037+806
Mann-Whitney U test P<0.001 P<0.027
EACA Urokinase
Number ofmetastases 90mgday-1 250iuday-
Controls mean+s.e. 14.5+3.7 14.5+3.7
Treatment 20.3+4.0 27.9+6.3
Mann-Whitney U test P<0.154 P<0.043
Stanozolol Stanozolol
Number ofmetastases 0.125mgwk-1 0.5mgwk-
Controls mean+s.e. 14.5 +3.7 12.9+4.8
Treatment 27.0+9.1 28.4+5.1
Mann-Whitney U test P<0.164 P<0.020
Further groups of 10 mice similarly treated were
implanted with 3LL and killed 3 weeks later when
the tumour was measured and metastases counted.
Mice receiving urokinase and stanozolol pro-
longing ECLT developed larger tumours and more
metastases. Host fibrinolysis thus affects malignant
growth and its manipulation may be of benefit in
limiting tumour spread.
Anti-timour activity and pharmacokinetics of
LM985 in mouse colon tumours
J.A. Double, M.C. Bibby & P.M. Loadman
Clinical Oncology Unit, University ofBradford,
Bradford BD7 JDP, UK.
NSC 293015 (LM985) is a chromone derivative
selected for clinical trials primarily for its activity
against colon tumour 38 as part of the NCI screen.
We have investigated its anti-tumour activity
against three differing transplantable adenocarci-
nomas of the mouse colon (MAC). Single i.p.
injection at maximum tolerated dose showed no
activity against MAC 1SA, moderate activity
against MAC 13 and produced a significant growth
delay against MAC 26. These responses against
MAC 13 and MAC 26 were considerably enhanced
by repeated injection 7 days later when greater than
90% tumour inhibition was seen in MAC 13 and
cures were achieved in MAC 26. Pharmacokinetic
studies using the method of Kerr et al. (Br. J.
Cancer, 52, 467, 1985) confirm the rapid degra-
dation of LM985 to LM987, the possible active
principle (t =96.5min in plasma at 370C in vitro).
Analysis ofplasma following different in vivo dose
levels of LM985 indicated a good dose response
relationship between levels of LM975 and the
administered dose. Analysis of area under the curve
for LM975 indicated a good relationship with
tumour responses (100mgkg-1, AUC =0.95+0.26
(s.e.) mgh- ml-1; 200mgkg-1, AUC=2.10+
0.31mgh-1ml-1; 400mgkg-1, AUC=3.89+0.54
mgh-1ml-1). The MAC system shows a good
correlation with human large bowel cancer with
responses only seen close to maximum tolerated
dose. These preliminary observations with LM985
would suggest that it or its metabolite LM975
may have a value in the management of large
bowel cancer but its ultimate clinical potential will
also depend on any acute and chronic toxicity
which need to be determined.154 PROCEEDINGS OF BACR 27TH AGM
Successful culture of gastric tumours by clonogenic
assay: Initial drug results
A.P. Simmonds', S.A. Smith' & C.S. McArdle2
'Cell Laboratory, Biochemistry Department and
2Department ofSurgery, Royal Infirmary, Glasgow,
UK.
We have cultured gastric tumours by clonogenic
assay and measured sensitivity of such specimens to
drugs in current clinical use. Tumour specimens
obtained were disaggregated mechanically and
2 x I05 viable cells exposed to adriamycin, cis-
platinum, methotrexate and 5-fluorouracil at 10%
peak plasma concentrations for 1 h. Drugs were
washed off and tumour cells plated in McCoy's
5A+ 10% FBS in 0.3% agar over an underlayer of
the same medium in 0.5% agar+ 1% rat rbc.
Incubation was at 370 C in 5% C02/air, high
humidity, for 12 days. Colonies stained with INT
violet were counted and drug effects expressed as
percentage survival of control, <50% being
sensitive. Of 9 patient samples tested, all grew with
PE from 0.015-0.05 (3/9 >0.03). Only 2/8 (25%)
were S to adriamycin, platinum and MTX and 1/8
(13%) S to 5FU. Resistance to 5FU was prnounced
(4/7 >70% survival) as was that to platinum (S
specimens <30% survival). Resistance to MTX and
adriamycin was also overt. Of 5 patients tested for
4 drugs, one was R to 4/4, 3 were R to 3/4 and 1 R
to 2/4. Of 4 patients tested with 3 drugs, 2 were R
to all and 2 were R to 1/3. One patient received
chemotherapy which was discontinued because of
toxicitiy. He was R to 3/4 drugs but S to platinum.
Since biopsy specimens came from patients with
'curative' resections, unlikely to receive drugs, the
value of this system lies in culture success and it
will now be used to investigate both new drugs and
modulators of cytotoxicity for management of
gastric cancer.
Responses of transplantable adenocarcinomata
of the mouse colon (MAC) to
N-[N'42-chloroethyl)-N-nitroso-carbamoyl](CNC)-
alanine and derivatives
M.C. Bibby & J.A. Double
Clinical Oncology Unit, University ofBradford,
Bradford BD7 JDP, UK.
2-chloroethyl-N-nitrosoureas are extremely effective
anticancer agents in experimental tumour systems.
Their clinical value is limited by their pronounced
and delayed bone marrow toxicity and the develop-
ment of new analogues with equally good anti-
tumour activity but with reduced toxicity would
provide a major contribution to cancer chemo-
therapy. Ehresmann et al. (Arch. Pharm. (Weinheim),
317, 481, 1984) have synthesised a series of nitro-
soureas in which the nitrosocarbamoyl residue was
linked to an amino acid or its derivatives. The
amide derivatives were subsequently shown to be
highly active against the L5222 rat leukaemia
(Zeller et al., J. Cancer Res. Clin. Oncol., 108, 249,
1984). The mouse adenocarcinoma of the colon
(MAC) series of transplantable tumours has been
shown to have a similar spectrum of chemo-
sensitivity to human large bowel cancer (Double
& Ball, Cancer Chemother. Rep., 59, 1083, 1975).
In this study the antineoplastic activity of
CNC-alanine, CNC-alanyl-alanine, CNC-alanine-
methylamide and CNC-glycine-methylamide was
examined in a solid line (MAC 13) and in an ascitic
line (MAC 15A). The compounds showed varying
degrees of activity with the methylamide derivatives
being highly active against both lines. CNC-alanyl-
alanine was the most active agent in this series
against the ascitic tumour, with a T/C of greater
than 400%. The activity of these compounds
against MAC 15A is particularly impressive as the
previous best recorded responses with this tumour
line seen with methylCCNU and mitozolomide are
only in the region of 170%. Studies on the delayed
and cumulative toxicity of these compounds par-
ticularly to the bone marrow are required to see
whether they are likely to have any therapeutic
advantage over the nitrosoureas in current clinical
use.
Drug resistance in carcinogen treated hepatocytes
H. James & M.J. Embleton
Cancer Research Campaign Laboratories, University
ofNottingham, University Park, Nottingham
NG72RD, UK.
The administration of three cycles of 0,06% 2-
acetylaminofluorene (AAF) diet to male Fischer
rats induces the formation of enzyme-altered foci
and hyperplastic nodules antecedent to hepatocarci-
noma. One of the reported characteristics of these
altered cell populations is a relative resistance to
certain chemical agents and carcinogens.
The effects of diethylnitrosamine (DENA), AAF
and cyclophosphamide on hepatocytes from control
or AAF-treated rats were determined using a short
term cytotoxicity assay. Hepatocytes were obtained
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nique and were transferred to a primary monolayer
cell culture system.
Following an attachment period, the cell cultures
were exposed to the effects of the chemical agents
at a range of concentrations for a total of 48h,
being pulsed with 75Se-selenomethionine after 24h.
The viability of the cells was assessed quantitatively
by their incorporation of the isotope. The toxic
effect of each drug was expressed as a percentage of
the survival in untreated cultures.
Preliminary results have shown that hepatocytes
from carcinogen-treated rats were less sensitive than
control hepatocytes to the toxic effects of AAF and
DENA, but were equally sensitive to those of
cyclophosphamide. This is observed at a time when
changes in enzyme activity and histological appear-
ance are evident in sections of altered-liver from
carcinogen-treated rats.
Comparison of dietary carbohydrate and fat on the
growth and cachectic effect of a transplantable
adenocarcinoma
R.A. Brennan & M.J. Tisdale
CRC Experimental Chemotherapy Group, Institute
ofPharmaceutical Sciences, Aston University,
Birmingham B4 7ET, UK.
The MAC 16 is a chemically induced transplantable
colon adenocarcinoma which produces extensive
weight loss in tumour-bearing animals. Weight loss
is directly related to the size of the tumour and
occurs without a reduction in food intake. In vitro
experiments show a high rate of glucose consump-
tion by MAC 16 cells and a low rate of palmitate
oxidation. In vivo the tumour is poorly vascularised
and might be expected to have a low oxygen
tension. The only metabolic substrate available for
use under such conditions is glucose, since the
Embden Meyerhoff pathway is the only means of
ATP production that does not require oxygen. In
order to investigate the effect of diet composition
on tumour growth rate and weight loss mice fed on
diets with increasing proportions of energy from fat
supplied as medium chain triglycerides (MCT) were
compared with mice fed additional calories as
sucrose. Mice consuming diets in which up to 80%
of their energy requirements were met by MCT
showed significantly lower weight-loss and de-
creased tumour size when compared with controls
fed normal laboratory pellets. However, tumour-
bearing mice fed a high carbohydrate diet had
significantly larger tumours and greater weight loss
than controls. These results suggest that it might be
possible to control tumour growth and weight loss
by feeding an appropriate diet.
Cancer control in GDR
A. Glaser
Chirurgische Klinik der Martin-Luther Universitat,
DDR 4020 Halle/Saale, Ernst-Grube-Str. 40 GDR
In 1952 the National Cancer Registry was founded.
Though every case of cancer has to be announced
to the registry with a complete follow-up of every
patient for 5 years, the incidence of cancer in-
creased heavily in the last 30 years depending on
improved registration by the time; e.g. cancer of the
rectum increased from 13.6 per 100,000 inhabitants
in 1961 to 20.3 in 1980. Six thousand, eight
hundred and twenty-eight cases of cancer of the
colon and rectum were counted in 1980 thus
occupying 3rd place in males and 2nd in females.
The 5-year survival rates differ greatly between
centres with comprehensive interdisciplinary ap-
proach, hospitals without comprehensive service
and hospitals treating less than 20 patients per year.
Therefore a system of organisation of cancer
control is to be established by founding cancer
centres in every administrative area.
Chemofluorescent location of leukaemic cells in
experimental animals
F.S. Steven', H. Jackson2, N.C. Jackson2,
M. Bock2 & T.L.H. Wong'
Department of'Biochemistry and Department Of
2Pharmacology, Stopford Building, University of
Manchester, Manchester M13 9PT, UK.
Our object has been to determine whether
leukaemic cells could be located by a fluorescent
marker for a cell surface protease (Steven et al.,
Eur. J. Biochem., 149, 35, 1985). A T-cell lympho-
blastic leukaemia in HO rats and the L1210 mouse
leukaemia were used for this purpose. The animals
were killed at intervals during the development of
leukaemia. The liver, kidney, testis and epididymis
were fixed in 10% formalin-saline. Frozen sections,
wax-embedded sections and resin sections were pre-
pared from each tissue. The sections were strained
with 9-aminoacridine to locate cells possessing the
cell surface protease. In all tissues the leukaemic
cells were clearly visualised by their chemofluor-
escense, these results being confirmed by con-156 PROCEEDINGS OF BACR 27TH AGM
ventional haematoxylineosin staining. We believe
that chemofluorescent staining is a valuable aid in
the assessment of leukaemic status before and after
drug therapy in animals. Chemofluorescent location
of leukaemic cells has the advantage that individual
cells can be clearly marked; these would possibly
escape detection by conventional staining.
animals including histological confirmation of
tumour viability are essential.
An in vitro model of oral carcinogenesis in rats
induced by 4NQO
S.S. Prime', J. Luker', I. Crane', A. Stone',
N.J. Maitland2 & C. Scully'
The 6-day subrenal capsule assay - limitations of
its use with primary surgical explants from gastric
adenocarcinoma
D. Cunningham', A. Jack2, M. Soukop',
D. McMurdo3, C.S. McArdle3, D.C. Carter3
& S.B. Kaye4
'Department ofMedical Oncology, 2University
Department ofPathology and 3Surgery, Royal
Infirmary, Glasgow and 4University Department of
Medical Oncology, I Horselethill Road, Glasgow,
UK.
The six day subrenal capsule (SRC) assay has been
used as a means of predicting the response of solid
tumours to chemotherapy. The method involves
transplantation of fresh surgical explants 1 mm3
under the renal capsule of normal immuno-
competant BDF I mice. The perpendicular
diameters of the implants are measured at the time
of transplantation and at the time of sacrifice using
a stereoscopic microscope with an oculometer. A
control group of mice is used to confirm viability of
transplanted tissue and hitherto, an increase in size
of 0.05 mm of the tumour diameters was considered
to indicate an evaluable assay. Inhibition of tumour
growth or a reduction in the tumour size of treat-
ment groups is used as a marker of
chemosensitivity.
We have transplanted tumour obtained from 17
patients with gastric cancer involving a total
(control and treatment groups) of 418 xenografts.
Using the above criteria, tumour from 14 patients
(82%) was viable. However, only 21 xenografts
(5%) contained tumour cells. The remaining xeno-
grafts consisted of fibrous tissue and a lymphocytic
infiltrate. An inflammation score was devised which
showed that the control groups had significantly
more infiltration (P<0.001) than the chemotherapy
groups (treated with 5FU, epirubicin, methotrexate
and cis-platin).
In gastric cancer, successful growth of surgical
explants in the SRC has not proved feasible. A
lymphocytic infiltration can produce apparent
growth in otherwise non-viable tumour tissue.
Stricter criteria for tumour growth in control
1University Department ofOral Medicine and Oral
Surgery and 2Department ofPathology, Bristol, UK.
Animal models of oral carcinogenesis enable more
controlled investigations into the pathogenesis of
such lesions. This report demonstrates for the first
time the successful transference of a rat model of
oral carcinogenesis into cell culture. Oral
carcinomas of the tongue and palate were induced
in Sprague-Dawley male white rats by painting
their palates 3 x weekly for 7-8 months with 0.5%
(w/v) 4-Nitroquinoline N-oxide (4NQO). Oral kera-
tinocytes from malignant and untreated control
tissues were cultivated using 3T3 fibroblast support
(Rheinwald & Green, Cell, 6, 331, 1975) and the
percentage of cells expressing anchorage indepen-
dence determined in gel culture (Macpherson &
Montagnier, Virology, 23, 291, 1964). In cell
culture, malignant keratinocytes were heterogeneous
with regard to cell size, shape and intercellular
packing unlike the regular organisation of the
normal cultures, but both the normal and malig-
nant cells stained positively with an anti-human
keratin polyclonal antibody. Malignant keratinocyte
cultures differed markedly from their normal
counterparts by a 5-fold increase in their growth
rate, the capacity for serial cultivation to the 16th
passage (to date), a loss of contact inhibition and
an independence of 3T3 fibroblast support. Malig-
nant keratinocytes expressed anchorage indepen-
dence in gel culture, whereas normal cells showed
no evidence of colony formation. The development
of this specialised cell culture system creates further
opportunities to investigate the pathogenesis of oral
squamous cell carcinomas.
Cell culture techniques to study colorectal cancer
C. Paraskeva & S. Powell
Department ofPathology, The Medical School,
University Walk, Bristol BS8 ITD, UK.
Cancer development in the large intestine is a good
example of the multistep nature of cancer. In thisPROCEEDINGS OF BACR 27TH AGM 157
malignancy it is thought that many, if not most,
cancers develop from premalignant adenomas in
what is often called the adenoma-carcinoma
sequence. To study the possible mechanism(s) and
factor(s) involved in the progression of adenomas
to carcinomas we have developed cell culture tech-
niques in which colorectal adenomas from both
familial polyposis coli and sporadic colorectal
cancer patients can be routinely grown in vitro.
These epithelial cells are grown in collagen coated
petri-dishes in the presence of mouse 3T3 feeder
cells in medium containing 20% foetal bovine
serum. The epithelial nature of the cells is con-
firmed by positive staining with keratin monoclonal
antibodies. The adenoma derived cell lines display
ultrastructural features characteristic of colorectal
epithelium including desmosomes, microvilli and
mucin droplets. The adenomas tested so far do not
produce tumours in athymic nude mice whereas
carcinoma derived cell lines reproducibly produce
tumours in athymic nude mice. Similarly the
adenoma cultures display no detectable chromo-
somal abnormalities whereas carcinoma derived cell
lines are invariably chromosomally abnormal. The
adenoma epithelial cell lines have been in culture
for various times; one of them, designated PC/AA,
appears to have become immortalised since it has
been in culture for -3 years. We are currently
using the adenoma derived cell lines in transfor-
mation experiments to try and understand how the
adenomas progress to carcinomas.
A trophic effect of EGF on rat colonic mucosa in
organ culture
K.J. Finney1, P. Ince1, D.R. Appleton2,
J.P. Sunter1 & A.J. Watson
'Department ofPathology, Royal Victoria Infirmary,
Newcastle upon Tyne NEI 4LP and 2 Department of
Medical Statistics, University ofNewcastle upon
Tyne, Newcastle upon Tyne, UK.
The development of an organ-culture system for rat
colonic mucosa has enabled a direct assessment of
the effect of epidermal growth factor (EGF) on cell
division. An augmented mitotic index (AIm) has
been employed to identify changes in cell
proliferation.
Explants of colonic mucosa from four animals
were maintained in a medium containing serum for
five days. On the fifth day of culture half of the
explants received EGF (40ngml-1) and the re-
mainder (controls) fresh medium only. At 6, 12, 24
and 48h thereafter both experimental and control
explants received vincristine (4yugml-1) for 3h prior
to fixation. Vincristine produces mitotic arrest and
so enables the proportion of dividing cells within
the explant to be determined. Analysis of the data
indicated that when serum is present exogenous
EGF exerts a trophic effect which increases with
time (P<0.001).
In a second experiment colonic explants from
four animals were maintained for five days in a
serum-free medium and were then divided into
groups each of which received one of a range of
concentrations of EGF. An AIm was determined for
each group after 36h. It was found that increasing
concentrations of EGF produce a small but signifi-
cant rise in cell proliferation (P<0.01). This effect,
however, was less pronounced than that seen when
serum was present.
These results suggest that EGF has a trophic
action on the colon and interacts with additional
factors found in serum.
Extended lifespan of fibroblasts cultured from
epithelial tumours
D. Wynford-Thomas, P. Smith, & E.D. Williams
Department ofPathology, University of Wales
College ofMedicine, Heath Park, CaridffCF4 4XN,
UK.
The ability to undergo an indefinite number of cell
divisions is a key feature of tumour cells. We have
investigated the possibility that changes in lifespan
of the supporting stromal cells also may be a
feature ofepithelial tumour development.
We have previously shown that long-term
elevation of serum thyroid-stimulating hormone
(TSH) levels induced by administration of goitrogen
(aminotriazole) leads initially to generalised thyroid
hyperplasia followed by the development of
multiple benign and eventually malignant epithelial
(follicular cell) tumours. Fibroblast monolayer
cultures were prepared from 8 normal, 8 hyper-
plastic and 3 tumour-bearing glands by multiple
collagenase/dispase digestion dollowed by filtration
through nylon mesh. Cells were grown in DME
medium supplemented with 10% foetal calf serum
and passaged 1 in 8 at confluence. Cell number was
assessed by hemocytometer counts of trypsinised
replicate cultures.
Cultures derived from normal glands ceased
growth (senesced) after an average 6.6+ 1.0
doublings (mean +s.e. of 8 replicates). Those from
hyperplastic glands showed a significant (P<0.01)
extension of lifespan to 16.6+2.1 doublings but all
have undergone senescence. All replicate cultures
from 3 tumour-bearing glands have failed to show158 PROCEEDINGS OF BACR 27TH AGM
any reduction in growth rate up to the present
time, and have undergone 53, 55 and 70 doublings
respectively. No spontaneous foci of transformants
have been observed and the cells still show normal
density-dependent growth inhibition and anchorage
dependence. We conclude that fibroblast-like cells
from epithelial-tumour bearing thyroids have a
greatly extended lifespan and may be truly
immortalised.
Unaffected children of patients with familial breast
cancer have abnormal skin fibroblast phenotypes
J.A. Haggiel, S.L. Schorl, A. Howell'
& R.A. Sellwood2
'Department ofMedical Oncology, Christie Hospital
and 2Department ofSurgery, Withington Hospital,
Manchester, UK.
Adult and foetal fibroblasts can be distinguished in
vitro by their different migratory phenotypes in 3D
collagen cells. We have previously shown that
foetal-like migratory patterns are found commonly
in the skin fibroblasts of breast cancer patients. In
order to try and ascertain if this anomaly antedates
the development of cancer we have studied the skin
fibroblasts of unaffected children of patients with a
family history of breast cancer as this group have a
cumulative lifetime risk of - 50% of developing
breast cancer themselves. The skin fibroblasts from
pre-menopausal patients with breast cancer and a
family history (defined as the presence of 2 1st
degree relatives from consecutive generations with
breast cancer), each with a corresponding un-
affected child were studied using a migration assay
as previously described (Schor et al., J. Cell. Sci.,
73, 221, 1985).
All 7 patients and 4/7 of their unaffected children
(median age 21: range 12-28) showed foetal-like
migratory fibroblast phenotypes. Forty-three per
cent of breast cancer patients without a family
history have a foetal phenotype (Schor & Haggie,
Int. J. Cancer, in press).
These data indicate that breast cancer patients
with a family history have a greater chance of
showing a foetal migratory phenotype than those
without a family history. The presence of the
abnormal phenotype in 57% of their children
suggests that this anomaly may antedate the de-
velopment of breast cancer and may also be linked
with their high breast cancer susceptibility,
Increased erythrocyte stearic acid desaturation in
rats with chemically induced colorectal carcinomas
N.A. Habib', R. Salem2, M. Hershman2,
K. Apostolov3, R.C.N. Williamson1 & C.B. Wood2
'Department ofSurgery, Bristol Royal Infirmary,
Bristol and Departments of2Surgery and 3Virology,
Royal Postgraduate Medical School, London, UK.
It has been shown that malignant transformation of
cells is associated with an increase in membrane
fluidity, predominantly due to increase of the oleic
acid content of membrane lipids relative to stearic
acid. Desaturation of the lipid layer of erythrocytes
has been noted in patients with malignancies. This
study investigated the stearic acid desaturation in
red blood cell membranes of rats during the in-
duction of colorectal tumours. Male Sprague-
Dawley rats were injected weekly with dimethyl-
hydrazine (DMH) and sacrificed at four weekly
intervals. Blood was withdrawn via heart puncture,
collected in EDTA bottle and erythrocytes
separated by centrifugation. Total lipid extraction
was carried out and analysed with gas liquid
chromatography. In the control rats (injected with
normal saline) the mean of the stearic to oleic acid
ratio in erythrocyte membranes was 2.0+0.3
(n=30, range 1.6-2.6) compared to a mean of
0.94+0.2 (n=30, range 0.5-1.57) in tumour bearing
rats (P<0.001). The increased desaturation
occurred in parallel with appearance of tumours.
These data suggest the regulation of stearic acid
desaturation is an important adaptive mechanism of
membrane fluidity and could be a useful chemical
marker for malignancy.
Erythrocyte stearic acid desaturation in patients with
colorectal carcinomas
N.A. Habib', M.J. Hershman2, P. Carter2,
K. Apostolov3, R.C.N. Williamson' & C.B. Wood2
'Department ofSurgery, Bristol Royal Infirmary,
Bristol and Departments of2Surgery and 3Virology,
Royal Postgraduate Medical School, London, UK.
Patients with cancer often suffer systemic effects of
the disease suggesting that the tumour produces a
factor(s) which act on the normal cells and are
responsible for the systemic changes. To assess this
phenomenon we have studied the desaturation of
erythrocyte cell membranes in patients with large
bowel cancer. Total lipid extracts of erythrocyte cell
membranes from 50 normal subjects, 20 patientsPROCEEDINGS OF BACR 27TH AGM 159
with inflammatory bowel disease and 44 patients
with colorectal carcinoma were analysed by gas
liquid chromatography (GLC). The ratio of stearic
to oleic acid was obtained from the GLC tracing
and was expressed as the saturation index (SI). The
mean SI in cancer patients (0.71+0.22) was about
half the value in normal subjects (1.54+0.32;
P<0.001), and in those with inflammatory bowel
disease (1.30+0.4; P<0.001). Following radical
resection the SI increased above unity, only to fall
again with the onset of tumour recurrence. Thus, it
would appear that a desaturation producing factor
is being released by the malignant cells. The
erythrocyte SI is therefore of potential value in the
diagnoses and postoperative monitoring of patients
with carcinoma of the large bowel.
Urinary 3-methyadenine as a marker of in vivo
methylation of DNA
E. Bailey, P.B. Farmer & D.E.G. Shuker
MRC Toxicology Unit, Woodmansterne Road,
Carshalton, Surrey SM5 4EF, UK.
The urinary excretion of 3-methyladenine (3-MeA),
following its excision from methylated DNA, could
be a marker of exposure to a methylating
carcinogen.
In rats 3-MeA appears to be unmetabolised with
>95% of oral and i.p. doses of 3-[3H3]MeA being
excreted unchanged in the urine over the 24h
period post-dosing (cf Hanski & Lawley, Chem.
Biol. Interact., 55, 225, 1985).
A method has been developed for the deter-
mination of unlabelled 3-MeA in urine. 3-MeA was
isolated on an XAD-2 column, purified using C,8
reverse phase HPLC, and converted to the stable
N6-(tert-butyldimethylsilyl) derivative. With 3-
[2H3]MeA as the internal standard, quantitation of
3-MeA was carried out by gas chromatography-
mass spectrometry using characteristic ions (m/z
206[do] and m/z 209 [d3]). Acceptable overall
recoveries (ca. 50%) were obtained using 3-
[3H3]MeA as a marker.
In preliminary experiments we have found low
levels of 3-MeA in urine (<10,Ig24h-') of humans
nominally unexposed to methylating agents.
We are currently confirming the presence of 3-
MeA in human urine and determining whether
levels are increased following exposure to
nitrosatable drugs or other potential methylating
agents.
Relevance ofendogenous nitroso compounds in
cirrhotics and patients with hepatocellular carcinoma
N.A. Habib1, C. Smadja',
H. Ohshima2, H. Bartsch2 & C.B. Wood1
'Department ofSurgery, Royal Postgraduate
Medical School, London and 2'nternational Agency
for Research on Cancer, Lyons, France
N-nitroso compounds (NOC) are carcinogenic and
are mainly formed endogenously following nitro-
sation of precursors amines. The amount of urinary
nitrosoproline (NPRO) excreted 24h-1 is an index
of endogenous nitrosation and can be analysed by
gas chromatography. We measured the urinary
NPRO in 18 control patients, 23 cirrhotics and 16
with primary hepatocellular carcinomas (8 with and
8 without liver cirrhosis). We found that the mean
of NPRO in ,ug24h-' were 1.2+0.95 in the
controls, 5.5+1.56 in the cirrhotics and 6.0+0.74
in the cancer patients (P<0.001). There was no
significant correlation between the presence or
absence of cirrhosis in patients with hepatocellular
carcinoma. Thus, the high urinary NPRO observed
in the cirrhotic patients reflects their high exposure
to endogenous carcinogens and therefore their
susceptibility to form carcinomas.
The detection of colorectal carcinomas with the use
of CA-50 radioimmunoassay inhibition test
N.A. Habib', M.J. Hershman2, J. Holmgren3,
L. Lindholm3, R.C.N. Williamson' & C.B. Wood2
'Department ofSurgery, Bristol Royal Infirmary,
Bristol, 2Royal Postgraduate Medical School,
London and 3Department ofMedical Microbiology,
University ofGoteborg, Sweden.
Tumours may secrete or express on their cell
surfaces 'foetal components' not normally present
in adult cells, which may circulate and be detected
in serum as 'oncofoetal antigens'. We used a radio-
immunoassay for the detection of the human
carcinoma-associated antigen CA-50 in the serum
of 50 normal subjects, 16 patients with inflam-
matory bowel disease and benign polyps and 77
patients with primary and secondary colorectal car-
cinomas. Serum levels in all normal patients and
those with benign disease were below 17Uml-1,
while 40 of 77 (51%) patients with carcinoma had160 PROCEEDINGS OF BACR 27TH AGM
levels above 17 Uml-1. The sensitivity of this test
was 22% for Duke's A carcinoma, 29% for Duke's
B, 59% for Duke's C and 73% for metastatic
disease. The CA-50 levels were elevated in 7 of 9
(78%) patients who developed tumour recurrence
following curative surgery compared to 15 of 43
(35%) patients who are alive today and tumour free
(P<0.05). Therefore, this test may prove useful in
the diagnosis and prognosis of patients with colo-
rectal carcinomas.
Cyclic nucleotides - possible tumour markers?
A.C. Williams & P.A. Light
Research Laboratories, Radiotherapy and Oncology
Centre, Bristol Royal Infirmary, Bristol BS2 8ED,
UK.
Cyclic nucleotides are important regulators of
cellular function and are implicated as factors in
the determination of cellular growth and differen-
tiation, although their actual role is still unclear.
The object of this study was to determine
whether there were any detectable changes in extra-
cellular cyclic nucleotide concentration with the
presence of a tumour, and whether any such
changes could be used to monitor the development
of the tumour.
Cyclic adenosine 3'5'-monophosphate (cAMP)
and cyclic guanosine 3'5'-monophosphate (cGMP)
were measured in 24h urine specimens from guinea
pigs by radioimmunoassay. Measurements were
taken before and after the guinea pigs were inocu-
lated with L2C leukaemia. A transient increase in
cGMP concentration occurred 3 days after inocu-
lation, which preceded any detectable change in the
white blood cell count. This peak was found to be
highly significant when compared with fluctuations
in urinary cGMP concentration in the guinea pigs
before transplantation of the leukaemia, or after
inoculation with irradiated L2C cells.
Urinary cyclic nucleotide concentrations were
therefore measured in patients with malignant
diseases, and it was found that in specific groups of
patients abnormally high urinary cGMP concen-
trations correlated well with the status of their
disease.
Birth cohort effect on cervical cancer incidence in the
West Midlands
C.A. Meanwell1, C. Roginski2, K.A. Kellyi,
S. Wilson2 & G. Blackledgei
I West Midlands CRC Clinical Trials Unit and 2West
Midlands Regional Cancer Registry (WMRCR), UK.
Recent changes in age-specific mortality rates for
invasive cervical cancer in England and Wales have
important implications with respect to current views
on cervical cancer aetiology and management. We
were therefore prompted to examine trends in
cervical cancer incidence in the West Midlands.
Case records of women with stage 11B-4B (Inter-
national Federation of Gynaecology & Obstetrics
staging) carcinoma of the cervix uteri registered
with WMRCR since 1957 were examined. The
percentage frequency of cases falling in the age
group 20-39 years rose from 9% (43 cases) in 1970
to 31% (152 cases) by 1978 to produce a bimodal-
type distribution. There was a slight decrease in
registration rates and shift of the mode for older
patients. Further analysis revealed a strong birth
cohort effect. Women born between 1885 and 1894
or between 1920 and 1929 had high risk of develop-
ing cervical cancer in old or middle age relative to
other cohorts. For women born between 1930 and
1959 there was a marked, progressive increase in all
available age-specific registration rates. These ob-
servations must be interpreted against a complex
background of confounding factors. Nevertheless,
the data indicate that there has been a large
increase in cervical cancer incidence in young
women since the early 1970s and that this trend
mainly reflects a birth cohort effect. The existence
of other 'high risk' cohorts with increased incidence
in middle or old age also suggests (1) that the
current 'young' cohort may remain at relatively
high risk throughout their lifetime and (2) that
studies of aetiology in cervical cancer should not
focus solely upon 'current events' such as use of the
oral contraceptive pill.
Cancer risk in duodenal and gastric ulcer patients
after surgery
C.P.J. Caygill, M.J. Hill, J.S. Kirkham
& T.C. Northfield
PHLS-CAMR, Salisbury, Wiltshire SP4 OJG and
Gastroenterology Unit, St. James Hospital, Balham,
London SW12 8HU, UK.
A detailed analysis of 4,466 patients, using a 'yearsPROCEEDINGS OF BACR 27TH AGM 161
at risk' calculation in 5 year bands showed that
duodenal ulcer (DU) patients, after surgery, had an
initial decrease in risk of mortality from gastric
cancer for the first 20 post-operative years followed
thereafter by a 4-fold excess risk. Gastric ulcer
(GU) patients, however, had a 3-fold excess risk
throughout the first 20 post-operative years in-
creasing to a 5.5-fold excess risk thereafter.
For cancer of the biliary tract there was a non-
significant excess risk of mortality for DU patients
but GU patients had a 15.8-fold excess mortality
risk 20 or more years after gastric surgery. This
excess risk appears to be exclusively in the gall-
bladder and is not found in the bile duct. Neither
site had any excess risk within the first 20 years.
For cancer of the pancreas there was a non-
significant decrease in mortality within the first 20
years followed by a 4-fold increase. After 20 years
both DU and GU patients have an excess risk of
pancreatic cancer mortality which is greater in GU
(7-fold) than DU (3-fold) patients.
One possible explanation for these site specific
excess cancer risks in gastric surgery patients is the
production of N-nitroso compounds in the hypo-
chlorhydric stomach. This would explain the
greater excess in GU than DU patients at all three
sites, since a proportion of GU patients will already
be hypochlorhydric at the time of surgery.
Pre-operative staging of rectal cancer with
transrectal ultrasound
J. Beynon', A. Roe1, D.M.A. Foy3, L.N. Temple4,
N.J.McC. Mortensen1 & J. Virjee2
Departments of 1Surgery, 2Radiology, 4Pathology
and 3Medical Physics, Bristol Royal Infirmary,
Bristol, UK.
Local invasion and para-rectal lymph node involve-
ment in rectal cancer is currently assessed by digital
examination which is highly subjective and related
to surgical experience. Using an ultrasound scanner
type 1846 (Bruel and Kjaer, Denmark) the effect-
iveness of endoluminal sonography in predicting
invasion and lymph node involvement is being
evaluated. Rotating 5.5 and 7.0 MHz transducers
provide 360° scans of the rectum and para-rectal
tissues. Examinations have been performed on 44
primary rectal cancers and results compared in 39
cases with histopathological findings and in 3 cases
with laparotomy observations. Local invasion was
graded according to the UICC classification. Sono-
graphically 5 cases were TI, 8 cases T2, 27 cases T3
and 4 cases T4. The coefficient of correlation
between sonographic and histopathological findings
was 0.93 (P<0.001). Invasion beyond the
muscularis propria was predicted with a sensitivity
of 97%, specificity of 92% and had a predictive
value of 97%. Lymph node involvement was
predicted in 19 cases. Correlation with histopath-
ology revealed the technique to have a sensitivity of
93%, specificity of 74% and predictive value of
68%.
Endoluminal ultrasound staging of rectal cancer
is more accurate than digital evaluation and its use
pre-operatively aids the planning of subsequent
treatment.
Prognostic factors and scoring system in small cell
lung cancer patients
T. Cerny1, V. Blair2, H. Anderson1 & N. Thatcher'
CRC Department ofMedical Oncology and
2Department ofStatistics, Christie Hospital,
Manchester, UK.
In 407 patients with small cell lung cancer (SCLC)
60 variables were evaluated in a Cox Multi-
regression Analysis to assess their prognostic value.
All patients received a short term intensive regimen
(cyclophosphamide, etoposide and methotrexate or
ifosfamide and etoposide, both followed by thoracic
irradiation, ifcomplete response was noted).
LDH (P=0.0001), stage (P=0.001), sodium
(P=0.0321), pre-treatment Karnofsky performance
score (KP, P=0.0009), alkaline phosphatase
(P=0,0186) and C02 (P=0.0321) were the only
prognostic significant factors. After allowing for
these 6 variables, the treatment modality was not a
significant factor. A simple scoring system using
these variables was established (Table), and shows
little loss of information compared to the Cox
analysis results. The group with a score of <2
included most of the long term survivors (15% over
2 years survival) whereas in the group with a score
of 2 and 3, only 4% and with a score of >4, no
long term survivors were found. This scoring
system may help to design new treatment strategies,
and may also facilitate the comparison of different
studies.
Scorefor SCLC
+ 1: if LDH >450iuPl-
+ 1: ifextensive disease
+ 1: if sodium < 132mmol 1
+1: if KP<60
+ 1: if alk.phos. > I10iuI
+1: ifC02<24mmolP1162 PROCEEDINGS OF BACR 27TH AGM
A computerised system for reporting phase II studies
C. Hilton, N. Stuart, K.A. Kelly, J. Kavanagh,
F. Lawton & G. Blackledge
West Midlands CRC Clinical Trials Unit
(WMCRCCTU), UK,
Phase II clinical trials play an essential role in the
introduction of new anti-cancer agents. After
formulation of the new treatment and initial
toxicity testing in a Phase I study, Phase II aims to
assess response in specific diseases and to document
toxicity. Many new anti-tumour agents are being
developed generating a large number of Phase II
studies, with some 30 to 40 being carried out at any
one time in the WMCRCCTU alone. The require-
ments of these studies are similar and a standar-
dised approach would improve the quality of the
data collected and analysis. A unified system
including general data collection forms and
computerised data input and reporting facilities has
been developed. Statistical analysis and graphical
representation of the data uses programs from the
statistical package BMDP. The main features of the
system developed by the WMCRCCTU will be
described by reference to a Phase II study of cis-
platinum, adriamycin and bleomycin followed by
escalating cyclophmsphamide consolidation in
advanced epithelial ovarian cancer.
Clinical investigations with trimelamol (N2,N4,N6-
trihydroxymethyl-N2,N4,N6-trimethylmelamine):
Phase I study with 2 dose schedules and evaluation in
ovarian cancer
I.R. Judson, C.J. Rutty, L. Gumbrell, G. Abel,
K.R. Harrap & A.H. Calvert
Drug Development Section, Inst. Cancer Res.,
Sutton, Surrey, UK.
Trimelamol is an analogue of HMM and PMM
undergoing clinical trial at the Royal Marsden
Hospital. It is less neurotoxic than PMM in rodents
due to reduced CNS penetration and has proved
less toxic and probably more active in man. Unlike
PMM it does not require metabolic activation and
produces much higher plasma levels of cytotoxic N-
hydroxymethylmelamines in patients. Sixty-four
patients, 43 with ovarian cancer, have been treated
either by single i.v. infusion every 3 weeks at 25-
2,400mgm-2 or with 3 daily doses of 400-
900mgm-2 every 3 weeks. Pharmacokinetic
analysis in 4 patients treated at 1,500mgm 2 gave
a mean plasma AUC 3,164uM.min which
compares favourably with the observed AUC of
2,834yM.min at 90mgkg-' i.v. in the mouse, the
ED90 versus the PC6 tumour. Myelosuppression,
mainly leukopenia, was dose-limiting for the single
dose schedule, median WBC nadirs at 1,800, 2,100
and 2,400mgm-2 were 4.0, 2.6 and 1.1x1091-1.
Thrombocytopenia was rare but some patients
required transfusion for drug-related anaemia.
Doses > 1,500mgm-2 caused WHO grade III
nausea and vomiting but no acute sedation. The 3-
day schedule was better tolerated and probably less
myelosuppressive, WBC nadirs at 700, 800 and
900mgm-2 x3 were 4.8, 3.0 and 2.8x 1091-1.
Responses have been observed in Hodgkin's
disease, colon and ovarian cancer at doses
>1,500mgm-2. The ovary patients were cis- or
carboplatin resistant or in 2nd/3rd relapse.
Responses were - 'single dose' (18 pts): CR 1; PR
3; MR 5 (22%) and '3-day' (8 pts): CR 0; PR 2;
MR 1 (25%). This promising activity requires
confirmation in a larger group ofpatients.
A Phase I study of Methylene Dimethane Sulphonate
D.B. Smith1, B. Fox2, N. Thatcher', J.H. Scarffe1,
J. Wagstaff', W.P. Steward1 & D. Crowther'
1CRC Departments ofMedical Oncology and
2Experimental Chemotherapy, Christie Hospital and
Paterson Laboratories, Manchester, UK.
Methylene Dimethane Sulphonate (MDMS) is the
first (Cn= 1) member of a homologous series of bi-
functional alkylating agents and MDMS is of
interest because its small molecular size allows
access to alkylating sites not available to larger
molecules. The starting dose for this study was
14mgm 2 (1/10th mouse LD1O) and escalation
used a modified Fibonacci search scheme. Twenty-
eight patients with advanced solid tumours have
been studied at 8 dose levels. No significant toxicity
was seen at doses below 100mgm-2. The
haematological toxicity at higher doses is
summarised below:
Dose Patientsl WBC x 109 1-1 Platelets x 1991-
mgm 2 Courses median (range) median (range)
125 7/8 1.8 (0.8-3.7) 64 (21-176)
170 6/10 2.5 (1.2-5.4) 46 (11-221)
225 1/1 0.6 11
In previously untreated patients wbc and platelet
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whereas in previously treated patients nadirs oc-
curred at day 14 with recovery delayed until day
30-42. GI toxicity was only seen above 125 mgm2
and was mild, affecting only 25% of patients. Total
alopecia occurred at doses above 125mgm-2 with
varying degrees of loss at lower doses. There was
no renal, hepatic or local toxicity. There has been
one PR in a patient with locally advanced
pulmonary carcinoid who received 225mgm -2. The
MTD for MDMS as a single bolus injection is
225mgm 2, the dose limiting toxicity being
thrombocytopenia. The recommended doses for
phase II studies are 125mgm-2 q35-42 days in
poor risk patients and 170mgm-2 q28 days in
good risk patients.
Neither blood group nor blood transfusion af-
fected subsequent survival but expression by the
tumour of blood group antigen H, in blood group
0 individuals, conveyed a significant survival
advantage.
The effect of peri-operative blood transfusion on
colorectal cancer recurrence
N.R. Parrott, T.W.J. Lennard, B.K. Shenton,
G. Proud, R.M.R. Taylor & I.D.A. Johnston
Blood transfusion blood group and blood group
antigen expression in colorectal cancer
N.C. Armitage, I.O. Ellis & J.D. Hardcastle
Departments ofSurgery and Histopathology,
University ofNottingham, Nottingham, UK.
It has been suggested that blood transfusion may
bear an adverse effect on survival in patients with
colorectal cancer and that expression by the tumour
of blood group antigens may also be related to
survival. One hundred and ninety-nine patients with
colorectal cancer, with at least 5 years follow-up,
were studied. Patients' blood group and trans-
fusions given were noted. In 104 cases the tumours
were stained for the presence of blood group anti-
gen H (Blood group 0 substance) by immuno-
histology using a monoclonal antibody and assessed
by two observers. There was no survival advantage
to any particular blood group. Fifty-two of 127
(40%) patients who were transfused survived 5
years, compared with 33/72 (46%) who were not
transfused (X2 =0.27, P=NS). Expression of blood
group antigen H by the tumour was associated with
a significantly improved survival.
5 year survival
H Positive H Negative
Blood Group 0 individuals 12/27 (44%) 1/18 (5%)*
Others 11/30 (37%) 7/29 (24%)t
Overall 23/57 (40%) 8/47 (17%)t
*X2=6.17 P<0.02 tX2=0.55 P=NS tX2=5.6 P<0.025
Department ofSurgery, Medical School, University
ofNewcastle upon Tyne, Newcastle upon Tyne
NE2 4HH, UK.
Nine hundred and one cases of colorectal cancer
treated between 1974 and 1985 have been reviewed
noting those who received peri-operative blood
transfusion, and those who did not. Information
was retrieved from case notes, microfilms, and
transfusion records. The recurrence rates of
tumours in each of the two groups have been
analysed. Three hundred and eighty-four patients
were excluded: 136 with metastases at operation;
106 had palliative surgery; 76 peri-operative deaths
and 66 with incomplete data. This left 517 patients
for analysis. Of these 373 (72%) received trans-
fusions and 144 (28%) did not. The two groups
were comparable in terms of age*, sex
distributiont, Duke's stagingt, histological differen-
tiationt, site of colonic lesiont and duration of
follow up*. The transfused group contained signifi-
cantly more rectal lesionst (P<0.001), had longer
operations*, (2.35 vs. 1.90h) (P<0.001), and a
greater operative blood loss* (837 vs. 333ml)
(P<0.001). In the transfused group there were 169
cases of tumour recurrence (45.3%) compared with
41 in the non-transfused group (28.4%). This
difference was highly significantly to the detriment
of the transfused patientst (P<<0.001). A similar
trend was seen in cancer related deaths; transfused/
non-transfused= 130/30 respectively (P<0.01)t.
The results of this study strongly suggest that peri-
operative blood transfusion may be significantly
detrimental to patients undergoing curative surgery
for colorectal cancer.
*Analysed by unpaired T test. tAnalysed by Chi-squared.164 PROCEEDINGS OF BACR 27TH AGM
Role of functional oestrogen receptors as biochemical
marker in breast cancer
U. Verma, K. Murugesan, K.R. Laumas,
B.M.L. Kapur & A. Farooq
Department ofReproductive Biology and Surgery,
All India Institute ofMedical Sciences, New Delhi
110029, India.
The role of oestrogen receptor (ER) assays in
determining therapeutic strategies for advanced
breast cancer is well established. Translocatable
receptors are categorised as 'functional'. In the
absence of nuclear translocation the tumour may be
scored as a false positive. Tissue from 114 primary
breast carcinomas and 10 metastatic axillary lymph
nodes from 59 pre- and 55 post-menopausal women
was screened for oestrogen receptors with a cut-off
value of 3fmol and lOfmolmg-1 protein respec-
tively, and 35 primary breast carcinomas were
screened for nuclear oestrogen receptors with a cut-
off value of 10fmol 100 ig1 DNA, with the results
as shown:
ER Pre-menopausal Post-menopausal
Total cytosol+ 54% 58%
Total nuclear+ 62% 57%
Cytosol+nuclear+ 44% 35%
Cytosol+nuclear- 9% 22%
Cytosol-nuclear+ 14% 18%
Cytosol-nuclear- 33% 25%
To rule out any defect in translocation step, the
functional or translocatable ER were quantitated in
a cross incubation study with breat cancer nuclei
and receptor rich uterine cytosol. Data indicated
that any tumour which contained cytosolic ER but
had translocation defect might not be hormone
dependent, while any tumour having low ER level
and intact nuclear translocation step might respond
to antioestrogen therapy. The study suggested that
evaluation of functional ER level would reduce the
number of tumours scored as false positive and
false negative.
Isolation of cloned cDNAs from mRNAs associated
with tumour progression and metastasis in colorectal
cancer
P. Elvin', I.B. Kerr2, G.D. Birnie'
& C.S. McArdle3
'Beatson Institutefor Cancer Research and
University Departments of2Pathology and 3Surgery,
Royal Infirmary, Glasgow, UK.
It is well recognised that the development of meta-
static disease in colorectal cancer is the most critical
prognostic factor. Furthermore, there is evidence to
suggest that these tumours may behave consistently
as metastasising or non-metastasising variants.
However no clinically applicable means of pre-
dicting the metastatic potential of a primary
tumour exists and the biological basis of metastasis
remains poorly understood.
Phenotypic changes associated with the
emergence of a metastatic population would be
characterised by changes in gene expression. We
have constructed cDNA libraries from the
poly(A)+ RNA of normal colonic mucosa and a
liver metastasis from a colonic adenocarcinoma.
Screening of these libraries using 32P-labelled
cDNA probes from poly(A)+ RNA of clinically
and histologically documented samples of normal
colonic mucosa, adenamatous polyps, adenocarci-
nomas and liver metastases by Grunstein-Hogness
and dot blot hybridisation has identified a number
of recombinant cDNA clones showing markedly
altered expression in the metastases relative to
normal and neoplastic colon.
These cDNA clones, and others identified in the
libraries may be of considerable clinical importance
both as diagnostic tools and in defining the pheno-
typic changes associated with tumour progression
and metastasis.
Rejoining of DNA strand breaks in BL6 murine
melanoma and its metastases
G.V. Sherbet, S. Jackson & A.L. Harris
Cancer Research Unit, University ofNewcastle upon
Tyne, Royal Victoria Infirmary, Newcastle upon
Tyne NE] 4LP, UK.
The metastatic variants of the BL6 murine
melanoma show differences in sister chromatid
exchange (SCE) compatible with their metastatic
potential. The high metastasis variant BL6 shows
higher SCE than the low metastasis variant Fl.
Intracranial tumours such as gliomas, which do not
ordinarily metastasise to extracranial sites, show
low levels of SCE. This suggests that genetic re-
arrangement may be associated with the evolution
of the metastatic phenotype (Sherbet et al., J. Cell
Biochem., Suppl. 1OA, 57, 1986). Since SCE occurs
under conditions of reduced DNA repair, it may be
predicted that primary tumours would repair DNA
damage more rapidly than their metastases.
The rejoining of bleomycin-induced strand breaks
in [3H]-thymidine labelled DNA of BL6 and cell
lines derived from its metastatic deposits (BL6-ML)
was therefore examined by alkaline sucrose sedi-PROCEEDINGS OF BACR 27TH AGM 165
mentation. Degree of rejoining was quantified by
determining % radioactivity found in high mol. wt
DNA at various intervals of cell recovery and the
half-maximal repair time. In BL6 cells, the rate of
repair was 41+12% h- (n=5). In contrast, in
BL6-ML cells the rate of repair was 14+3%h-1
(n=5). The difference was statistically significant
(P<0.005) The half-max. repair time was 0.5 and
1.2h respectively for BL6 and BL6-ML cells.
Metastatic heterogeneity: Karyotypic evidence for
genetic drift as a post-dissemination event
D.M. Teale & R.C. Rees
Department of Virology, Sheffield University
Medical School, Beech Hill Road, Sheffield
S10 2RX, UK.
The heterogeneity of primary tumours is now
recognised as the probable origin of the diverse
phenotypes associated with cell lines derived by
spontaneous or artificial metastases. This pheno-
menon has been investigated further in a spon-
taneously metastatic HSV-2 induced hamster fibro-
sarcoma model, using in vivo and in vitro derived
sublines, which differed with respect to their NK
susceptibility, immunogenicity, metastatic potential
and karyotypic make-up. Using flow cytometry, the
diploid karyotype was consistently associated with
the metastatic phenotype, whilst a higher ploidy
number was correlated with the non-metastatic cell
lines. The parent cell line however, shown to be
weakly/non-metastatic, was uniformly tetraploid
with no minority diploid population pre-existing
within the tumour.
We conclude that in this model an unusually
distinct and readily distinguishable genotype
(diploid) is associated with the metastatic pheno-
type. In this system, metastasis would appear not to
be the expression of strongly selected variant cells
pre-existing within the primary neoplasm, but a
genotypic drift towards the metastatic phenotype as
a post-dissemination event.
Analysis of cellular DNA content of fixed cell
aspirates of breast carcinoma using flow cytometry
A. Owainatil, R.A. Robins', M. WilliamS2,
C. Hinton2, C. Dowle2, R.W. Baldwin'
& R.W. Blamey2
'Cancer Research Campaign Laboratories and
2Professorial Unit ofSurgery, Nottingham
University, Nottingham NG7 2RD, UK.
The purpose of this study is to overcome incon-
venience in preserving tumour cells, for DNA
analysis, during the time lapse between sampling
and analysis.
Cell samples from 29 human breast carcinomas
were obtained by suction aspiration from the
tumour mass. Each sample was divided into two.
One aliquot was fixed in 10% formalin. Cells in
the other aliquot were preserved fresh in sterile
Eagle's minimal essential medium at 40 C until
analysed. Fixed cells were washed twice with dis-
tilled water and digested with 0.5% pepsin. Isolated
nuclei were stained with 1 ugml-I diamidinophenyl
indol (DAPI). From the fresh sample, suspensions
of tumour cells obtained by 1% collagenase
were stained with a combination of mithra-
mycin (93.6mgml-1) and ethidium bromide
(37.5mgml-1). Both samples were analysed by flow
cytometry (Becton Dickinson FACS IV).
Twenty-six of the 29 samples (90%) showed
considerable modal DNA values. Those that did
not, had poorly resolved histograms because of low
numbers of cells. Further comparison between
modal DNA values of single tumour cells dis-
sociated from solid tumour and fresh suction
aspirates from the same tumour, showed a similar
high rate ofcomparability (48 out of 50, P<0.0001).
This study shows comparability between DNA
modal values of solid tumours and suction
aspirates, fresh or formalin fixed. This choice of
preparation allows tumour samples to be preserved,
stored and transported conveniently at room
temperature before analysis. This, plus overall speed
and patient acceptability, means that repeated
sampling of inoperable tumours becomes feasible
and tumour cell DNA can be monitored during
cytostatic and endocrine treatment in relation to
tumour progression.
Flow cytometric analysis of the DNA content of
primary breast carcinomas: Relationship to survival
and other prognostic parameters
A. Owainatil, R.A. Robins1, C. Hinton2,
M. Williams2, I. Ellis3, C.W. Elston3,
R.W. Baldwin' & R.W. Blamey2
'Cancer Research Campaign Laboratories,
2Professorial Unit ofSurgery and 3Department of
Pathology, University ofNottingham, Nottingham
HG7 2RD, UK.
Cellular DNA content of primary tumours from
268 patients with operable breast carcinoma was
determined by flow cytometry using nuclei from
paraffin sections stained with DAPI. Seventy-three166 PROCEEDINGS OF BACR 27TH AGM
of them have been further analysed for their DNA
content using single suspension of fresh tumour
cells stained with mithramycin and ethidium
bromide. One hundred and ninety-nine were
followed for 7-13 years after surgery. Histological
grading, according to Bloom and Richardson, was
on a scale of 1 to 3, well to poorly differentiated
tumours respectively. Mantel's life table analysis
was used to compare survival between different
patient groups.
Overall 66% of the tumours contained aneuploid
populations. Survival was not significantly different
in patients with diploid and aneuploid tumours.
Aneuploidy was, however, significantly related to
histological grade, as has been found by others.
Thus 11/49 (22%) grade 1, 55/97 (59%) grade 2,
and 92/125 (72%) grade 3 tumours were aneuploid.
In view of the clear relationship between histo-
logical grade and survival in this series of patients,
it is surprising that there is no relationship between
aneuploidy and survival. More detailed analysis
shows that aneuploidy is significantly associated
with better survival in grade 2 patients (P<0.01); a
similar trend is observed in grade 1 patients, but no
difference was observed in grade 3 patients. Com-
parisons between the modal DNA values of fresh
and paraffin embedded samples showed a high rate
of comparability (66/74 P<0.0001). These studies
show that tumour aneuploidy is not associated with
poor survival in primary breast carcinoma. There is
a complex relationship between histological grade,
aneuploidy, and survival. Aneuploidy is associated
with better survival in patients whose tumours are
not poorly differentiated.
Changes in cellular DNA content in mucosa adjacent
to colonic carcinoma
J. Matthews & T. Cooke
Department ofSurgery, Charing Cross and
Westminster Medical School, London W6 8RF, UK.
We have previously reported that in an animal
carcinogenesis model the mean DNA content per
epithelial cell in the upper regions of the colonic
crypts increases as carcinogenesis progresses. We
have now studied the DNA content of colonic
mucosa in patients with colorectal carcinomas.
Using microdensitometry, DNA content was
measured in the cells in the proliferative and
functional zones of histologically normal Feulgen
stained sections taken adjacent to and distal from
colonic carcinomas, and related to stem cell DNA
content. DNA content was measured similarly in
cytological brushings from the same areas and the
percentage ofdiploid cells calculated.
There was a significant increase in the amount of
DNA in the proliferative cells adjacent to the
tumours (100% + 1.3) compared to distally (91%
+2.0, P<0.002). Although similar increase was
seen in the functional cells adjacent to the tumours
compared to distally the difference was not
significant. In cytological preparations there was an
increase in the proportion of dividing or aneuploid
cells in the transitional mucosa (7.3%+1.2) com-
pared to distal mucosa (3.5% +0.9, P<0.02) and to
the mucosa of patients with non-cancer related
bowel problems (2.1% +0.5, P<0.001).
These results support the concept of field changes
in premalignant mucosa.
Influence of sialomucins at the resection margin on
survival of patients with colorectal cancer
P.M. Dawson', N.A. Habib2, J.B. Bradfield3,
R.C.N. Williamson2 & C.B. Wood'
'Department ofSurgery, Royal Postgraduate
Medical School, London and Departments of
2Surgery and 3Pathology, Bristol Royal Infirmary,
Bristol, UK.
In a multicentre prospective trial, 281 patients
undergoing 'curative' resection for colorectal cancer
were followed for a mean of 13.6 months (s.d. 7.2
months). The presence or absence of sialomucin at
the resection margin was studied histochemically
using the high iron diamine - alcian blue (HID-AB)
stain. There were 49 deaths relating to tumour
recurrence: 21 in the sialomucin positive group
(n=77) and 28 in the sialomucin negative group
(n =204) (P<0.02). Life table survival was
correlated against the presence or absence of
sialomucin in the resection margin. At the mean
follow up (13.6 months) 85.6% of patients were
alive in the sialomucin negative group, and 76.4%
of patients were alive in the sialomucin positive
group. Regression analysis predicts 32.8% and
18.9% five year survivals for sialomucin negative
and positive groups respectively. There was no
significant statistical correlation between the
presence of sialomucin in the resection margin and
the Duke's staging, site or tumour differentiation.
The appearance of sialomucin in either resection
margin appears to be an early marker of poor
prognosis for patients with colorectal cancer.PROCEEDINGS OF BACR 27TH AGM 167
Comparison of plasminogen activator activity
between transformed hamster cell lines of varying
metastatic potential
I.A. Khidair, R.C. Rees, D.M. Teale & C.W. Potter
Department of Virology, University ofSheffield
Medical School, Beech Hill Road, Sheffield
S10 2RX, UK.
Elevated levels of plasminogen activator (PA) have
been strongly associated with the degradative
processes involved in malignancy and a role for PA
in the metastatic process has been inferred. In the
present study the ability of a primary HSV-2
induced hamster fibrosarcoma and sublines derived
from its in vitro metastases, to produce enzymes
was investigated using the indirect I1 25-labelled
fibrin plate method. Fresh tissue culture lines estab-
lished from primary HSV-2-333-2-26 tumours were
shown to produce similar levels of PA to its
sublines derived from lung or kidney foci which
developed following resection of primary tumours.
In comparison, normal hamster embryo fibroblast
(NHEF) and baby hamster kidney cells produced
little or no PA, although baby hamster lung fibro-
blasts produced intermediate levels of PA. Co-
culturing of tumour cells with normal baby hamster
lung fibroblasts, however amplified the PA
secretion in some cell lines.
We conclude that although no correlation
between PA secretion and the metastatic process
was detected, PA production can be stimulated
when tumour cells and normal cells are co-cultured
in vitro.
The lack of structural requirements for activity in a
series of solvents which induce the terminal
differentiation of HL-60 cells
S.P. Langdon', E. O'Reilly2 & J.A. Hickman2
1ICRF Medical Oncology Unit, Western General
Hospital, Edinburgh EH4 2XU and 2CRC
Experimental Chemotherapy Group, Aston
University, Birmingham B4 7ET, UK.
We have previously reported that in a series of N-
alkylformamides, acetamides and ureas which
induce terminal differentiation of HL-60 human
promyelocytic cells to granulocyte-like cells, there
was a correlation between potency and the mol. wt
of the compounds (Langdon & Hickman, Br. J.
Cancer, 51, 601, 1985). We have extended this study
and find that the potency of solvents with unrelated
molecular features is also predictable in this way.
5 x l04 HL-60 cellsml-l were incubated continu-
ously for 96h with each solvent at 370 in RPMI
medium 1640 with 10% foetal calf serum. Bio-
chemical and functional tests of differentiation were
made at 96h, (the ability to produce superoxide
and phagocytose yeast). In addition to solvents like
dimethylsulphoxide, dimethylformamide and di-
methylacetamide methanol, ethanol and acetone
were found to be potent inducers of differentiation
(>70% cells NBT+) and their activity fitted a
regression line (r=0.96) which related the logarithm
of the optimal concentration to promote differen-
tiation and mol. wt. All cells which underwent
differentiation went through at least one doubling.
When cell doubling was inhibited by high concen-
trations of solvent (i.e. no increase over 5 x 104
cellsml-1) viable cells did not differentiate and a
linear, parallel, relationship to the one above was
found between the logarithm of the concentration
to bring about cytostasis, without differentiation,
and mol. wt. No correlation existed between
potency and the octanol-water partition coefficient
for each agent. We conclude that a sub-toxic
challenge by solvents, irrespective of their structure,
to HL-60 cells is sufficient to induce differentiation.
Reversal of HL-60 leukaemic status by the activation
of suppressed differentiation factor(s)
B. Djulbegovic, S.E. Christmas & M. Moore
Immunology Department, Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester M20 9BX, UK.
The human promyelocytic cell line HL-60 can be
induced to differentiate along the granulocytic or
monocytic pathways. The recent findings that HL-
60 can be induced to differentiate by various
physiological compounds (Metcalf, Leukaemia Res.,
7, 117, 1983) as well as by conditioned medium
from normal blood cells (Harris et al., Cancer
Res., 45, 3090, 1985) support the concept that
leukaemogenesis is not an autonomous process but
rather a regulated one with an abnormal set of
control parameters. If this is the case, then in some
instances a leukaemic system, once corrected by
exogenous factors, e.g. those inducing differen-
tiation, may then be capable of self-regulation by
production of endogenous factor(s). We have
shown that conditioned medium produced by HL-
60 cells which had been induced to differentiate
into monocyte/macrophages by 1.25(OH)2 Vit.D3
was itself capable of inducing differentiation in
fresh HL-60 cells. Differentiation was measured by
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induction of the monocyte enzyme non-specific
esterase as well as the monocyte/macrophage anti-
gens recognised by Mo2, EBIl and OKM-1 mono-
clonal antibodies. Conditioned medium acted in a
dose dependent manner and also abolished HL-60
clonogenicity in a soft agar assay indicating that it
was acting on leukaemia progenitor cells. Activity
was shown not to be due to residual vitamin D3, y-
interferon or CSF. A possible molecular mechanism
might involve switching on a gene for the produc-
tion of differentiation factor(s) which then compete
with growth factor(s) autonomously produced by
the undifferentiated cell population.
Struct. Funct., 10, 89, 1985). In TLX5 cells incu-
bated with 106mm NMF for 48h total intracellular
glutathione (measured according to Griffiths,
Analyt. Biochem., 106, 207, 1980) was reduced to
19.7+6.4% of controls. We consider the fall in
intracellular glutathione may be responsible for the
reversible decrease in cell growth rate but that
NMF does not terminally differentiate TLX5
lymphoma cells in vitro.
The expression of tartrate resistant acid phosphatase
in a series of B-non-Hodgkin's lymphoma stimulated
with phorbol ester
Effects of N-methylformamide (NMF) on the
glutathione status and cell cycle of TLX5 murine
lymphoma cells in vitro
C. Bill, J.A. Hickman & A. Gescher
CRC Experimental Chemotherapy Group,
Pharmaceutical Sciences Institute, Aston University,
Birmingham B4 7ET, UK
NMF is an experimental antitumour agent which
has good activity against murine tumours in vivo
yet has no effect on the growth of the bone marrow
(Langdon et al., Eur. J. Cancer Clin. Oncol., 21,
745, 1985). NMF is also one of many solvents
which promotes the terminal differentiation of
certain malignant cells in vitro. We wished to
determine whether the in vivo and in vitro activities
of NMF were related. 5 x 104 TLX5 cellsml-I
incubated continuously in vitro with NMF over
72h showed a progressive loss of viability and a
decrease in cell growth rate over the concentration
range 43mm to 170mm (50% growth in-
hibition=68mM). 106mm NMF incubated for 48h
caused a 37% growth inhibition of the TLX5 cells
but >80% were viable (trypan blue exclusion).
Drug removal led to cells regaining normal growth
characteristics. Cell cycle analysis of these cells by
fluorescence activated cell sorting showed a
decrease in the proportion of S and G2M phase
cells with a concomittant increase in the G1
population. Higher NMF concentrations (> 150mm
48h), although causing a progressive decrease in
viability, resulted in complete loss of S phase cells
with 99% of cells in G1. Murine lymphoma cells
have been shown to be arrested in the G1 phase by
reduction of cellular glutathione (Ishii et al., Cell
S. Schrape, D.B. Jones & D.H. Wright
University Department ofPathology, General
Hospital, Southampton S09 4XY, UK.
Previous studies describe that the treatment of CLL
cells with phorbol ester leads to the expression of
tartrate resistant acid phosphatase. This enzyme is
a marker for hairy cell leukaemia. This trans-
formation is significant to the relationship of the 2
disease types. CLL cells frequently express Leu-1,
as do cells from diffuse centrocytic lymphoma and
we were, therefore, interested to see if centrocytic
lymphoma cells are also TRAP positive after
treatment. All cells were dispersed from fresh
lymph node biopsies and were cultured for 48h
with, and without, phorbol ester. Cytocentrifuge
preparations were stained for TRAP by a standard
technique. Seven cases of CLL became TRAP
positive in more than 20% of the cells following
this treatment. The percentage of TRAP positivity
occasionally approached 90%. Treatment of 5 cases
of centrocytic lymphoma resulted in TRAP
positivity in 20-50% of the tumour cells. How-
ever, when this study was extended to lymphomas
classified as centroblastic/centrocytic or centro-
blastic/diffuse, cytoplasmic TRAP positivity was
also seen in many of the tumour cells. These results
suggest that the appearance of TRAP after phorbol
stimulation does not specifically relate to the
relative positions in differentiation of CLL cells and
hairy cells. This observation was confirmed when
all cells cultured were stained with a group of
antibodies known to identify hairy cell leukaemia.
In no case was the appearance of TRAP positivity
associated with the demonstration of hairy cell
antigens.PROCEEDINGS OF BACR 27TH AGM 169
A comparison of the effects of differentiation
inducers against human ovarian adenocarcinoma cell
lines
S.P. Langdon, I.P. Hayward, S.S. Lawrie
& J.F. Smyth
Imperial Cancer Research Fund Medical Oncology
Unit, Western General Hospital, Edinburgh, UK.
We wish to identify inducers of terminal differen-
tiation (TD) in human ovarian carcinoma. No
conclusive marker of TD in this disease has yet
been found. However lipid (L) production has been
proposed as a possible marker of this process
(Buick, J. Cell Physiol., suppl. 3, 117, 1984). In
colon cell lines, increases in alkaline phosphatase
(AP) activity correlate with changes toward a more
benign phenotype (Tsao et al., Cancer Res., 42,
1052, 1982). Three agents, sodium butyrate (SB),
retinoic acid (RA) and dimethylsulphoxide
(DMSO), capable of inducing TD in leukaemic cell
lines were studied against two human ovarian
adenocarcinoma cell lines derived from the same
patient before (PEOI cells) and after (PE04 cells)
the onset of clinical resistance to chemotherapy.
Cells (4 x 104 35mm- ' well) were plated in 10%
FCS/RPMI. Three days later drugs were added.
Four days later cells were stained and assessed for
viability. Cells producing L and AP were identified
histochemically (see Table). At cytostatic concen-
trations, SB produced increases in the number of
PE04 cells expressing AP and L relative to control
cells. Furthermore preliminary experiments with
monoclonal antibodies indicate changes in antigen
expression. Experiments are underway to assess
whether these effects produced by SB are truly
indicative of TD in ovarian carcinoma.
% cells + ve
PE04 cells PEOJ cells
Cytostatic
Inducer conc. L AP L AP
Control 7+2 6+2 9+3 <1
SB 2mM 84+6 38+8 81+11 <1
RA 30lM 69+11 5+2 79+6 <1
DMSO 380mM 1+1 4+2
250mM 1+1 <1
Rat hepatic glutathione S-transferase isoenzymes and
aflatoxin carcinogenesis in vivo and cell
transformation in vitro
G.E. Neal', U. Neilsch2 & D.J. JudahI
1MRC Toxicology Unit, Carshalton and
2Department ofPharmacology, Bristol University,
Bristol, UK.
The potent hepatocarcinogen, aflatoxin B1, (AFB1)
requires metabolic activation to exert its toxic and
carcinogenic effect. Detoxification can occur by
glutathione S-transferase mediated conjugation with
reduced glutathione (GSH). GSH-S-transferase
isoenzymes have been fractionated on IEF gels
followed by detection using model substrate
(CDNB DCNB and monobromobimane) and assay
of AFB1-conjugating capacity using microsomally
activated AFB1. Using fractionated cytosol from
control male rat liver, AFB1-conjugating activity
was associated with fractions having IEP -8.8, 6.5
and 6.4. Development of pre-neoplastic and neo-
plastic liver lesions, by feeding AFB1, results in a
resistance to cytotoxicity of AFB . Total liver
cytosol fractions from these animals had increased
(>100%) conjugating activity towards the model
substrates and towards AFB . IEF showed that the
increased activity towards the model substrates was
due to increased levels of the basic isoenzymes (1:1,
1:2 and 2:2), the less basic 3:3, and the appearance
of the 7:7 isomer. The identity of 7:7 and its
absence from fractions from control livers was
confirmed by Western blotting coupled with
identification by specific antibody. The 7:7
isoenzyme did not catalyse conjugation of AFB1 to
any significant extent. The increased activity
(AFB1) in preneoplastic and neoplastic tissue was
mediated by the basic isoenzymes (1:1, 1:2 and
2:2). In rat liver derived epithelial cell line, trans-
formation in vitro by activated aflatoxin or ras
transfection also resulted in increased levels of
GSH-S-transferase activity (>500%) as assessed by
the model substrate. Increased level of the 7:7
isoenzyme in the in vitro transformed cells was also
demonstrated by Western blotting.
Assessment of aflatoxin exposure in rats and man
with the aid of anti-aflatoxin antibodies
F. Tursil, C.P. Wild2, R. Montesano2
& R.C. Garnerl
'Cancer Research Unit, University of York,
Heslington, York YOJ SDD, UK and 2IARC, 150
Cours Albert-Thomas, Lyon, France.
We are interested in determining whether or not we
can devise a non-invasive technique to measure
aflatoxin (AF) binding to cellular macromolecules
in man in order to examine individual differences.170 PROCEEDINGS OF BACR 27TH AGM
We have used the rat as an experimental model for
our studies prior to assaying human urine samples
for AF. AF administration to rats results in
covalent binding to cellular and tissue macro-
molecules. In addition, AF metabolites are excreted
in the urine and faeces. Correlations have been
found between species susceptibility or resistance to
the hepatocarcinogenicity of AF and how much
carcinogen is covalently bound to liver DNA. After
giving single doses of (3H)AFB1 to rats, we have
found that there is a dose-related increase in liver
DNA binding. Doses of 10, 100 and 200 gkg-' by
oral intubation resulted in 178, 1,638 and
2,401 pgmg- liver DNA being bound respectively.
Binding to serum albumin gave values of 49, 506
and 719pgmg-1 protein respectively for these
doses. The liver DNA/serum albumin binding ratio
for 10, 100 and 200pgkg-1 was 3.7, 3.2 and 3.4.
After daily administration of 1Ig AF for 24 days
(excluding weekends) the liver DNA binding
peaked by day 14 with values of liver DNA and
serum albumin binding of 260 and 150pgmg-1
respectively. Once this plateau phase had been
reached, the ratio of 1.7 liver DNA/serum albumin
binding remained constant. Urine and faecal
analysis indicated that, in chronically dosed
animals, the daily amounts of AF metabolites
excreted were constant, except after days in which
AF was not administered, when the amounts
excreted fell.
Instead of using radioactive tracer to measure
covalent binding, an immunoassay procedure and a
rabbit anti-aflatoxin antibody has been utilised. A
reasonable correlation between radiotracer measure-
ment and immunoassay results was seen; the only
exception to this was when urine was analysed. In
all cases AF concentration as measured by
immunoassay over-estimated the urine AF concen-
tration, probably due to some metabolites having
higher affinity for the antibody than AF. Using
these immunoassay procedures we have examined
urine from persons thought to be exposed to AF in
the Gambia.
Transformation of rat liver derived epithelial cells in
vitro
S. Sinha1, G.E. Neal1, C.J. Marshall2
& L.J. Hockin'
1MRC Toxicology Unit, Carshalton, Surrey
SM5 4EF and 2Chester Beatty Labs., Institute of
Cancer Research, Fulham Road, London, UK.
A rat liver derived epithelial cell line (BL8) was
transformed in vitro by ras oncogenes and by
aflatoxin B1 (AFB1). Ha-ras and N-ras plasmids, in
conjunction with genes for drug (G418) resistance
were introduced into cells by transfection, and
colonies selected out by resistance to G418 (Sinha
et al., Cancer Res., 46, 1440, 1986). Colonies of
transformed cells had an altered appearance and
tended to pile up in culture. To transform cells with
aflatoxin, cells partially synchronised in S phase
were treated with AFB1 activated by the presence
of quail microsomes and a NADPH generating
system. Cells transformed with aflatoxin had a
morphology similar to cells transformed with ras
oncogenes. In cells transformed by both methods
there was a strong association of the acquisition of
a neoplastic phenotype, as shown by anchorage
independent growth and mouse tumourigenicity,
with the induction of y-glutamyl transferase (GGT)
which is a sensitive marker for the preneoplastic
and neoplastic changes in rat hepatocarcinogenesis.
A heterogeneity in staining for GGT was seen even
in the early passages of transformed cells. Further
subcloning showed that while there is a strong
association of GGT with cell transformation in
early passages, altered levels of the enzyme do not
influence tumourigenesis in the nude mouse.
The induction of specific mRNAs during aflatoxin
Bl-induced hepatocarcinogenesis
C.A. Power', J.L. Simpson', M.M. Manson',
Y. Laperche2 & G. Guellaen2
1MRC Toxicology Unit, Carshalton, Surrey
SM5 4EF, UK and 2Henri Mondor Hospital, Creteil,
France.
We are using aflatoxin B1 (AFB1)-induced carcino-
genesis in rat liver and liver-derived cell lines to
examine alterations in transformed cells with par-
ticular reference to actin (an abundant mRNA
species) and y-glutamyl transferase (GGT) (a low
abundance mRNA species).
Recently, it has been suggested that changes in
the level of specific forms of actin may be a marker
of transformation in fibroblasts (Leavitt et al.,
Nature, 316, 840, 1985). We have used Northern
and dot blot analysis ot total RNA to study
changes in actin expression. Nick translated probes
prepared from a plasmid pRT3 (containing an
11 kb genomic clone of mouse DNA recognising
and actin) revealed a 2-3 fold elevation of actin
mRNA in AFB1-treated liver and hepatoma. A
hepatoma-derived, highly tumourigenic cell line,
JB1 contained -8 times more actin mRNA than
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GGT has for many years been used as a tumour
marker. In normal adult rat liver it is confined to
bile duct epithelia, but appears in preneoplastic foci
of hepatocytes and tumours upon administration of
AFB1. Using a rat kidney GGT cDNA probe, we
have shown by Northern blot analysis of poly A'
mRNA that one form of GGT mRNA is elevated
in AFB1-treated liver and in a hepatoma-derived
cell line, and is not detectable in primary hepato-
cytes or a cell line derived from normal liver.
These results indicate that transformation is
accompanied by changes in expression of high
abundance mRNAs as well as of low abundance
species. Although actin and GGT may not play a
central role in the carcinogenic process, they may
be important in maintaining the transformed
phenotype.
We thank Dr. K. Willison (ICR, Lond6n) for
providing plasmid pRT3.
glands overlying the breast. These results suggest
that RAP-5 recognises a normal cellular component
the expression of which is not significantly
amplified in hyperplastic or neoplastic conditions.
The expression of mutant forms of ras p21
exclusively expressed in malignant tumours would
not be detected by this reagent.
Transcription of the c-fos oncogene in the
adenoma-carcinoma sequence in colorectal cancer
P. Elvin1, P. Kelly2, G.D. Birniel & I.B. Kerr2
1Beatson Institutefor Cancer Research, and
2University Department ofPathology, Royal
Infirmary, Glasgow, UK.
Immunohistochemical detection of ras oncogene p21
product in human benign and malignant mammary
tissue
A.K. Ghoshl, M. Moore' & M. Harris2
'Department ofImmunology, Paterson Laboratories
and 2Department ofPathology, Christie Hospital &
Holt Radium Institute, Manchester M20 9BX, UK.
Although activated ras oncogenes have been
detected in a wide variety of human tumours and
transformed cell lines in culture, controversy
remains whether ras activation is a primary event in
carcinogenesis or appears during tumour pro-
gression. With the introduction of monoclonal anti-
bodies to ras oncogene products it is now possible
to examine ras expression in pre-malignant and
malignant conditions at the cellular level and to
determine if there is a correlation between enhanced
ras expression and a particular neoplastic state. We
have used an immunohistochemical technique to
study the expression of ras p21 in 2 cases of normal
breast tissue, 23 benign and 22 maglignant breast
epithelium using the monoclonal antibody RAP-5
generated against a synthetic peptide corresponding
to amino acid positions 10-17 of the ras p21
protein. The staining intensity and intracellular
distribution of RAP-5 was similar between the three
epithelial populations and extended to other tissue
elements including myoepithelial cells, smooth
muscle, myelin, capillary endothelium and stromal
fibroblasts as well as sebaceous glands and sweat
Transcription of the c-fos oncogene has been
described in a number of human malignancies,
including carcinomas of the colon and rectum, but
its significance in colorectal carcinogenesis is not
clear. Ue have isolated total cellular RNA from
specimens of normal colonic mucosa, adenomas
and carcinomas, and have examined the level of
c-fos homologous RNA by a doubling dilution dot
blot assay using a 32P nick-translated c-fos probe.
Equivalent steady state levels of c-fos RNA were
found in mucosa, adenoma, and carcinoma speci-
mens, comparable to those in TPA induced (differ-
entiated) HL-60 cells. In contrast, steady state levels
of c-myc RNA were found to be considerably lower
in all specimens examined, although the levels of c-
myc RNA in carcinomas were generally higher than
in mucosae and adenomas.
The presence of both c-fos and c-myc
homologous RNAs in these tissues was also demon-
strated by in situ hybridisation using [3H]-labelled
c-fos and c-myc probes. Both oncogene transcripts
were detected throughout the epithelial crypt popu-
lation as well as in stromal cells, suggesting that the
transcription of the two oncogenes is not confined
to proliferating cells. No differences in cell specific
location of either oncogene probe was observed
when the grain count distribution over epithelial
and stromal elements in both normal mucosa and
adenoma specimens were compared.
Thus a comparison of steady state RNA levels
and of tissue localisation of oncogene transcripts
suggest that c-fos RNA levels do not correlate with
any stage of colorectal carcinogenesis.172 PROCEEDINGS OF BACR 27TH AGM
Correlation between staining for p21 product of
K-ras oncogene and histological degrees of dysplasia
in human colonic epithelium
J.W.B. Bradfield', G.U.A. Igboakal, N.A. Habib2,
R.C.N. Williamson2, P.M. Dawson3 & C.B. Wood3
Departments of'Pathology and 2Surgery, Bristol
Royal Infirmary, Bristol and 3Department of
Surgery, Royal Postgraduate Medical School,
London, UK.
The K-ras oncogene has been associated with
human colonic cancer in transfection studies. The
object of this work was to investigate the histo-
logical distribution, and intensity of expression, of
the p21 polypeptide product of this oncogene in
normal and neoplastic colonic epithelium. The
peptide was detected by an indirect immunoperoxi-
dase technique in formalin-fixed paraffin-embedded
sections using a monoclonal antibody directed
against the amino acid sequence 96-118 of a
synthetic p21 peptide (Scripps Research Center, La
Jolla, USA). Cases were categorised histologically
by examination of routinely stained sections;
further sections were then stained for the p21
polypeptide. In the normal colonic epithelium there
was some positive patchy staining in the surface
epithelium with minimal staining of the base of the
crypts. In contrast, with increasing degrees of
dysplasia there was an increase in the distribution
and intensity of staining, particularly within the
crypts.
Staining at base ofcrypts
Intensity Distribution
(Number (Number
with marked with >50%
n staining) positive)
Normal 20 0 0
Metaplastic 21 1 1
Dysplastic mild 6 1 2
moderate 27 11 14
severe 32 16 22
The results show a correlation between increasing
expression of p21 and increasing degrees of
dysplasia in neoplastic human colonic epithelium.
myc and ras expression in experimental
carcinogenesis
N.A. Habib', R. Salem2, R.C.N. Williamson',
C.B. Wood2 & K. Sikora3
'Department ofSurgery, Bristol Royal Infirmary,
Bristol, 2Royal Postgraduate Medical School,
London and 3Ludwig Institutefor Cancer Research,
Cambridge, UK.
Activation of more than one oncogene is
responsible for cancer formation. Overexpression of
myc oncogene occurs early and is responsible for
the immortalisation of the cell. Activation of ras
oncogene is responsible for tumour propagation
and is thought to be a late event in the multistep
carcinogenic process. Using immunohistochemical
techniques we studied the distribution of p62 (for
myc) and p21 (for ras) in neoplastic and non-
neoplastic colonic tissue in 42 rats undergoing
chemically induced carcinogenesis with 20mgkg-'
dimethylhydrazine (DMH). We found that both
p62 and p21 were absent in 10 control rats injected
with normal saline solution and present in 27 rats
with colonic carcinomas. In the group of rats
treated with DMH without tumour formation 11 of
15 had p62 without p21 overexpression. These
experimental findings suggest that both myc and ras
are overexpressed in carcinomas and that myc
activation is an early event in this experimental
model as it was expressed before the development
of overt carcinomas. Therefore myc oncogene over-
expression could have useful clinical application as
it may be of potential value in screening patients at
risk of malignant change.
Effect of dietary f-naphthoflavone on DNA
alkylation in the rat large intestine after
1,2-dimethylhydrazine
A.M. Tacchi-Bedford, G.D. Whyman
& A.E.M. McLean
Toxicology Laboratory, Department ofClinical
Pharmacology, University College London,
University Street, London WCIE 6JJ, UK.
Many vegetables, especially the Brassicas, have
powerful inducing effects on the mixed function
oxidase activity of the large intestine. This can be
reproduced by feeding a diet containing 50ppm Ii-
naphthoflavone (BNF) which causes a three fold
increase in MFO activity in one week (McDanell &
McLean, Biochem. Pharmacol., 33, 1977, 1984). We
studied the effect of feeding BNF on the large
intestine DNA alkylation induced by the colon
carcinogen 1,2-dimethylhydrazine (DMH) in male
Wistar rats. After a week on a BNF containing
diet, or a semi-purified diet with minimal inducing
activity (MID), the rats were injected with
20mgkg-' [14C]DMH subcutaneously (-40MCi)PROCEEDINGS OF BACR 27TH AGM 173
and killed at various time intervals up to 24h.
DNA was isolated from the colon mucosa by
phenol extraction and the abnormal purines N7-
and 06-methylguanine were measured by HPLC
and liquid scintillation counting or fluorimetric
detection. Both N7 and 06 MeG were present to a
greater extent in the BNF rats than in the MID
group. At 6h when the peak of alkylation was
reached, N7 MeG accounted for 1,100 and
700 pmolmol- G in the BNF and MID animals
respectively. 06 MeG, however, was detectable only
in the BNF group, with values in the range of 52-
93pmolmol- G between 1-12h. These results
suggest that enzyme induction, metabolic activation
of a carcinogen and covalent binding to DNA in
the large intestine may be directly correlated and
that composition of the diet may play an important
role in the process of colon tumour initiation.
Proliferative instability and neoplastic development at
the site of a colonic anastomosis in experimental
carcinogenesis
R. Roe & R.C.N. Williamson
Department ofSurgery, Bristol Royal Infirmary,
Bristol BS2 8HW, UK.
Colonic anastomoses are common sites for
'recurrent' cancer in man and for chemically-
induced cancer in the rat. The possibility that
proliferative instability around the anastomosis
during the healing period promotes neoplastic
development at the suture line was investigated.
Sprague-Dawley rats received the first of a 5 week
course of azoxymethane (total dose, 50mgkg-1)
either immediately after transection of the descend-
ing colon or at 2, 4, 8 and 12 weeks later. Control
rats received handling of the bowel. The prolifer-
ative status of colonic crypts was assessed by auto-
radiography following [3H]TdR injection. All rats
were killed 28 weeks after the first azoxymethane
injection. Susceptibility to develop tumours de-
creased with age in both control and transected
groups. However, a constant overall increase (44%)
in the proportion of tumours was found in tran-
sected groups which was due to the presence of
anastomotic tumours. No detectable changes in
morphology or proliferative index of colonic crypts
occurred between young control rats and those 12
weeks older. Changes in both parameters were
observed in transected rats over time, these being
most dramatic in crypt positions 1-10 away from
the anastomosis. Crypts at this site were increased
in height at 2, 4 and 8 weeks (P<0.001) respec-
tively but returned to normal morphology by 12
weeks. Similarly, crypt labelling indices were
increased at 2, 4 and 8 weeks (P<0.001) respec-
tively and although diminished by 12 weeks
remained higher (P<0.05>0.02) than control
levels.
These findings suggest that increased crypt cell
proliferation in the immediate vicinity of morpho-
logically 'healed' anastomoses contributes to the
susceptibility of this site for tumour development.
Hypothermia produces intestinal adaptation without
promoting experimental intestinal carcinogenesis
J.B. Rainey, P.W. Davies & R.C.N. Williamson
University Department ofSurgery, Royal Infirmary,
Bristol, UK.
Adaptive hyperplasia stimulated by intestinal
operations enhances experimental intestinal carcino-
genesis (Williamson & Rainey, Scand J.
Gastrienterol., 19, suppl. 104, 57, 1984), but the
effects of non-surgical promoters of mucosal
growth, such as hypothermia (Heroux &
Gridgeman, Can. J. Biochem. Physiol., 36, 209,
1958), are uncertain. The tropic and tumour-
promoting potential of hypothermia were tested in
two groups of male Sprague-Dawley rats housed at
100 C for 30 weeks. One group (n=10) received a 6
week course of azoxymethane (total dose
90kgmg-1); the other group (n=7) acted as hypo-
thermic controls. Two further groups, kept at
220C, received azoxymethane (n=15) or served as
normothermic controls (n= 15). Mean daily food
intake was 42% higher in the hypothermic groups,
yet at sacrifice mean body weight was 11% lower
than in the normothermic groups (P<0.01). The
combination of hypothermia and azoxymethane
increased crypt cell production rate (as determined
stathmokinetically) by 170% in the duodenum,
172% in the jejunum, 74% in the ileum and 227%
in the proximal colon, compared with normo-
thermic controls (P=0.05-0.01). Individually,
azoxymethane and hypothermia had no such effect.
In rats receiving azoxymethane, intestinal tumour
yield did not differ significantly between the hypo-
thermic group (2.3 +0.8 tumours/rat: mean+s.e.)
and normothermic (1.7+0.3) group. Hypothermia174 PROCEEDINGS OF BACR 27TH AGM
causes hyperphagia and adaptive hyperplasia in
small bowel and right colon when combined with
azoxymethane, but does not promote carcino-
genesis.
Faecal steroids and colorectal cancer: Faecal bile
acids in Scandinavian populations at different risk
R.W. Owen, C. Walton, M.J. Hill
& M.H. Thompson
PHLS-CAMR, BMRL, Salisbury, Wiltshire
SP4 OJG, UK.
Some bile acids, especially lithocholic acid (LCA)
and deoxycholic acid (DCA) have been shown to
act as tumour promoters in animal models of
colorectal cancer (CRC). These observations
support the established correlation between risk of
developing CRC and the consumption of a diet
depleted in fibre and containing high levels of fat
and protein; a diet that will undoubtedly influence
the excretion of faecal bile acids (FBA). In this
IARC study the FBA excretion patterns were
determined in groups of healthy male volunteers
from four different Scandinavian populations with
a four-fold variation in the risk of developing CRC.
Unlike many earlier population studies which en-
compassed groups exhibiting extreme differences in
life style this investigation compares the relation-
ship between diet, faecal steroid profiles and CRC
risk in comparable populations. Whilst the marker
of individual risk, namely the LCA/DCA ratio
(Owen et al., Br. J. Cancer, 52, 445, 1985), is on
average low throughout these populations, the high
risk Danish population excrete LCA and DCA at
higher concentrations. That is, the high risk group
is exposed to higher concentrations of known
tumour promoters.
Population No. LCAa DCA
Perrikala (F) (30) 1.96+1.53 3.11+2.04
Helsinki (F) (29) 1.96+ 1.07 3.11 +2.97
Them (D) (30) 1.68+1.12 3.05+2.64
Copenhagen (D) (29) 3.09+1.66 5.33+3.12
Population LCA +DCA LCA/DCA CRC inc.b
Perrikala (F) 5.07+3.31 0.72+0.46 14.2
Helsinki (F) 5.06+2.97 0.74+0.35 25.7
Them (D) 4.74+3.60 0.72+0.46 27.9
Copenhagen (D) 8.42+4.58 0.64+0.29 42.1
amgg-l dry faeces; bCases 10-5 males p.a. (age adjusted);
F =Finland; D=Denmark.
Is intragastric nitrosation responsible for gastric
cancer?
P.W.J. Houghton1, R.W. Owen2, S. Leach2,
N.J.McC. Mortensen', M.J. Hill2
& R.C.N. Williamson
'Department ofSurgery, Bristol Royal Infirmary and
2PHLS Centre, Porton Down, UK.
Intragastric nitrosation, with the formation of car-
cinogenic N-nitrosocompounds, may be responsible
for the pathogenesis of gastric carcinoma in
patients with pernicious anaemia and those who
have undergone gastric surgery for peptic ulcer
disease. The evidence for nitrosation is contro-
versial: some workers report high levels of intra-
gastric nitrosamines but others find no such
increase. We have assessed intragastric nitrosation
in 35 at-risk patients and 11 controls by measuring
their 24h urinary excretion of N-nitrosoproline
(N-NP). Following ingestion of 300mg sodium
nitrate and 500mg L-proline, intragastric nitrosation
results in the formation of N-NP which is excreted
in the urine. At-risk patients had previously under-
gone vagotomy with or without pyloroplasty
(n= 14) or partial gastrectomy (n= 12), or had
pernicious anaemia (n=9). The median N-NP levels
were 2.9ng24h-1 (range 1.6-11.8ng) in controls,
3.6ng24h-1 (0.6-11.2ng) in vagotomy patients,
2.1 ng24h-1 (0.2-14.5ng) in partial gastrectomy
patients and 3.8ng24h-1 (1.3-8.1 ng) in pernicious
anaemia patients. There was no significant
difference in N-NP excretion between any of the
groups (Mann Whitney U test).
In this study we have not confirmed the theory
that achlorhydria results in increased intragastric
nitrosation with the production of potentially
carcinogenic nitrosamines.
Some preliminary evaluations of bacterial
N-nitrosation reactions
S. Leach1, A. Cook1, A. Challis2, M.J. Hill'
& M. Thompson1
1PHLS-CAMR, BMRL, Porton Down, Salisbury
and 2Department ofChemistry, Imperial College,
South Kensington, London, UK.
It is important to rigorously determine whether
bacteria have any direct and significant role in
endogenous N-nitrosation reactions. A direct
bacterial catalysis of this reaction has beenPROCEEDINGS OF BACR 27TH AGM 175
demonstrated unequivocally (refs. a, b, c in table)
but the reported rates are low, questioning their
clinical relevance. Much faster rates of reaction
have been obtained more recently in our laboratory
using certain aerobic denitrifying isolates of
bacteria (Table). An assessment of the carcinogenic
risk of endogenous N-nitrosation requires a knowl-
edge of the important factors of influence for such
reactions in vivo. It now seems likely that an
important factor for endogenous N-nitrosation in
chronic bacterial infection is the metabolic
capability of the particular colonising organism(s)
rather than the development of a flora per se.
Rate of
nitrosation
mmolnMOR
[NO] [Morpholine] mg-1
Organism mm mm protein h- RefJ
E. coli A10* 25 7.5 61 a
E. coli A10* 25 25 154
E. coli (range)* 25 7.5 0-55 b
E. coli
(clin. isolate)* 25 27 270 c
E. coli (range)* 25 8 0-76
Pseudomonas
aeruginosa* 25 16 0-24,000
Other d
denitrifiers* 25 16 0-3,200
P. aeruginosa
BM1030
grown in
chemostat
model 25 16 1,300-15,000
aK. Suzuki & T. Mitsuoka, IARC Sci. Pub., 57, 275,
1984; bCalmels et al., Carcinogenesis, 6, 911, 1985.;
cLeach et al., Biochem. Soc. Trans., 13, 381, 1985;
dPresent study. Organisms grown anaerobically
+NO3 /NOI.
*Assay conditions - washed cells c.1mgml- protein;
pH7-7.5; incubation time, 30min-2h.
Radiation response of human oesophageal cells
in vitro
C. Mothersill1, C. Seymour', P.J. Byrne2
& T.P. Hennessy2
'Saint Luke's Hospital, Rathgar, Dublin 6 and
2TCD Department ofSurgery, St. James's Hospital,
Dublin 8, Eire.
Accurate experimental information on the response
of human tissue to chemotherapy or radiotherapy is
of great importance. However, there are major
problems in extrapolating from in vivo or in vitro
results obtained on animal tissue. This is mainly
because most models use rodents or undifferen-
tiated established rodent cell lines which are diffi-
cult to correlate with results from human clinical
trials.
Our group has been trying to establish an assay
that enables us to look directly at the dose response
of human oesophageal tissue to chemotherapy or
radiation in terms of reduced growth rate. Our
preliminary results have used radiation as the cyto-
toxic agent. To determine the growth rate pieces of
tissue are plated as explants. The resulting area of
cellular outgrowth is irradiated and then measured
at weekly intervals. This enables us to monitor the
effectiveness of treatment in terms of reduction of
outgrowth from an explant. Preliminary results on
8 patients, involving measurements on 160 explants,
show that the method can be used to determine the
dose response to radiation and show a reduction of
66+15% at 2.5Gy, 80+5% at 5Gy and 91+8%
at 7.5Gy. These values correlate very well with
expected survival values for human cells after
irradiation. The technique has been applied to
colon explants with similar success.
It is intended to extend the method to allow the
effectiveness of combination therapy to chemo-
therapy regimes to be assessed.
Differential radiosensitivity between human bladder
and testicular tumour cell lines
C.N. Parris1, C.F. Arlett2, S. Harcourt2
& J.R.W. Masters1
'Department ofHistopathology, St. Paul's Hospital,
Institute of Urology, 24 Endell Street, London
WC2 9AE and 2MRC Cell Mutation Unit,
University ofSussex, Falmer, Brighton BNI 90G,
UK.
Chemotherapy can cure advanced non-
seminomatous testicular germ cell tumours, whereas
advanced transitional cell carcinomas of the bladder
generally are incurable. This differential sensitivity
is retained in vitro, in that 5 S times as much cis-
platin or adriamycin is required to produce the
same cytotoxicity in bladder cancer compared with
testicular cancer cell lines (Walker et al., Br. J.
Cancer, 52, 459, 1985). To determine whether these
cell lines differ in radiosensitivity, clonogenic cell
survivals of five testicular and five bladder cell lines
were compared following exposure to a 60Co source176 PROCEEDINGS OF BACR 27TH AGM
at a range of cytotoxic doses. Colony-forming
abilities of control and treated cells were compared
after plating cells onto 105 lethally irradiated
homologous feeder cells. The testicular cell lines
were all radiosensitive (DlOs, doses reducing clono-
genic cell survival by 90%, ranging from 2.2-
3.4Gy), similar to that of a fibroblast cell line
(AT5BIVA: 2.2Gy) derived from a patient with
ataxia telangiectasia. In contrast, the bladder cell
lines were all relatively radioresistant (D10s ranging
from 4.0-5.8Gy), similar to a fibroblast cell line
(MRC5: DIO, 4.7Gy) derived from a clinically
normal individual. The data indicate that testicular
tumours, potentially curable using chemotherapy,
have a radiosensitivity similar to that of cells
derived from a patient with a disease associated
with a DNA repair deficiency.
Radiation response of small cell lung cancer lines
T.T. Kwok, P.R. Twentyman & N.M. Bleehen
MRC Clinical Oncology and Radiotherapeutics Unit,
MRC Centre, Hills Road, Cambridge, UK.
Human small cell lung cancer (SCLC) is usually
responsive to both radio- and chemotherapy upon
initial presentation but becomes resistant to both
forms of therapy in late stage disease. We have
examined the radiation response characteristics of
11 lines of SCLC, 7 of them derived from patients
undergoing treatment in our Unit. Six of the lines
are from untreated patients whilst 5 are from
patients with recurrent disease following multi-drug
chemotherapy. Most of the lines grow as free
floating aggregates of cells with varying degrees of
'tightness of aggregation' whilst the remaining line
(COR-L88 - from a recurrent patient) grows as a
monolayer attached to plastic. Radiation response
was determined using a soft agar clonogenic assay
both immediately or 24h after irradiation of
aggregates or plateau phase monolayers.
All of the lines except one were extremely re-
sponsive to radiation with small extrapolation
numbers (n =0.68-2.05) and steep slopes (Do =
0.65Gy-1.34Gy). Line COR-L88, however, although
having a small extrapolation number (n = 1.06)
had a much less steep slope (Do =2.35Gy). By
growing this line on an agar base, it could be
induced to grow as floating aggregates rather than
a monolayer, but its radiation response parameters
remained unchanged. None of the lines was able to
exhibit significant recovery from potentially lethal
radiation damage (as determined by comparison of
cell survival determined at Oh and 24h after
irradiation). Split dose experiments in the one line
studied to date indicate that recovery from sub-
lethal damage is also absent.
Studies of line COR-L88 aiming at providing an
explanation of its relatively low radiosensitivity are
currently in progress.
Does verapamil enhance cytotoxic effects of
anticancer drugs for lung tumours in vitro?
A.P. Simmonds1, P. Moyes', A. Nicoll,
K.G. Davidson2 & A. Faichney2
'Cell Laboratory, Biochemistry Department and
2Cardiothoracic Surgical Unit, Royal Infirmary,
Glasgow, UK.
Using a modification of REL medium successful in
culure of NSCCL (Simmonds et al., Br. J. Cancer,
52, 429, 1985) we have investigated the influence of
verapamil on the measured cytotoxic effects of cis-
platinum and vindesine against squamous cell carci-
noma of lung in vitro. Viable cells (2 x 105) were
exposed for 1 h to concentrations of drugs repre-
senting 10% peak plasma values with and without
verapamil and to verapamil alone at 1pm. Cells
were washed and plated in enriched McCoys 5A in
0.3% agar over an underlayer of the same medium
+1% rat rbc in 0.5% agar. Incubation was at
370C in 5% C02/air and colony scoring of INT
stained plates was done at 12 days. Colony counts
in drug treated plates were expressed as percentage
survival of control, <50% classed as sensitive.
Results on 12 patients have indicated resistance to
both drugs in vitro; percentage survivals ranged
from 52-100% (15/24 tests >60% survival). The
presence of verapamil had no effect on 5 patients'
samples, with either drug. Pronounced changes
were observed in 4 patients' response to vindesine;
this changed to sensitive, the magnitude of the
change ranging from 24-38% in percentage
survival. For one of these patients, a 40% change
in response to platinum was also demonstrated.
Smaller changes in response to both drugs were
recorded for the remaining patients and for
platinum response in those with enhanced
sensitivity to vindesine. It is clear from this study
that 1yM verapamil has sensitising effects, which
may be pronounced, on some 58% of patients
evaluated to date. The effect is more marked with
vindesine. Verapamil alone against tumour cells has
minimal effect. This study is continuing.PROCEEDINGS OF BACR 27TH AGM 177
The development of the VmDk murine astrocytoma
as a therapeutic model of human glioma
R. Bradford, J.L. Darling & D.G.T. Thomas
Department ofNeurological Surgery, Institute of
Neurology, Queen Square, London WCIN 3BG, UK.
The choice of agents in current use for the chemo-
therapy of glioma has largely depended on results
obtained from experimental models. Few, if any of
these fulfil the criteria for an ideal therapeutic
model for human glioma. Cell lines derived from a
spontaneous astrocytoma originally arising in the
inbred Vm strain of mice have been extensively
characterised (Pilkington et al., J. Neurol. Sci., 62,
115) but are poorly tumourigenic in syngeneic mice.
We have isolated a panel of 9 lines from one of
these lines (P.497), 2 of which 497-P(1) and 497-
C(1) produce subcutaneous and intracranial
tumours with a uniform latency and predictable
growth rate. One of these lines, 497-P(1), has been
used to study the effects of procarbazine (PCB),
vincristine (VCR), BCNU and CCNU in vivo. PCB,
VCR, CCNU and BCNU produced specific growth
delays of 0.7, 1.2, 1.7 and 3.7 in s.c. tumours
respectively. Mice inoculated in the right cerebral
hemisphere with 1 x 106 497-P(1) cells die with a
predictable mortality distribution (range 10-14
days). A course of chemotherapy with PCB
(100mgkgI x 5) had no significant effect on
survival while VCR (270,ugkg -1 x 5), CCNU
(6mgkg- I x 5) and BCNU (6mgkg- I x 5) pro-
duced 128, 128 and 140% increase in survival
respectively. The similarity in response between
VmDk murine astrocytomas and human glioma
make this a valuable system for drug screening and
studies of drug resistance.
The relationship between cell biological
characteristics and drug sensitivity in six clonal lines
derived from a spontaneous murine astrocytoma
J.L. Darling" 3, R. Bradford', H. Koppel2,
J. Martin2, G.J. Pilkington2, P.L. Lantos2
& D.G.T. Thomas'
Institutes of'Neurology, 2Psychiatry and 3Cancer
Research, London, UK.
Heterogeneity in drug sensitivity must, in part,
account for the relative lack of success with single
agent chemotherapy for malignant glioma. In order
to examine this phenomenon in vitro we have
derived 6 clonal cell lines from the P497 cell line
originally isolated directly from the VmDk
spontaneous murine astrocytoma. These clones
have been extensively characterised using a variety
of morphological, cell biological and immunocyto-
chemical markers (Koppel et al., J. Neurol. Sci., in
press). In addition the drug sensitivity of these lines
has been determined using a 35S-methionine uptake
assay (Morgan et al., Br. J. Cancer, 47, 205, 1983).
The greatest differences in sensitivity between
clones was observed for vincristine (VCR) and
vindesine (VDS), where the ID50's varied between
13.7 and 20-fold respectively. Culture doubling
times varied between 19.1 and 24.2h but there was
no correlation between drug sensitivity and either
growth rate or saturation density. There was a
relationship between cell morphology and
sensitivity; lines predominantly composed of cells
with few processes were more resistant to VCR,
VDS, CCNU and adriamycin (ADR). Cells with
large numbers of intermediate filaments and/or
microtubules tended to be resistant to vinca
alkaloids. Cultures comprised of cells with 60-70
chromosomes/cell were more resistant to BCNU,
CCNU and cis-platinum than cells with more
(>90) chromosomes. The presence of minute
chromosomes in more than 50% of cells in a
culture was related to resistance to ADR. There
appeared to be no relationship between cytoskeletal
marker expression and chemosensitivity. The re-
lationship between phenotypic characteristics and
chemosensitivity is, complex, although we have
demonstrated a clear relationship between geno-
typic changes and alkylating agent sensitivity. We
are currently examining combinations of these
clones in an attempt to determine the effects of cell-
to-cell interaction on chemosensitivity and pheno-
typic expression and whether this will provide
useful information for the development of new
treatment strategies for malignant glioma.
Therapeutic resistance in lung cancer subpopulations
G.A. Walls & P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit,
MRC Centre, Hills Road, Cambridge CB2 2QH,
UK.
We have examined the possibility that the response
to therapy of small cell (SCLC) and non-small cell
(NSCLC) lung cancers may depend on the intrinsic
properties of different tumour cell sub-populations.
Two approaches were taken: (i) cell clones from
one NSCLC and 3 SCLC cell lines were isolated
using the clonogenic method of Courtenay & Mills178 PROCEEDINGS OF BACR 27TH AGM
(Br. J. Cancer, 37, 261, 1978). The responses of
clonal sub-populations to X-rays (2Gy) or adria-
mycin (ADM, 0.5pgml-1 for 1 h) were then deter-
mined; (ii) Cells from the same lines were X-
irradiated 4 times (3 x 4Gy, 1 x 6Gy) over 2
months. One SCLC cell line was exposed on 3 to 4
occasions to various doses of ADM, CCNU or
vincristine. Response of these multi-treated cells to
re-treatment with either X-rays or drugs was then
determined. In all experiments, cells were in log
phase growth at the time of treatment and cell kill
was quantitated using clonogenic assay. Within a
single experiment, clonal sub-populations of SCLC
and NSCLC showed 2 to 4 fold differences in
response to either X-rays or ADM but the relative
response of different clones was not consistent
between experiments. The response of multi-treated
cells to further treatment was similar to that of the
untreated population. However, in almost all
instances, the plating efficiencies of the multi-
treated cells were 1.5 to 2 fold higher than those of
untreated cells. These results indicate that clonal
sub-populations derived from cultured cell lines
generally do not show major intrinsic differences in
response to X-rays or ADM. Although multiple
treatment with X-rays or drugs did not result in cell
populations with increased resistance to further
treatment, it did increase the proportion of
clonogenic cells.
The effect of 3-Acetamidobenzamide on the
proliferation of normal and transformed cells
M.R. Purnell, J.M. Lunn & A.L. Harris
Cancer Research Unit, Royal Victoria Infirmary,
Newcastle upon Tyne NE] 4LP, UK.
3-Acetamidobenzamide (AAB) is the most potent
inhibitor of poly(ADP-ribose)synthetase known to
date with a ki of 0.4gM. We compared the effect of
AAB on the proliferation of three human cell lines
(WI38, embryonic lung fibroblasts; VA13, an SV40-
transformed subline of W138; A549, an epithelial
line derived from a lung adenocarcinoma). A
marked difference was observed between the IC50
values over 4 days between W138 cells and the
transformed lines - 0.8mm AAB for W138 versus
3mM (VA13) and 2.7mm (A549). The difference
was independent of growth rate because WI38 and
VA13 had similar doubling times. Treatment of
cells with cytostatic concentrations of AAB [3mM
(WI38) and 5mM (VA13, A549)] for up to 24h
were reversible as judged by recovery of cell pro-
liferation. Closer examination revealed that viable
A549 cells had been blocked in G1 phase because
over 20h were required following removal of the
drug before the cell number increased over controls
and the increase was blocked by the presence of
2mm hydroxyurea. WI38 cells were also blocked in
G1 because inclusion of AAB in complete medium
added to serum-starved Go cells prevented cells
from entering S phase as judged by 3H-thymidine
incorporation (IC50 =0.5mm AAB). The block
appears to be relatively late in G1 because if 10h
were allowed to elapse between serum stimulation
and AAB addition, the inhibition was the same.
ADP-ribosylation reactions appear to be more
active in W138 cells because treatment with 3mM
AAB for 1 h causes a 60% increase in NAD levels
compared to <20% increase in VA13 cells. In view
of the ability of AAB to protect against the cyto-
toxicity of cell cycle-specific drugs, the differential
sensitivity of normal and transformed cells to AAB
will be discussed in relation to improving the
therapeutic index of these drugs.
N10-propargyl-5,8-dideazafolic acid polyglutamates:
Synthesis, biochemical properties and formation in
vitro
E. Sikora, D.R. Newell, A.L. Jackman,
K. Pawelczak, T.R. Jones & A.H. Calvert
Drug Development Section, Institutefor Cancer
Research, Sutton, Surrey, UK and Chemical
Institute, Opole, Poland.
N10-propargyl-5,8-dideazafolic acid (CB3717), a
tight binding inhibitor of thymidylate synthase
(TS), is a novel antifolate currently undergoing
clinical evaluation. Intracellular polyglutamation is
a known metabolic pathway for both natural
folates and antifolates, which results in increased
cellular retention and greater affinity for certain
folate-dependent enzymes. We have, therefore, in-
vestigated the formation and biological properties
of CB3717 di- and triglutamate. CB3717 polygluta-
mates were synthesised from the tert-butyl esters of
p-aminobenzoic acid di- and triglutamate, charac-
terised by NMR and analysed by reverse phase
HPLC (pBondapak C18 column, 5-16% CH3CN
(10min) in 0.1M NaCH3COO pH5). Against L1210
TS CB3717 di- and triglutamate were 30- and 84-
fold more potent inhibitors than the parent com-
pound, respectively. Ki apparent: CB3717 26+ 3 nM,
CB3717 diglutamate 0.89+0.05nm and CB3717 tri-
glutamate 0.32+0.02nm. Against L1210 cells,
cultured in the presence of heat-inactivated serum,
CB3717 and CB3717 diglutamate were equipotent
(IC50 48h exposure 3sM). However, HPLCPROCEEDINGS OF BACR 27TH AGM 179
analyses indicated that there was no degradation
of CB3717 diglutamate to CB3717 within 48h.
Following a 24h exposure of L1210 cells to 25yM
3H-CB3717, 85-95% of the cellular 3H could be
extracted by boiling in 0.1 M Tris-HCI pH10. This
extract was shown, by HPLC, to contain CB3717
and CB3717 di- and triglutamate. These studies
indicate that CB3717 can be polyglutamated by
L1210 cells in vitro, the products being markedly
more potent than CB3717 as TS inhibitors. How-
ever, against whole cells CB3717 diglutamate was
no more potent than the parent compound.
Comparative studies of DNA cross-linking reactions
following methylene dimethane sulphonate and its
hydrolytic product formaldehyde
P.M. O'Connor & B.W. Fox
Paterson Laboratories, Christie Hospital & Holt
Radium Institute, Manchester M20 9BX, UK.
Methylene dimethane sulphonate (MDMS)
possesses marked antitumour activity against the
rodent Yoshida lymphosarcoma cell line (YS) and
is currently undergoing Phase I trials at Christie
Hospital, Manchester. MDMS is rapidly hydrolysed
(t =22min., 37°C) to release Formaldehyde
(HCHO). Since HCHO can itself be cytotoxic, a
study of the contribution of HCHO to MDMS
induced cytotoxicity was undertaken.
The technique of alkaline elution was employed
to study the interaction of MDMS and HCHO
with DNA from YS cells. MDMS and HCHO
produced a proteinase K sensitive filter retention
which indicated the presence of DNA-protein cross-
links. MDMS also produced some proteinase K
resistant filter retention which was believed to
indicate DNA-interstrand cross-linking. Some single
strand breaks were also detected in the presence of
HCHO. Co-incubation with semi-carbazide pre-
vented all DNA-protein cross-links and single
strand breaks induced by MDMS and HCHO,
while tending to increase the number of DNA-
interstrand cross-links from MDMS. Under these
conditions no DNA-interstrand cross-linking can be
seen following HCHO treatment.
Semicarbazide reduced HCHO induced cyto-
toxicity in the YS cell line while no significant
alteration in MDMS induced cytotoxicity was
observed. These results suggest that HCHO induced
DNA-protein cross-links and single strand breaks
do not contribute to MDMS induced cytotoxicity.
Therefore, MDMS induced DNA-interstrand cross-
links is the likely cytotoxic lesion of this agent.
Gel electrophoretic analysis of HCHO and
MDMS induced DNA-protein cross-links showed
that some proteins cross-linked to DNA by MDMS
differed from those cross-linked by HCHO.
Mechanism for resistance to cyclophosphamide and
its metabolites
A. McGown & B.W. Fox
Paterson Laboratories, Christie Hospital,
Withington, Manchester M20 9BX, UK.
A Yoshida sarcoma tumour (YR/cyclo) showing
decreased sensitivity to cyclophosphamide has been
developed from the parental (Ys) tumour by incre-
mental challenge with the drug in vivo. Resistance
to metabolically activated cyclophosphamide and
phosphoramide mustard has been shown to be
retained when cell lines derived for these tumours
are grown in culture. The ID50 concentrations for
the YR/cyclo and Ys cell lines in vitro, are for
activated cyclophosphamide 36.4jM, and 1.9MM,
and for phosphoramide mustard 47pM, and 2.1 yM
respectively. These values show a similar level of
resistance ( 20-fold) for both the parent drug, and
one of its ultimate metabolites.
Resistance is shown to be associated with a 6-
fold increase in activity of the glutathione S-
transferase group of enzymes, as determined by use
of 1-chloro,-2,4-dinitrobenzene as a substrate. An
increase in glutathione (.2-fold), the co-substrate
for the enzyme, is also seen.
The YR/cyclo cell line is also shown to exhibit a
decreased level of cellular damage, as measured by
alkaline elution, following treatment with phos-
phoramide mustard, compared with the parental
line.
The mechanism of resistance in the YR/cyclo cell
line is proposed to be increased cellular deacti-
vation of potentially damaging metabolites of
cyclophosphamide by the glutathione S-transferase
enzymes, resulting in decreased cellular damage in
resistant cells.
Proteins associated with multidrug resistance in
human lung cancer cell lines
J.G. Reeve & P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit,
MRC Centre, Hills Road, Cambridge CB2 2QH,
UK.
Multidrug resistance (MDR) is often associated
with reduced cellular accumulation of the drugs180 PROCEEDINGS OF BACR 27TH AGM
involved and with changes in plasma membrane
protein composition. Of particular note is the
expression of a 170,000 dalton plasma membrane
glycoprotein which is invariably associated with this
pleiotropic phenotype. A number of multidrug
resistant variants of lung cancer cell lines have
recently been derived in vitro in our laboratories.
Membrane and cytoplasmic proteins of these
variants together with their sensitive counterparts
are currently being investigated using SDS-PAGE.
To date, such studies reveal that MDR in LX4, a
multidrug resistant variant of the small cell lung
cancer cell line NCI-H69, is associated with loss of
a 90Kd membrane protein, hyperexpression of a
100Kd membrane protein and with the acquisition
of a 22Kd cytosolic protein. A rabbit antiserum
has been raised against LX4 cells and following
extensive absorption with NCI-H69 reacts strongly
with LX4 in solid phase RIA. This antiserum
immunoblotted a number of membrane proteins
which are apparently hyperexpressed in LX4 but
not in NCI-H69. The reactivity of this antiserum
with multidrug resistant variants of human non-
small lung cancer cell lines and with murine
multidrug resistant cell lines is currently being
investigated with a view to identifying common
molecular mechanisms of drug resistance.
Elevation of glutathione and glutathione-dependent
enzymes during cell division in ovarian and breast
cancer cell lines
A.D. Lewis & C.R. Wolf
Imperial Cancer Research Fund, Laboratory of
Molecular Pharmacology, Hugh Robson Building,
George Square, Edinburgh, UK.
Glutathione (GSH) and glutathione-dependent
enzymes play a central role in protecting tumour
cells from the effects of cytotoxic drugs. Previously
we have obtained evidence that these enzymes may
be regulated in normal cells during mitosis. We are
interested in the regulation of glutathione and
dependent enzymes in tumour cells in relation to
drug resistance and have investigated these factors
during mitosis. Three tumour cell lines, Ovarian,
PEOI and PE04, and breast cancer, MCF7 were
used and GSH, glutathione transferase (GST), y-
glutamyl-cysteinyl synthetase (GCS), y-glutamyl
transpeptidase (GGT), glutathione peroxidase (GP)
and glutathione reductase (GR) determined in
rapidly dividing log phase and confluent cultures. A
highly significant 2- to 3-fold elevation of GSH was
measured in log cultures of all three cell lines. In
cells synchronised by serum depletion up to 4-fold
elevations were observed. In parallel with these
changes a significant elevation in GCS (-2-fold)
GST (2- to 3-fold) and GP ( 2-fold) were
measured. The increase in GCS, the rate limiting
enzyme in glutathione synthesis, will account for
the increased GSH levels. GGT and GR levels were
not changed in the log cultures. We are currently
evaluating the importance of these observations in
cell division and drug sensitivity.
Effects of glutathione depletion on the toxicity of
cytotoxic agents to tumour cells
M.' d'Arcy Doherty, J. Jordan & G.M. Cohen
Toxicology Unit, The School ofPharmacy,
University ofLondon, 29/39 Brunswick Square,
London WCIN lAX, UK.
Glutathione (GSH) plays a critical role in cellular
defences against alkylating agents, oxidative stress
and free radicals. We have used buthionine sulfoxi-
mine (BSO), a specific inhibitor of GSH synthesis,
to deplete GSH in human colonic tumour cells in
culture. Following an overnight incubation with
BSO (0.1-0.2mM), cellular GSH was depleted to
<20% of the control value. The effect of GSH
depletion on the toxicities of some model
compounds including alkylating agents (melphalan
and helenalin), a compound which redox cycles
(menadione) and a peroxide (H202) was investi-
gated. Pretreatment with BSO had the greatest
effect on the toxicity of helenalin resulting in a 4-
fold decrease in IC50 as measured by an inhibition
of protein synthesis. BSO caused less than a 2-fold
decrease in ICSO values for the other compounds.
As the degree of potentiation was not great and
was only observed over a limited dose range, the
relevance of these findings to the proposed use of
BSO in the clinic as an agent to enhance the
effectiveness of some antitumour agents will be
discussed.
The influence of pH on drug cytotoxicity in vitro
E. Groos, L. Walker, & J.R.W. Masters
Department ofHistopathology, Institute of Urology,
St. Paul's Hospital, 24 Endell Street, London
WC2H 9AE, UK.
Intravesical chemotherapy is used in the manage-
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conditions for its administration have not been
defined. In this study we investigated the influence
of pH on the cytotoxicities in vitro of the four most
frequently used drugs: adriamycin, epodyl, mito-
mycin-c and thiotepa, in addition to cis-platin and
epirubicin. The colony-forming ability of RTI 12 (a
continuous cell line derived from a transitional cell
carcinoma of the human bladder) was measured
following a 1 h exposure to each drug at eleven pH
values ranging from 5.2 to 9.7. Mitomycin-c, cis-
platin and thiotepa showed increasing cytotoxicity
as the pH became more acidic. For example, repro-
ductive cell survival fell from 91.3% to 16.2%
following exposure to 8pgml-1 thiotepa when the
pH was reduced from 8.0 to 6.1. In contrast with
adriamycin and epirubicin cytotoxicity was greatest
in alkaline media. Epodyl showed similar activity
throughout the pH range. It is concluded that the
therapeutic value of intravesical chemotherapy
might be enhanced by instilling the drugs in
solutions buffered at the optimum pH for each
agent.
The influence of osmolality on drug cytotoxicity in
vitro
E. Groos, L. Walker & J.R.W. Masters
Department ofHistopathology, St. Paul's Hospital,
24 Endell Street, London WC2H 9AE, UK.
The osmotic strength of the instillate is one of the
factors that could influence the effectiveness of
intravesical chemotherapy for superficial bladder
cancer. In this study we investigated the effect of
osmolality on the cytotoxicities of the four drugs
most frequently used: adriamycin, epodyl, mito-
mycin-c and thiotepa, in addition to cis-platin and
epirubicin. The colony-forming ability of RT112 (a
continuous cell line derived from a transitional cell
carcinoma of the human bladder) was measured
following a 1 h exposure to each drug in media
of six osmotic strengths ranging from 125-
590mOsmkg- 1 H20. Osmotic strength was
modified by adding either distilled water or 50%
dextrose to tissue culture medium. Osmolality had
little effect on the cytotoxicities of adriamycin and
epodyl, but the other drugs killed more cells in
hypo-osmotic media. For example, reducing the
osmolality from 290 to 200mOsmkg- I H2O
increased the clonogenic cell kill of 2.5Migml-1 of
cis-platin from 20% to 99%. Urine from bladder
cancer patients before treatment had osmolalities
ranging from 187-852mOsmkg-1 H20, and these
had decreased on average by 135mOsmkg-1 H20
at the completion of intravesical chemotherapy. The
osmotic strengths of solutions of clinical prepar-
ations of the drugs at a concentration of 1 mgml -
were (a) in distilled water, 63-1,015mOsmkg-1
dH2O and (b) in 0.9% saline, 301-
1,038mOsmkg-1 dH2O. It is concluded that the
therapeutic value of intravesical chemotherapy
might be enhanced by reducing the osmotic
strength of the instillate.
The reversal of the cytotoxicity of folate-based
thymidylate synthase inhibitors in cultured L1210
cells
A.L. Jackman', L. Cameron1, R. Moran2
& A.H. Calvert
1Drug Development Section, Institutefor Cancer
Research, Sutton, Surrey, UK and 2Children's
Hospital ofLos Angeles, USA.
Some analogues of folic acid have been shown to
be inhibitors both of isolated thymidylate synthase
(TS) and of dihydrofolate reductase (DHFR),
enzymes linked in the oxidation-reduction cycle of
tetrahydrofolic acid (FH4). Mathematical modelling
demonstrated that a dual inhibitor should act
effectively at one locus, which would be TS until Ki
TS/Ki DHFR approaches 3,000 (Jackson et al.,
Biochem. Pharmacol., 32, 3783, 1983). One com-
pound that clearly acts by inhibition of TS is N10-
propargyl-5,8-dideazafolic acid (CB3717: Ki TS
4nM; IC50 in culture=5pM). In L1210 tissue culture
(48 h exposure), thymidine (dThd) reversed the
cytotoxic effects of CB3717 and this reversal was
dose-independent. However, if exposure to both
drug and dThd was for 72h a marked CB3717
dose-dependent reversal was observed such that any
concentration above 50/iM was poorly reversed by
dThd (0.1 mm and 1 mm CB3717 gave 50% and
30% of control cell growth respectively). This dose-
dependent dThd reversal was even more apparent
with compounds having a greater Ki TS/DHFR
ratio. Cytotoxicity at 72h was readily reversed by
the addition of either a purine or folinic acid,
together with dThd. A DHFR overproducing cell
line (L1210:R7A) was insensitive to 1 mm CB3717
in the presence of dThd even at 72h. In tissue
culture, dividing cells are dependent on the uptake
and reduction of folic acid from the medium in
order to maintain the level of intracellular reduced
folates. We suggest that the weaker inhibitory
effects of these compounds on DHFR may become
important in the presence of dThd, by preventing
this reduction. When DHFR is overproduced the
cells become insensitive to the DHFR effects, a
purineless state is not induced and consequently
dThd alone is an effective rescue agent.182 PROCEEDINGS OF BACR 27TH AGM
Organ-culture of colonic tissues as a model for
investigating the mechanism of anti-metabolite action
M. Moorghen1, P. Incel, K.J. Finney1,
A.L. Harris2 & A.J. Watson1
Departments of'Pathology and 2Clinical Oncology,
University ofNewcastle upon Tyne, Newcastle upon
Tyne, UK.
Organ-culture is a means of studying in vitro cell
proliferation in human and rodent colonic tissues.
We have used the technique to investigate the
biochemical effects of anti-metabolite drugs on
intact epithelium.
Explants of rat colonic mucosa were incubated
with [methyl-3H] thymidine (*TdR) together with
other drugs at varying concentrations. After a 4h
incubation period, the explants were washed. They
were then dissolved by overnight incubation at
room temperature in 0.2M NaOH, and the uptake
of *TdR measured by liquid scintillation counting.
Total DNA was also measured by the DAPI
fluorometric method.
1 mm of Hydroxyurea caused maximum inhi-
bition of *TdR uptake. This is similar to obser-
vations made in cell lines. 5-Fluorouracil (5 FU)
and 5-Fluoro-2-deoxyuridine (5 FUDR) failed to
show an effect on *TdR uptake in this system,
despite the finding in cell-lines of an increased
uptake. This absence of effect may be related to an
RNA rather than a DNA-directed effect.
The metabolic effects demonstrated by this
method, as compared to methods involving cell
lines, are likely to reflect more closely the in vivo
action of this class of drugs.
We are now studying 5 FU and 5 FUDR to-
gether with biochemical modulators in normal
colonic mucosa and carcinoma tissues from humans
and rats.
12-0-Tetradecanoylphorbol-13-acetate (TPA) and the
antitumour drug adriamycin (ADR) modulate
morphological transitions of human erythrocytes
(RBC)
M.G. Thompson, S.B. Chahwala, T.F. Walker,
B. Jones & J.A. Hickman
CRC Experimental Chemotherapy Group, Aston
University, Birmingham B4 7ET, UK.
The effects of the tumour promoter TPA on cell
morphology resemble those brought about by the
transforming tumour viruses, and are, at least in
part, the consequence of direct effects upon the cell
membrane/cytoskeleton (Dreidger et al., Cancer
Res., 37, 3257, 1977). Recently, attention was
drawn to the similarities in the effects of TPA and
the antitumour drug adriamycin on membrane
structure and function (Zuckier & Tritton, Exp.
Cell. Res., 148, 155, 1983). We have reported that
ADR modulates the morphological transition of
RBC from discocyte to echinocytes (Cancer Res.,
45, 4986, 1985). When 107 RBCml-1 were incu-
bated under conditions of ATP depletion at 370 in
an isotonic Tris-salt buffer, 10-7 M TPA delayed
the formation of echinocytes: after 2h controls
contained 65% echinocytes, TPA-treated cells 23%.
Echinocytosis was complete by 3 h in controls and
5h in TPA-treated cells. Preincubation for 10min
of 107RBCml-1 with TPA (200nM) inhibited by
50% the echinocytosis induced by 0.2mmCa2+ and
5Mm A23187. TPA and ADR had no effect per se
on discocyte morphology at concentrations of up to
100UM, and are therefore unlike the amphipathic
drugs, such as phenothiazines, which modulate
morphological change but are themselves able to
alter morphology to stomatocytes. The distinctive
effects of ADR and TPA on RBC morphological
change suggest that they may be acting via a
common biochemical mechanism.
Involvement of Ca2 + in anthracycine resistance
A. McGown & B.W. Fox
Paterson Laboratories, Christie Hospital & Holt
Radium Institute, Withington, Manchester
M20 9BX, UK.
Resistance to daunorubicin has been shown to be
associated with a 3 fold decreased drug accumu-
lation in resistant P388R8/13 cells as compared
with the parental cell lines. The technique of flow
cytometry has been used to directly quantitate
daunorubicin levels in individual cells by utilising
the intrinsic fluorescence of the drug. The agents
verapamil, perhexiline maleate, flunarizine,
cinnarizine, nicardipine, nifedipine, lidoflazine, and
diltiazem are known to alter calcium transport in
certain tissues. These are shown to be able to
increase intracellular daunorubicin in resistant P388
cell lines, to the level observed in the parental line.
No effect on daunorubicin accumulation is seen in
the parental cell line. The effects of these agents on
Ca2+ influx into the parental and resistant cell lines
have been studied by using 45Ca2 . None of these
agents show any effect on 4'Ca2+ influx in either
the resistant or parental cell lines at concentrations
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daunorubicin itself does not alter 45Ca2+ flux in
these cell lines. The calcium ionophore A23187
which increases intracellular 45Ca2+, is also shown
to elevate daunorubicin levels.
Since anthracycline accumulation in resistant cells
is not directly associated with inhibition of calcium
transport, it is concluded that it may be possible to
design agents capable of altering anthracycline
sensitivity but without the toxicity associated with
inhibition of calcium transport.
Effects in spheroids of anthracyclines of different
lipophilicity
T.T. Kwok & P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit,
MRC Centre, Hills Road, Cambridge, UK.
Adriamycin (ADM) is a widely used drug in the
therapy of solid tumours. It has, however, been
found to penetrate poorly into cellular aggregates
and to be relatively ineffective against plateau
phase cells in vitro. Using a selective disaggregation
method, we have previously shown (Kwok &
Twentyman, Int. J. Cancer, 35, 675, 1985) that a
short exposure to ADM kills relatively few cells in
the innermost regions of large (-800p diameter)
multicellular spheroids of the EMT6/Ca/VJAC
mouse tumour cell line. One property of ADM
which may be involved in its poor penetrating
ability is its low lipophilicity (octanol/water
partition coefficient (PC)=0.46). We have therefore
examined the differential cytotoxicity within
spheroids of a number of anthracycline analogues
produced by Roche Products Ltd and differing
widely in PC. The compounds studied are Ro 31-
1741 (PC= 13), Ro 31-1215 (PC=28) and Ro 31-
2035 (PC>100). All 3 novel anthracyclines showed
much greater cytotoxicity towards cells in the outer
compared with the inner region of EMT6 spheroids
at the dose levels studied. Direct comparison of
relative cell killing is complicated by the different
potencies of the drugs studied. However, the slope
of the cytotoxicity curve against spheroid depth is
less steep for Ro 31-2035 than for the other agents
(including ADM). Fluorescence measurement of the
cellular drug content within different cell fractions
isolated from spheroids indicate that, for a given
external medium concentration, the accumulation
of Ro 31-2035 is 3-10 x that of the other drugs. A
considerable differential in drug content between
outer and inner cells is, however, seen for all 3
agents. Studies on log and plateau phase monolayer
cells (in progress) will enable a more detailed
analysis of the spheroid data to be carried out.
The effect of the surfactant Brij 30 on cellular
uptake and cytotoxicity of adriamycin (ADR) in lung
tumour monolayers and spheroids
D.J. Kerr1, T.E. Wheldon2, J. Russell2,
A.T. Florence3 & S.B. Kaye'
1Department ofMedical Oncology and
2Radiobiology Group, Glasgow University and
3Department ofPharmacy, Strathclyde University,
Glasgow, UK.
Resistance of intact spheroid cells to adriamycin
treatment has been reported and the existence of
drug penetration barriers has been postulated. We
have studied the effects of a polyoxethylated
surfactant (Brij 30) on monolayer uptake and
spheroid penetration of adriamycin. Human lung
non-small cell tumour monolayers (L-DAN line)
were exposed for varying times to ADR (±Brij 30,
0.001% solution) over a wide concentration range.
Intracellular drug levels were measured, after
organic extraction, by a sensitive HPLC assay. The
cytotoxicity of ADR (±Brij 30) was tested in a
standard clonogenic assay after exposure of mono-
layers and intact spheroids to drug for 1 hour, with
subsequent disaggregation to a single cell suspension.
Spheroids were exposed to ADR (±Brij 30) for 1 h,
and then transferred to multiwell petri dishes where
consecutive measurements of diameter were made
using an image analysis system. Co-incubation with
Brij 30 increases intracellular ADR levels by 2-3 fold.
ADR+Brij is significantly more cytotoxic (mono-
layer ID90 0.6 gm1-1; disaggregated spheroid
ID50 1.9Mgml-1) than ADR alone (monolayer ID90
2.1Mgml
-1;disaggregated spheroidID50 3.3Mgml
-1).
In addition, fluorescence microscopy has shown that
Brij 30 increased the intraspheroidal depth to which
ADR diffused. Conclusion: Brij 30 enhances mono-
layer cytotoxicity of ADR and may overcome
spheroidal penetration barriers with an improved
cytotoxic effect.
Comparison of cis-platin-induced DNA damage in
human bladder and testicular tumour cell lines
P. Bedford, J.R.W. Masters & B.T. Hill
Imperial Cancer Research Fund Laboratories,
Lincoln's Inn Fields, London WC2A 3PX and
Institute of Urology, Endell Street, London
WC2 9AE, UK.
Cis-platin is an effective chemotherapeutic agent in
the treatment of bladder and testicular tumours184 PROCEEDINGS OF BACR 27TH AGM
(Prestayko et al., Cancer Treat. Rev., 6, 17, 1979).
Since DNA is an important target for this drug, we
compared DNA damage and repair following cis-
platin exposure in human tumour continuous cell
lines derived from two transitional cell carcinomas
of the bladder T24 and RT112) and one testicular
germ cell tumour (SUSA). Concentrations of cis-
platin reducing in situ colony formation to 10% of
the control after a 1 h exposure were 3.1, 7.6 and
14.6pgml-l for SUSA, T24 and RT112 cells
respectively. DNA-DNA interstrand crosslinks and
DNA single-strand breaks were measured at 0, 5,
14 and 24h after a one hour exposure to a range of
cis-platin concentrations (2-20pgml-1) using the
technique of alkaline elution (Kohn et al., In DNA
Repair: A Laboratory Manual of Research
Procedures., Vol. 1. Part B. (eds.) Friedberg et al.,
Marcel Dekker, NY, p. 379, 1981). Maximum
numbers of crosslinks were detected at 5h for T24
cells and at 14h for RT112 cells with a subsequent
decrease at 24h. In the SUSA cell line crosslinking
continued to increase up to 24h. Single-strand
breaks were detected only in the SUSA cells. Peak
numbers of crosslinks in SUSA, T24 and RT112
cells were 28.8, 97.7 and 54.6 rad-equivalents
respectively after exposure to 10pgml-l cis-platin.
Further studies are in progress to determine if these
differences in total numbers of crosslinks are a
consequence of differential drug penetration or
binding to DNA.
In vitro drug resistance; interactions between
X-irradiation and etoposide
R.B. Lock & B.T. Hill
Laboratory ofCellular Chemotherapy, Imperial
Cancer Research Fund, Lincoln's Inn Fields, London
WC2A 3PX, UK.
A human tumour continuous cell line (HN-1) has
been made resistant to etoposide (VP-16-213) by
either exposure to fractionated X-irradiation or
continuous exposure to VP-16-213 (Lock & Hill,
Br. J. Cancer, 52, 425, 1985). Drug responses were
established by cell survival assays using soft agar
(Courtenay & Mills, Br. J. Cancer, 38, 77, 1978).
ICso values for the parent (HN-1), X-irradiation
treated (HN-1/DXR-5) and drug treated (HN-
1/VP-2) cells were 3.1, 5.0 and 9.7 M respectively
following a 1 h exposure to VP-16-213. These
differential responses to etoposide could not be
accounted for in terms of altered accumulation of
VP-16-213, since drug uptake studies revealed no sig-
nificant differences between the three lines: exposure
to 3.1 gM [3H]-etoposide for 30min resulted
in 18.3+ 1.9, 20.1 +0.5 and 19.1 +4.6pmolmg-1
protein associated with the HN-1, HN-I/DXR-5 and
HN-1/VP-2 cells respectively. Although altered
levels of non-protein sulphydryl compounds have
been implicated in resistance mechanisms, no signi-
ficant differences were detectable in logarithmically
growing cells from the 3 lines (Lock & Hill, 1985)
and glutathione S-transferase activity was also
comparable in the parental and drug treated lines
with activities of 249+24 and 234+17nmolmg-1
min-' respectively. However, alkaline elution
studies have revealed a reduction in total DNA
breakage and estimated single-strand breakage
(SSB) in the drug treated subline (HN-1/VP-2)
compared to the parental line after exposure
to equimolar concentration of VP-16-213. Rad-
equivalent values for total DNA breakage are
346+35 and 461+ 11, and for SSB are 625+ 131
and 1,252+309 for HN-1/VP-2 and HN-1 cells
respectively (8.5yM VP-16-213, 1 h). These data
suggest that resistance to VP-16-213 in these cells
may be associated with reduced activity of DNA
topoisomerase II.
Drug resistance in human non-small cell lung cancer
cell lines - the role of membrane transport
S. Merry, E.R. Courtney, S.B. Kaye
& R.I. Freshney
Department ofMedical Oncology, University of
Glasgow, I Horselethill Road, Glasgow G12 9LX,
UK.
We have shown (Fetherston et al., Br. J. Cancer,
51, 598, 1985) that 6.6jM verapamil (VPM)
increased the sensitivity (up to 29-fold) of human
non-small cell lung cancer cell lines to adriamycin
(ADR), vincristine (VC) and etoposide (VP16).
None of these cell lines had been exposed to
cytotoxic drugs in vitro. Here we report the effects
of 6.6pM VPM on ADR, VC and VP16 accumu-
lation in 2 resistance cell lines (A549 and SK-MES-
1). Exponentially growing cells (105 cellscm-2)
were seeded into 10mm diameter soda glass
specimen tubes and, after 3 days, radio-labelled
drug was added to replicate tubes for 0, 30, 60 or
90min in the presence or absence of VPM. Drug
accumulation was then determined by scintillation
counting of the washed, solubilised cell monolayer.
For VC increases in accumulation of up to 4-fold
were seen, with the greatest increase seen in the cell
line SK-MES-1 in which the greatest effect of VPM
on cytotoxicity was noted. For ADR and VP16
smaller increases in drug levels (up to 1.6-fold) were
seen. This suggests that enhancement by VPM ofPROCEEDINGS OF BACR 27TH AGM 185
ADR and VP16 activity in these cell lines may
operate through mechanisms additional to its effect
on intracellular drug levels. Another cell line (WIL)
has been established as a subcutaneous xenograft
tumour line in nude mice. In this model 40ugg-g
VP16 i.p. together with 25pgg-' VPM i.p. was
shown to produce a significantly longer (P=0.01)
tumour volume doubling time compared to
40pgg-1 VP16 alone. Studies of the effect of VPM
on VP16 levels in WIL xenografts are in progress.
Furthermore a randomized clinical trial assessing
the role of verapamil in the treatment of lung
cancer is also in progress.
synthesis inhibitor, failed to significantly increase
cis-platinum sensitivity. Preliminary experiments
show no difference in cis-platinum uptake into the
resistant cells as measured by atomic absorption
spectroscopy but using the alkaline elution
technique there is a 2-fold difference between the
cell lines in cis-platinum-induced DNA cross-
linking.
Apparent lack of repair of carboxymethylated DNA
by alkyltransferase proteins
Resistance to cis-platinum and patterns of
cross-resistance in two autologous human ovarian
adenocarcinoma cell lines
I.P. Hayward, S.S. Lawrie, A.R.R. Laudonio,
A. McDonald & J.F. Smyth
Imperial Cancer Research Fund Medical Oncology
Unit, Western General Hospital, Edinburgh, UK.
Two human ovarian carcinoma cell lines have been
established from ascites samples from the same
patient before (PEOl) and after (PE04) the onset of
clinical resistance to a combination of 5-
fluorouracil, chlorambucil and cis-platinum. Their
sensitivity to various drugs in vitro (72h exposure)
was investigated by a clonogenic assay on plastic.
PE04 shows a 3 x increase in resistance to cis-
platinum (ID50 0.20 M for PE04 vs. 0.064pm for
PEOI) and chlorambucil (ID50 3.2ym vs. 1.0pM)
but not to 5-fluorouracil (ID50 5.2yM vs. 4.8,pM).
PE04 showed various levels of increased resistance
compared with PEOI to cis-platinum analogues
with 7 x difference to malonato platinum (JM40),
2.7x difference to carboplatin (CBDCA) and no
difference in sensitivity to isopropylamine platinum
(CHIP). Small increases in resistance between 1.5-2
fold were observed towards adriamycin, vincristine
and mitozantrone. Another alkylating agent,
melphalan, showed a 3-fold increase in resistance
for PE04. Possible mechanisms for the increased
resistance observed in PE04 against cis-platinum
have been investigated. PE04 has increased levels of
glutathione and glutathione-S-transferases (Wolf et
al., Br. J. Cancer, 50, 276, 1984). However incu-
bation with minimally toxic doses of buthionine-
S-sulfoximine (100 M for 24h), a glutathione
D.E.G. Shuker', J. Brennand2 & G.P. Margison2
1MRC Toxicology Unit, Woodmansterne Road,
Carshalton, Surrey SM5 4EF and 2Paterson
Laboratories, Christie Hospital, Manchester
M20 9BX, UK.
N-nitrosoglycocholic acid (NOGC) is a mutagenic
and carcinogenic derivative of the naturally occur-
ring bile acid conjugate, glycocholic acid. NOGC
reacts with calf thymus DNA in vitro to give a
number of carboxymethyl adducts of which N-7-
carboxymethylguanine and N-3-carboxymethyl-
adenine have been identified (Shuker &
Tannenbaum, Br. J. Cancer, 52, 443, 1985).
Using extracts of E. coli harbouring a plasmid
containing a gene coding for 06-AG alkyltransferase
(AT; Margison et al., Nucl. Acid Res., 13, 1939,
1985) in an in vitro competition assay we found
that NOGC-treated calf thymus DNA inhibited the
action of the AT on methylated DNA. This
suggested that repairable carboxymethyl adducts
were present, however, we were unable to detect
any transfer of (I4C)-carboxymethyl groups from
(14C)-NOGC treated DNA to the repair protein as
has been observed for other alkyl groups. More-
over, the profile of adducts in DNA hydrolysates
did not change following treatment of the DNA
with the AT-containing extracts.
We have now established that O6-carboxymethyl
guanine (06-CMG) is present in NOGC treated
DNA and that it is not removed by E. coli AT.
Human fibroblast AT also appeared to be
ineffective in removing 06-CMG.
We are currently attempting to establish whether
our results may be due to extremely low rates of
AT action on 06-CMG.186 PROCEEDINGS OF BACR 27TH AGM
Potentiation of the cytotoxic action of DTIC:
Involvement of 06-methylguanine-DNA
methyltransferase
J.M. Lunn', A.L. Harris', P.M. Brown1,
C. Pierpoint 2 & B.T. Golding2
'Cancer Research Unit and 2Department of Organic
Chemistry, University ofNewcastle upon Tyne, New-
castle upon Tyne NE] 4LP, UK.
The cytotoxicity of MTIC, the active metabolite of
the antitumour drug 5-(3,3-dimethyl-1-triazeno)-
imidazole-4-carboxamide (DTIC), was assessed by
measuring proliferation following exposure of
cultured cells to MTIC.
Sensitivity of cells to MTIC correlated with their
Mer/Rem phenotypes. Sensitivity increased in the
order HT29 (Mer+Rem+) <A549 (Mer+Rem-)
<VA13 (Mer-Rem-), indicating involvement of
the 06-methylguanine lesion in cytotoxicity.
Further, 06-methylguanine has been detected by
HPLC in DNA treated in vitro with MTIC. Pre-
treatment of cells with non-toxic levels of MTIC
rendered them ore sensitive to subsequent exposure
to chloro-nitrosourea (CNU).
MTIC cytotoxicity was potentiated by 3-
acetamidobenzamide (3AAB), an inhibitor of
adenosine diphosphoribosyl transferase (ADPRT).
The enhancement was 3-4-fold for A549 cells.
However, such treatment did not render HT29 cells
as sensitive to MTIC as VA13 cells. It seems
probable that more than one type of cytotoxic
lesion is involved.
Sensitivity of methotrexate resistant colorectal cancer
cells to monoclonal antibody targeted methotrexate
L. Durrant, N.C. Armitgage, M.C. Garnett,
R.W. Baldwin & J.D. Hardcastle
Departments ofCancer Research and Surgery,
University ofNottingham, Nottingham, UK.
A major problem in the chemotherapy of colorectal
cancers is resistance to most cytotoxic drugs which
may be due to insufficient cellular transport
mechanisms. Drugs conjugated to monoclonal anti-
bodies recognising tumour antigens may overcome
these difficulties providing access of active agents to
the tumour cells. The antitumour monoclonal anti-
body 791T/36, shown to localise in patients with
colorectal cancer (Armitage et al., Br. J. Surg., 71,
407, 1984) has been investigated as a potential
targeting antibody. Three cell lines (C146, C168,
C170) were newly established from surgically
resected material and the cytotoxicity of 791T/36-
methotrexate compared with that of free metho-
trexate by a 75Se-selenomethionine incorporation
assay. The dose necessary to achieve 50% cell
killing (IC50) was calculated. Antibody binding was
measured flow cytometrically by indirect
fluorescence.
Antibody binding
FI units/cell
Cell lines Control NMT 791T/36
C146 26+8 377+70
C168 19+9 181+44
C170 11+5 182+16
Cytotoxicity LC50 (ngml-1)
Cell lines Methotrexate 791T/36-Methotrexate
C146 972+66 51+11
C168 5,179+ 1,166 357+42
C170 1,790+ 168 162+26
In all cell lines there was significant binding of
antibody (T=6.7, df 8 P<0.001) and significant
cytotoxicity for 791T/36-methotrexate with resis-
tance to free methotrexate (T=4.1, df 9 P<0.005).
Monoclonal antibody directed chemotherapy
rendered methotrexate resistant colorectal cancer
cells sensitive to that agent, providing further
impetus for trials of antibody-drug conjugates in
patients with colorectal cancer.
Cytotoxicity against human tumour cells by
'cocktails' of monoclonal antibody-drug conjugates
M.J. Embleton', J. Harte', V.S. Byers2,
M.C. Garnett', J. Gallegol & R.W. Baldwin'
'Cancer Research Campaign Laboratories,
University ofNottingham, Nottingham NG7 2RD,
UK and2The XOMA Corporation, Berkeley, CA
94710, USA.
In an attempt to increase in vitro cytotoxicity
against cultured human tumour cells mediated
by drug-antibody or antibody-toxin conjugates,
tumour cells were exposed to different conjugates in
combination. The conjugates used were; (a) metho-
trexate linked by human serum albumin to C24, a
monoclonal antibody to CEA/NCA; (b) metho-
trexate linked by human serum albumin to anti-
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sarcoma cells; (c) daunomycin linked directly to
791T/36, and (d) ricin toxin A chain linked directly
to 791T/36. Cytotoxicity was analysed by a 40h
75Se-selenomethionine incorporation test on cell
lines 791T (osteogenic sarcoma), MKN45 (gastric
carcinoma), and LS174T and C170 (colon car-
cinomas).
Each conjugate as a single agent was toxic to
cells expressing the antigen detected by its
respective antibody moiety and most were selective,
although their individual levels of performance were
variable (d>b>a>c). Mixtures of conjugates
prepared with the same antibody (79IT/36) but
different drugs showed no increase in cytotoxicity
over that obtained with the most effective single
agent, but there was a trend towards greater cyto-
toxicity when conjugates prepared with different
antibodies reacting with the same target cell line
were used in combination. These results support the
conclusion that the effectiveness of agents targeted
with a single antibody is limited by target antigen
density, but conjugates prepared with antibodies
recognising different target epitopes may have an
additive effect. It is suggested that, given conjugates
of optimal performance, cocktails of conjugates
recognising different target cell antigens might offer
a means of achieving significantly increased anti-
tumour activity.
Conjugates of N-(2-hydroxypropyl)methacrylamide
copolymers and daunomycin: Toxicity against L1210
leukaemia in vitro and in vivo
R. Duncan1, P. Kope6ekova-Rejmanova2,
J. Kope6ek2 & J.B. Lloyd'
1Department of Biological Sciences, University of
Keele, Keele, Staffordshire ST5 SBG, UK and
2Institute of Macromolecular Chemistry,
Czechoslovak Academy of Sciences, 162 06 Prague
6, Czechoslovakia.
Drugs used in cancer chemotherapy are notorious
for their lack of specificity of action. Over recent
years we have developed a soluble synthetic polymer
(N-(2-hydroxypropyl)methacrylamide; HPMA) as
a drug carrier for tumour-specific drug delivery
(Kopecek et al., Ann. New York Acad, Sci., 446,
93, 1985). HPMA copolymers have been synthesised
bearing the side-chains P-GlyPheLeuGly-dauno-
mycin (biodegradable) or P-GlyGly-daunomycin
(non-biodegradable). Certain polymers also have
pendent fucose residues (L1210 leukaemia cells have
a cell-surface receptor that recognises and binds this
carbohydrate moiety). The conjugates were tested
against L1210 cells in vitro and in vivo.
HPMA copolymers bearing daunomycin
inhibited growth of L1210 in vitro. Although less
active than equivalent concentrations of free drug,
activity did correlate with the enzymic degradability
of the polymer-drug linkage. The presence of fucose
residues potentiated toxicity of the conjugate in
vitro. Conjugates with biodegradable polymer-drug
linkages significantly increased the lifespan of mice
previously inoculated i.p. with 105 L1210 cells.
Conjugates with a nondegradable linkage were
completely ineffective in vivo.
A comparison of monoclonal anti-CEA antibodies for
localisation and therapy of gastrointestinal
malignancies
F. Macdonald, W.H. Allum, P. Life
& J.W.L. Fielding
Surgical Immunology Unit, Queen Elizabeth
Hospital, Birmingham, UK.
Antibodies for use as carriers of isotopes or drugs
for radioimmunolocalisation or drug therapy have
to be carefully characterised before use in patients.
Four monoclonal antibodies to CEA, recognising
four different epitopes, have been compared alone
and in combination for their ability to localise CEA
expressing tumours in a mouse xenograft model
(HT29 and MKN-45 cell lines). One antibody, 11-
359-6, lost its anti-CEA activity on labelling. 11-
357-5 showed the highest tumour:blood ratios, 1.84
by 72h but this ratio decreased by 96h suggesting
specific loss by the tumour. In addition, this anti-
body cross-reacted with normal stomach. Both 11-
285-14 and 14-95-55 showed increasing ratios in the
tumour up to 96h (1.45 and 1.31 respectively) but
no uptake by normal tissues. The maximum
tumour:blood ratio obtained by either 11-285-14 or
11-357-5 alone N\as not increased by mixing the two
antibodies. However the ratios of the mixture at
24h and 48 h were higher than either antibody
alone at these times. In addition, high specific
counts were obtained in the tumour.
Combinations of 11-285-14 and 14-95-55 did not
increase the tumour:blood ratio and showed signifi-
cantly lower levels than either alone (max. ratio at
96h of 0.9). The fate of cell surface associated
antibodies was followed by FACS analysis. 11-357-
5, 11-359-6 and 11-285-14 remained associated with
the cell surface at 370 C and 40 C. However at
370 C, 14-95-55 is endocytosed.
These results suggest that 11-285-14 is the most
suitable antibody for radioimmunolocalisation with
11 I-labelled antibody since it may be dehalo-
genated if internalised, resulting in loss of isotope188 PROCEEDINGS OF BACR 27TH AGM
from the cell. 14-95-55 may be more suited to
targeted therapy particularly if drugs or toxins have
to enter the cell to have cytotoxic effects.
Monoclonal antibody-drug conjugate 791T/36-
methotrexate localisation in colorectal cancer
K.C. Ballantyne, A.C. Perkins, M.V. Pimm,
M.C. Garnett, N.C. Armitage, R.W. Baldwin
& J.D. Hardcastle
Experimental and clinical imaging of gastrointestinal
carcinomas with IIIIn-labelied anti-CEA monoclonal
antibodies
M.V. Pimm1, A.C. Perkins2, K.D. Ballantyne3,
L. Durrant1, I. Pawluczyk1, L. Jacobs1,
M.R. Price1, J.D. Harcastle3 & R.W. Baldwin'
'Cancer Research Campaign Laboratories,
University ofNottingham and Departments of
2Medical Physics and 3Surgery, University Hospital,
Nottingham, UK.
Monoclonal antibodies against CEA have wide
potential as radiopharmaceuticals for tumour
imaging and in the present study three new anti-
bodies have been examined.
Antibodies 161 and 198 (IgGl), reacted with a
CEA/NCA epitope. Antibody 228 (IgG2a),
produced against purified CEA, reacted with a
CEA specific epitope. Antibodies were radiolabelled
with "1'In because of the attractive physical charac-
teristics of this radionuclide for immunoscinti-
graphic studies. To permit radiolabelling, antibodies
were conjugated to diethylenetriamine penta acetic
acid (DTPA) by reaction with DTPA anhydride at
a 2:1 molar ratio. Subsequent chelation of "'1In
gave products with specific activities of
100MBqmg-1 and which bound to CEA pro-
ducing target cells but not to antigen negative cells.
Gel filtration chromatography of labelled anti-
bodies in the serum of mice showed radiolabelled
material predominantly as monomeric IgG, with no
aggregated product or transfer of "1'In to
transferrin. Gamma scintigraphy of nude mice with
LS174T and HT29 colon carcinoma and MKN 45
gastric carcinoma xenografts showed localisation of
"'In-labelled antibodies in tumours.
The levels of radioactivity in tumour and normal
colon from five patients given 111In-161 antibody
gave mean tumour:normal issue uptake ratios of
5.8:1 but no tumour sites were detected by external
imaging. 11In-198 antibody also failed to image
tumours, but showed high bone marrow uptake.
11In-228 antibody showed intermediate bone and
liver uptake.
These studies illustrate the diverse nature and
tumour imaging properties of anti-CEA monoclonal
antibodies.
Departments ofSurgery, Medical Physics & Cancer
Research Campaign Laboratories, University of
Nottingham, Nottingham, UK.
The monoclonal antibody 791T/36 has previously
been shown to localise in colorectal cancer with
a tumour:nontumour (T:NT) ratio of 2.5:1
(Armitage et al., Br. J. Surg., 71, 407, 1984). This
antibody has been successfully conjugated to
methotrexate (MTX) for use in anticancer therapy
(Garnett et al., Int. J. Cancer, 31, 661, 1983). The
aim of this study was to establish whether
conjugation of this antibody affected its tumour
localisation or biodistribution.
Ten patients with primary colorectal cancer were
injected intravenously with 131I-radiolabelled
791T/36-MTX (200,ig antibody and 1.6pg
methotrexate), following a subcutaneous test dose.
Gamma-camera antibody images were obtained at
48-72h and analysed using computerised sub-
traction. Freshly resected surgical tissue (tumour
and normal colon) and daily serum samples were
counted and T:NT uptake ratios and blood
clearance profiles calculated. The distribution of
791T/36-MTX was similar to that of free antibody.
On direct measurement there was positive tumour
uptake in all cases with a mean T:NT of
3.9+2.1: 1. The clearance of the drug-antibody
conjugate was biphasic with a biological half life of
22h.
Conjugation of methotrexate to the monoclonal
antibody 791T/36 did not change its tumour local-
isation or biodistribution and trials of drug-
antibody conjugate are indicated in colorectal
cancer.
Dose dependent biodistribution and tumour
discrimination with a radiolabelled monoclonal
antibody
M.V. Pimm, R.A. Robins, W. Pascoe, M.R. Price
& R.W. Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, Nottingham, UK.
There are now numerous clinical reports of in vivo
tumour localisation of radiolabelled monoclonalPROCEEDINGS OF BACR 27TH AGM 189
antibodies against tumour associated antigens.
Sometimes efficiency of tumour detection is im-
proved by increasing the dose of radiolabelled
antibody (Murray et al., Proc. Amer. Assoc. Cancer
Res., 25, 250, 1984) but since doses of radionuclide
remain constant the reason(s) for this are obscure.
In the present study a dose dependent discrimi-
nation between tumour and normal tissues has been
demonstrated and investigated in a rat mammary
tumour model.
The mouse IgGI monoclonal antibody 226 was
prepared against rat mammary carcinoma (Sp4).
Cytofluorimetry showed that it did not react with
cells of other rat tumours, including mammary
carcinomas. Purified antibody was labelled with
125I and normal mouse IgGl with 1311 for dual
label in vivo distribution studies in rats with Sp4
tumour. With large doses (20mgkg-1) of antibody,
tissue to blood (T:B) ratios of 125I-antibody in
tumour were higher than those of intestine, lung,
heart, spleen, kidney and muscle. With lower doses
(30pgkg-1) those of intestine and lung exceeded
that of tumour, and this was most marked with
lung with T:B ratios 3.5 times that of tumour. With
even smaller doses (6pgkg-1) T:B ratio of kidney
also exceeded that of tumour and in comparison
with normal IgGl, maximum localisation indices of
antibody in intestine, lung and kidney were 9, 8 and
5 compared with 2 for tumour. Circulating immune
complexes were demonstrated in serum of rats
receiving low but not not higher does of antibody.
Complexes were ot seen with normal IgGl.
Immunohistochemistry subsequently confirmed
reaction of the antibody with luminal surfaces of
intestine, but clear reaction with lung and kidney
was not seen.
These studies indicate that improved
discrimination between tumour and normal tissues
with increased doses of monoclonal antibody may
be due, at least in part, to low levels of antigen
expression in normal tissues.
Tissue-localisation of adriamycin (ADR) using
albumin microspheres
N. Willmott', D. Kerr2, H. Lewi3, J. McKillop4
& C. McCardle3
'Department ofPharmaceutics, University of
Strathclyde, 2Department ofMedical Oncology,
University ofGlasgow, 3Department ofSurgery and
4Department ofNuclear Medicine, Royal Infirmary,
Glasgow, UK.
Microspherical drug delivery systems of requisite
size hold out the possibility of conferring specificity
on cytotoxic anti-cancer drugs by chemo-
embolisation in capillary beds of organs harbouring
tumour deposits. This will lead to increased
exposure of the organ to drug combined with
correspondingly lower systemic levels, resulting in
increased therapeutic ratio. To examine these points
in experimental systems, rats (70pgADR intra-
venously and rabbits (220pg ADR via a renal
artery) were injected either with ADR in solution
or in microspherical form (15pm diam., rat; 25,pm
rabbit). In both systems, by the use of light and
fluorescence microscopy, and 99mTc-labelled
particles, it was seen that microspheres were
trapped with high efficiency in rat lung and rabbit
kidney, i.e. in the first capillary beds encountered. In
the rat, mean systemic serum levels of ADR im-
mediately after injection were considerably reduced
after administration in microspherical form
(270ngml-1 (n=2) versus 46ngml-1 (n=6) as
were mean systemic rabbit plasma levels
(118ngml-1 (n=2) versus <5ngml-1 (n=2).
99mTc-labelled microspheres have been co-
administered with 5-fluorouracil (1 g) to a patient
with multiple hepatic metastases from colorectal
carcinoma, via a catheter surgically implanted in
the hepatic artery. Using radionuclide angiographic
tomography it has been possible to visualise the
hepatic metastases, and preliminary evidence
suggests that intrahepatic arterial infusion of angio-
tensin II might increase delivery of microspheres to
tumour deposits.
The effect of niosome encapsulation on the
distribution of adriamcyin in the mouse
A. Rogerson1, J. Cummings2 & A.T. Florence1
Departments of1Pharmacy, Strathclyde University
and 2Medical Oncology, Glasgow University,
Glasgow, UK.
Thse use of carriers (e.g. liposomes and macro-
molecular complexes) to deliver drugs to target
organs and modify drug disposition has been
widely investigated. We have been studying a new
vesicle-forming synthetic system based on non-ionic
surfactants. These multilamellar vesicular systems,
termed niosomes, have the capacity to entrap and
retain drugs such as methotrexate and adriamycin.
We have compared the tissue distribution of adria-
mycin in two forms of niosomes (comprising 100%
surfactant and 50mol % surfactant/cholesterol)
with free adriamycin in male NMRI mice bearing
the subcutaneous rapidly proliferating sarcoma
S180 tumour. Three mice were sacrificed per time190 PROCEEDINGS OF BACR 27TH AGM
point at intervals, up to 48h, following an i.v.
bolus of 5mgkg-1 adriamycin. Plasma and tissue
levels of adriamycin and its metabolites were
measured by an HPLC technique employing
fluorescence detection. Encapsulation of adriamycin
decreased its peak plasma levels (t= 10m) from
14,700-6,800ngml-1 and prolonged its circulation
(there being a five-fold enhancement of drug in
plasma at 16h from 20-90ngml-1), as was
similarly reported for methotrexate-loaded nio-
somes, but there was no significant increase of
adriamycin in the liver. However in the liver, spleen
and heart, adriamycin levels were highest following
administration of drug in cholesterol-containing
niosomes. In the plasma there was no difference
between the niosomes types. Levels of niosomal-
adriamycin were slightly higher in the S180 tumour
and its rate of growth was significantly reduced by
administration of 2.5mgkg-1 adriamycin in
cholesterol-free niosomes (mean growth rate of 0.45
versus 0.24gday 1 over a period of 16 days).
Quantitation of anti-tumour antibody and antibody
conjugate binding activity by competition with
fluorochrome labelled antibody
R.A. Robins', R.R. Laxton2, M. Garnett',
M.R. Price1 & R.W. Baldwin
'Cancer Research Campaign Laboratories and
2Department ofMathematics, Nottingham
University, Nottingham NG7 2RD, UK.
Binding of unlabelled monoconal antibody prepar-
ations has been assessed by competition at
saturation with fluorochrome labelled homologous
antibody for binding to antigen bearing target cells.
The extent of competition was measured by
quantitative flow cytofluorimetry, and simple
mathematical procedures have been developed to
allow interpretation of competition data in terms of
antibody binding activity. In the system studied,
non-specific (non-competitive) fluorescence was
minimal, but an iterative method to calculate its
contribution to the measured signal is given. This
approach has the advantage that the antibody
preparation to be tested does not need to be
labelled or modified; this is particularly important
when evaluating the binding activity of therapeutic
antibody conjugates. Comparison to a well charac-
tertised standard antibody preparation provides a
rapid, sensitive and accurate quality control pro-
cedure. Qualitative (affinity) changes in modified
antibody are detectable, as well as quantitation of
total loss of binding activity. This test is also simple
to perform, requiring only mixing of labelled and
unlabelled antibodies with target cells, a single
incubation, followed by analysis without washing
the target cells.
TRITC-HSA-antibody conjugates: A convenient
reagent for assessment of endocytosis of cell surface
antigens
M.C. Garnett & R.W. Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, University Park, Nottingham
NG7 2RD, UK.
When tetramethyl rhodamine isothiocynate (TRITC)
was coupled to human serum albumin (HSA) at
high molar substitution ratios (12 to 30mol
TRITCmol-1 HSA), rhodamine fluorescence was
quenched by over 90%. On conjugation of TRITC-
HSA to 791T/36 monoclonal antibody a reagent
useful for monitoring endocytosis was obtained.
When 788T or 791T cells expressing high levels of
791T/36 antigen were stained at 0°C the cells could
be visualised by a dim, even surface fluorescence.
However, on incubation of the cells at 370C for a
few hours (4.5h) a bright punctate perinuclear
distribution of fluorescence was seen due to the
endocytosis and digestion of the reagent to reveal
the unquenched fluorescence. Unlike similar work
performed with fluorescein compounds (Br. J.
Cancer, 52, 432, 1985), no further addition of
modifiers was required to demonstrate the
fluorescence by alteration of the pH of intracellular
organelles. Results were therefore easy to obtain
and their interpretation was unambiguous. The
sensitivity of this assay for endocytosis of cell
surface antigens has been investigated using a
number of cultured cell lines expressing different
amounts of cell surface antigen. In particular on a
bladder carconoma cell line T24 expressing only
3 x 104 antigens per cell, initial surface fluorescence
was undetectable with TRITC-HSA-791T/36, but
endocytosis after 4h was clearly visible. This
suggested that levels of endocytosis of -10,000mol
could be visualised using this method. No endo-
cytosis was seen on a melanoma cell line Mel 57
expressing no detectable antigen. The results of this
assay using conjugates with antibodies recognising
other antigens will be presented. This assay which
was carried out on living cells is less subject to
misinterpretation than other more lengthy
procedures e.g. electron miscroscopy and can be
performed in a few days including synthesis of
conjugate. This assay may help to resolve the
question of whether all or just some cell surface
antigens are endocytosed.PROCEEDINGS OF BACR 27TH AGM 191
Binding of a panel of monoclonal antibodies to
primary and metastatic colorectal cancer
K.C. Ballantyne, L.G. Durrant, N.C. Armitage,
R.A. Robins, R.W. Baldwin & J.D. Hardcastle
Departments ofSurgery and Cancer Research,
University ofNottingham, Nottingham, UK.
Although there are reports of the pattern of antigen
distribution in primary colorecral tumours as
defined by monoclonal antibodies, the distribution
and degree of antibody binding to metastatic
compared with primary colorectal cancer has not
yet been fully evaluated. Using flow cytometry and
immunohistology we have now assessed the binding
of the monoclonal antibodies 791T/36, antiosteo-
sarcoma, C14/1/46, anticolonic adenoma, C154/14
anticolorectal carcinoma and C161/25 anti
CEA/NCA to 50 primary colorectal cancers, 17
lymph node metastases and 21 hepatic/peritoneal
metastases.
After disaggregation tumour cell binding was
measured by flow cytometry using indirect
immunofluorescence. Median linear fluorescence
values (MLF) were corrected for non-specific
binding using normal mouse immunoglobin (Table).
Immunohistology was performed using the indirect
peroxidase technique. Immunohistology demon-
strated that the antigen distribution of primary
colorectal cancer is retained in metastatic tumour
deposits. Confirmation that metastases retain
similar pattern of antigen expression to primary
colorectal cancer provides further evidence that
targeted immunotherapy may effectively treat
metastatic colorectal cancer.
(Range) Fl.U
Median tumour MLF Lymph node
Antibody Primary tumours metastases
791T/36 134 (0-655) 139 (0-888)
C14/1/46 415 (44-2,481) 689 (0-2,345)
C154/14 242 (0-1,108) 289 (0-1,206)
C161/25 899 (0-3,432) 547 (0-2,848)
Antibody Hepatic/peritoneal metastases
791T/36 139 (0-995)
C14/1/46 392 (0-2,349)
C154/14 391 (51-2,081)
C161/25 803 (96-3,614)
Effect of endotoxin on the expression of drug
metabolising enzymes
C.R. Wolf, R.L. Lindsay, L. Roger & D.J. Adams
Imperial Cancer Research Fund, Laboratory of
Molecular Pharmacology, Hugh Robson Building,
George Square, Edinburgh, UK.
Our interest in the effects of endotoxin and
interferons on the drug metabolising enzymes stems
from the potential effects of inflammation and
infection on the activation of chemical carcinogens
and changes in normal and tumour tissues when
cytotoxic drugs are used in combination with
lymphokines. Using Western Blots and isozyme
specific substrates a single high dose of entotoxin
(25,ug) had profound effects on cytochrome P-450
gene expression in the liver. Total cytochrome P-
450 levels were reduced by 40%, 44% and 61% in
control, phenobarbital (PB) and methylcholan-
threne (3-MC)-treated mouse liver. There was
however, a differential effect on P-450 isozyme
levels, the major PB-inducible isozyme (PB3) being
virtually unaffected by this endotoxin-treatment. It
was very interesting that at lower doses of endo-
toxin (7.5,ug) the induction of the major 3-MC-
inducible P-450 (MClb) was potentiated (2.2 fold).
The induction of the PB-inducible isozymes PB1
and PB2 was also significantly increased, maximal
elevation being 3 and 1.7 fold above controls
respectively. These changes were substantiated by
measuring the metabolism of 7-ethoxyresorufin and
7-ethoxycoumarin. These data indicate that inflam-
matory and antiviral response could have signifi-
cant effects on the activation and/or deactivation of
chemical carcinogens and that the use of lympho-
kines may significantly alter the action and side
reactions ofcancer chemotherapeutic agents.
Benznidazole inhibition of CCNU hydroxylation by
hepatic microsomal cytochrome P.450
P. Workman1, F.Y.F. Lee1, J.T. Roberts1,
M.I. Walton1, K.H. Cheeseman2 & N.M. Bleehen1
'MRC Unit and University Department ofClinical
Oncology, Hills Road, Cambridge and 2Biochemistry
Department, Brunel University, Kingston Lane,
Uxbridge, UK.
Benznidazole is a potent nitroimidazole chemo-
sensitiser. It produces an improved therapeutic
index with the nitrosourea CCNU in mice, and this
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combination is now being evaluated clinically in an
MRC randomised Phase 2 study of recurrent
glioma. We have previously shown that benzni-
dazole inhibits the clearance of CCNU and reduces
the rate of hydroxylation by hepatic microsomal
cytochrome P-450. In continuing studies of the
mechanism of action of benznidazole we have used
optical difference spectroscopy to demonstrate that
benznidazole binds to cytochrome P-450 of pheno-
barbitone-induced mouse liver microsomes in vitro.
Binding is predominantly type II but with some
suggestion of a type I component. The in vitro
kinetics of inhibition of CCNU hydroxylation by
control mouse liver microsomes are of the mixed
competitive-non-competitive type. Ki (0.044mM)
was lower than Ki' (0.17mM) indicating the pre-
dominance of the competitive component. Using
these in vitro data we have estimated the amount of
inhibition of CCNU hydroxylation likely to result
from concentrations of benznidazole achieved in
man. The extent of inhibition of CCNU
metabolism in man, measured by the appearance of
parent CCNU in the plasma, correlated well with
the predicted inhibition of CCNU hydroxylation.
For benznidazole doses of 20-25mgkg-1 the pre-
dicted inhibition was in range 20-43%. This was
comparable to that achieved in optimal chemo-
sensitisation protocols in mice.
Inhibitors of aromatase based on 3-phenylpyrrolidine
2,5-dione: Structure-activity relationships
G.W. Jones, W.M.A. Nazareth, M.J. Daly,
M.I. James, P.J. Nicholls & H.J. Smith
Welsh School ofPharmacy, UWIST, Cardiff, UK.
The aromatase inhibitor, aminoglutethimide (I, 3-
(4-aminophenyl)-3-ethyl piperidine-2,6-dione) has
been used for the treatment of oestrogen-receptor
positive breast cancer in post menopausal women.
It is co-administered with a glucocorticoid to
suppress the resulting reflex-rise in ACTH level due
to inhibition of the CSCC enzyme. We have
recently shown that unsubstituted and 3-alkyl sub-
stituted 3-(4-aminophenyl) pyrrolidine-2,5-diones
(II) are equipotent with (I) as inhibitors of placental
aromatase and we consider that they are potentially
more useful clinical agents than (I) since they
showed little or no activity against bovine CSCC in
vitro. We have prepared further analogues of (II)
where (a) the heterocyclic ring has been altered (b)
a spacer group (-CH2-) placed between the two
rings, (c) rotation of the aryl ring has been
restricted. These changes were usually accompanied
by loss of ability to inhibit aromatase. We have
examined the structure-activity relationships be-
tween (I), (II) and the other types of compounds
mentioned here using molecular graphics
(Chemgraf) and our findings are that the active
inhibitors have (1) a near-flat hydrophobic mono-
heterocyclic ring, (2) a p-aminophenyl (or 4-pyridyl)
ring which is in a plane above (below) the plane of
(1), (3) restriction of the conformer population
about C3 to a limited number of low energy forms
with torsion angles (C2-C3-Cl'-C2'(aromatic)) of
- I0-+500 in order that the 'active conformation'
may be relatively more populated.
Aziquone (AZQ) instability in frozen solutions
A.G. Bosanquet
Department ofClinical Investigation, Royal United
Hospital, Combe Park, Bath BAJ 3NG, UK.
Common sense would suggest that drugs in
solution would be more stable frozen than not
frozen except where solubility limits are exceeded at
the lower temperatures, and this is the case for
most anticancer drugs. I have used a high-
performance liquid chromatographic method to
investigate the stability of AZQ in various solutions
at temperatures from -196°C to +500 C. AZQ
dissolved at 20mgml-1 in dimethyl-acetamide
(DMA) and diluted to 1 mgml-1 with the
phosphate (®) buffer provided, was (after 9 days)
most stable at +4° and < -70' C. Minimum
stability was found at -12° C with increasing
stability as the temperature was lowered. When
diluted further with ® buffered saline (PBS), the
drug was again most stable at +40 C and
<-860 C. However, the minimum stability was
found to be at -35°C (with <30% of the initial
AZQ concentration remaining after only 24h) with
samples stored at -12'C being almost as stable as
those at +40 C. Identical samples at -20°C
showed enormous variation in stability - most
being unstable (<30% AZQ remaining after 24h),
but a few being essentially stable (>90% remain-
ing). In dilute solutions (10 gml-1) in ® or other
ions (but without Cl- present) AZQ was
reasonably stable frozen (>90% present at day 7).
In another experiment with dilute solutions, where
different ions were mixed with NS, only the ® /NS
mixture produced instability at -35°C. The
products of AZQ's degradation in PBS are chloro-
AZQ and dichloro-AZQ where first one and then
both aziridinyl rings open to become chlorethyl-
amino groups. Degradation at positive temperatures
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assignment) as would be expected in aqueous en-
vironments. Obviously AZQ should not be frozen
in solutions containing ® or ®/NS. AZQ
dissolved in DMA and diluted with 0.15 M
citrate/NaOH pH 6.3 to 10pgmlPl has successfully
been stored at -20°C and -700 C for 2 months
with no significant degradation taking place.
Investigation into the stability of a combination of
adriamycin, vincristine and etoposide
D.G. Poppit & B.W. Fox
Paterson Laboratories, Christie Hospital & Holt
Radium Institute, Manchester M20 9BX, UK.
The three drugs: adriamycin (doxorubicin),
vincristine (oncovin) and etoposide (VP16 -
vepesid) at concentrations of 1.5, 0.05 and
12mgml-1 respectively were investigated both
singly and in combination for stability over three
days by high pressure liquid chromatography and
UV absorption spectroscopy. The agents were in
the formulation supplied by the manufacturers and
dilutions were with saline. On a Lichrosorb 5Si60
analytical column, adriamycin and etoposide could
be resolved with a running solvent of 35%
acetonitrile in 0.01 M phosphoric acid but a gradient
of 5%-50% acetonitrile in 0.01 M phosphoric acid
was necessary to resolve vincristine from etoposide.
Using this gradient system vincristine, etoposide
and adriamycin have retention times of 265, 310
and 445sec respectively at a flow rate of 1 mlmin 1
and UV detection at 254nm. UV spectra showed
absorption maxima at 496, 295 and 258 nm
attributable to adriamycin, etoposide and vin-
cristine respectively. There was no evidence of any
change in either the HPLC elution profile or the
UV spectra over the 3 days studied. Further tests
after 14 days indicated similar stability.
Inhibition of oestradiol biosynthesis in vivo by
aminoglutethimide and related compounds
M.H. Pourgholami, M.J. Daly, P.J. Nicholls
& H.J. Smith
The Welsh School ofPharmacy, PO Box 13,
Redwood Building, CardifCFJ 3XF, UK.
We have developed a series of compounds possess-
ing selective aromatase inhibitory activity, and have
evaluated two of these compounds for their effects
on oestradiol (E2) biosynthesis in the rat. Ten week
old female rats were primed with pregnant mares
serum gonadotrophin (100iu s.c.) every other day
for 10 days, followed on the 11th day by a single
i.p. dose (50mgkg-1) of either aminoglutethimide
(1), 3-(4-aminophenyl)-3-ethyl- pyrrolidine-2,5-dione
(2) or the 1-methyl analogue of the latter (3). Three
hours later, cardiac blood was collected under ether
anaesthesia for the determination of E2 blood levels
by radioimmunoassay. Each compound decreased
E2 blood levels to 7, 7 and 28% of control levels
respectively (n=6). Residual aromatase activity,
assessed by incubating the homogenised ovaries
with [lfl,2fl-3H] androstenedione (0.2yM), indicated
that enzyme activity was also reduced compared
with controls. The new aromatase inhibitors 2 and
3 are therefore effective inhibitors of E2 bio-
synthesis in the rat with functioning ovarian
activity. The human ovary is resistant to the effects
of 1, which denies pre-menopausal breast cancer
patients potentially beneficial therapy. The
selectivity of the new agents may enable their use in
either pre- or post-menopausal women with breast
cancer, or E2-dependent ovarian disease.
Primary H/D kinetic isotope effect on the
metabolism of the antitumour agent N-
methylformamide
M.D. Threadgill, P. Kestell, K.C. Farrow
& A. Gescher
CRC Experimental Chemotherapy Group,
Pharmaceutical Sciences Institute, Aston University,
Birmingham, UK.
Methylamine (I) and S-(N-methylcarbamoyl)-N-
acetylcysteine (II) have been identified as major
urinary metabolites of the hepatotoxic antitumour
agent N-methylformamide (III; CCRG 80011) in
rodents and in man (Kestell et al., Drug Metab.
Disposit. 13, 587, 1985; & this meeting). Formation
of II must involve oxidative rupture of the formyl
C-H bond in III, whereas methylamine may arise
either from enzymatic hydrolysis of the parent III
or via some intermediate in which this bond has
already been oxidatively cleaved (e.g. in II). A
known mixture of deuterated isotopomers of III
(OHCNHCD3+ODCNHCH3) was given i.p. at a
total dose of 400mgkg- to 3 CBC/CA mice.
Methylamine in 24h urine collections from each
mouse was converted to N-methyl-2,4-dinitroaniline
(IV) by treatment with l-fluoro-2,4-dinitrobenzene
and its isotopic composition was determined by
mass spectrometry. A primary hydrogen/deuterium
kinetic isotope effect of 5.5+0.2 was observed for194 PROCEEDINGS OF BACR 27TH AGM
the metabolism of III to I, such a large effect
indicating that cleavage of the formyl carbon-
hydrogen bond is rate-limiting in this process, thus
ruling out direct hydrolysis. A H/D effect of
1.6+0.4 was observed for the formation of II.
The possible role of in vivo cardic drug metabolism
in the cardiotoxic actions of adriamycin (ADR) and
4'-deoxydoxorubicin (4'-deoxy) in mice
J.G. Morrison, D. Kerr, J. Cummings & S.B. Kaye
Department ofMedical Oncology, University of
Glasgow, Glasgow, UK.
ADR and 4'-deoxy are two anthracycline drugs
which are reported to produce different degrees of
cardiotoxicity in animal models. We have deter-
mined the cardiac kinetics and metabolism of ADR
and 4'-deoxy. NMRI mice were injected i.p.
(10mgkg-1) with ADR and 4'-deoxy. The animals
were killed with ether at intervals of up to 24h (4
animals were used for each experimental point). A
plasma sample was taken and the hearts rinsed
once in saline, blotted dry and then frozen at
-20° C until analysed. The levels of ADR, 4'-
deoxy and their metabolites were estimated by
sensitive and specific HPLC techniques devised in
our laboratory. The kinetics of cardiac disposition
were similar for both drugs; peak levels (ADR
2.5 pgg-1, 4'-deoxy 2.3 ugg-1); cardiac AUC (ADR
18 pg -1 h, 4'-deoxy 20pgg -1 h); elimination half-
life (ADR 38h, 4'-deoxy 36h). It was not possible
to detect formation of deoxyaglycones from 4'-
deoxy, whereas the deoxyaglycones of adriamycin
(4% of total drug content) and adriamycinol (3%
of total drug content) were present in significant
amounts. There is evidence to suggest that the
cardiotoxicity of adriamycin is mediated via a semi-
quinone free radical and superoxide free radical
generated in cardiac mitochondria. 7-Deoxyagly-
cones are end products of semi-quinone free radical
production. It is possible that differential intra-
cardiac aglycone production, and by inference free
radical formation, could account for different
cardiotoxicity of these two 2 drugs.
Preclinical evaluation of 1-p-Carboxy-3,3-
dimethylphenyltriazene (CB 10-277) - An alternative
to DTIC
C.J. Rutty, M.A. Graham, G. Abel, I.R. Judson
& P.M. Goddard
Inst. Cancer Res., Sutton, Surrey, UK.
l-p-Carboxy-3,3-dimethylphenyltriazene (CB 10-
277) has been selected for phase I clinical study as
an alternative to DTIC (Dacarbazine). This parti-
cular phenyltriazene has shown marked activity
against experimental murine tumours and melanoma
xenografts, and is significantly more effective than
DTIC in inhibiting the growth of the Walker
tumour grown in the rat. In common with other
dialkyltriazenes CB 10-277 requires oxidative N-
demethylation in order to exert its antitumour effect.
The parent dimethyl compound is relatively non-
toxic to PC6 cells in culture whereas the metabolite
1 - p - carboxy - 3 - hydroxymethyl - 3 - methyltriazene
(CB 10-440) is highly toxic (ID50= 5.9pm). In
rodents cytotoxic levels of this metabolite are
readily achieved, especially in the rat where the
peak plasma level is 56.2+3.5pM as opposed to
25.3 + 1.8gM in the mouse, in marked contrast
to DTIC. In addition the acyl-glucuronide of
CB 10-277 is a major metabolite present in the
plasma and urine of both species. Both CB 10-277
and CB 10-440 are extensively bound to plasma
proteins (95%) leading to stabilisation of the active
metabolite (ty=60min). Furthermore, the carboxy-
triazene penetrates the mouse CNS relatively poorly
(brain/plasma ratio =0.32) which may result in
reduced neurotoxicity. CB 10-277 is highly water
soluble and can be readily formulated as a stable
preparation in 150mM NaHCO3 pH 8.3 (t> 16h)
for i.v. administration to patients.
Pharmacological studies with the anthrapyrazole
Cl 941: A new DNA complexing drug
M.A. Graham, D.R. Newell & A.H. Calvert
Drug Development Section, Institutefor Cancer
Research, Sutton, Surrey, UK.
The anthrapyrazole CI 941 is one of a new series
of mitozantrone analogues the anthra[1,9cd]pyrazol-
6(2H)-ones, which have been selected for further
clinical investigations because of broad spectrum
activity against rodent tumours (e.g., B16, L1210
and P388) and their novel biochemical properties
(Fry et al., Biochem. Pharmacol., 34, 3499, 1985).
The pharmacokinetics and toxicity of CI941 have
been investigated prior to clinical studies. Following
an i.v. bolus injection (15mgkg-1) to female
Wistar rats the drug is rapidly cleared from the
plasma t2a=3.11 min, tfl =34.4min, clearance =
131mlmin-ikg-1) and is subjected to both urinary
(<1% dose) and biliary excretion (12-18% dose).
Tissue distribution, 3h post administration, shows
6.4%, 7.3% and 0.5% of the dose present in the
kidneys, liver and heart with corresponding tissuePROCEEDINGS OF BACR 27TH AGM 195
concentrations (wet weight) of 221Mugg-1, 36upgg 1
and 20jgg-1 tissue respectively. Drug was undetect-
able in brain and red blood cells (<2jugg-1). Three
toxicities have been observed in male BDF1 mice.
Bodyweight loss and leucopenia. At a maximally
tolerated dose (31 mgkg-) there was a 26% decrease
in bodyweight (nadir on day 10) and pronounced
leucopenia (87% decrease, nadir day 3). Platelet
and red blood cell counts remained normal.
Convulsions. At 48mgkg-1, convulsions were
universally lethal (4/4 dead). The LD50 was
41mgkg-1 (95% limits 36-46mgkg-1). 50mgkg-I
mitozantrone did not induce convulsions but
was a lethal dose in 4/4 mice (deaths on days
5-6). The anticonvulsants phenytoin (100mgkg-1),
phenobarbital (30mgkg-1) and valproic acid
(300mgkg-1) administered 1 h prior to CI 941 did
not prevent this effect. CI 941-induced convulsions
are not due to cardiac arrest. The acute onset of
convulsions and the relatively high levels of the
drug found in the kidneys following administration
may be important determinants in defining the dose
limiting toxicity of this agent in man.
Autoradiographic analysis of the intra-renal
localisation of cis-platin
C. Ewen1, J.H. Hendry', H. Sharma2, A. Perara3
& C.A. McAuliffe3
1Department ofRadiobiology, Paterson
Laboratories, 2Department ofMedical Biophysics,
Manchester University, 3Department ofChemistry,
UMIST, Manchester, UK.
Knowledge of the dose of cis-platin or its
metabolites received by the target cell populations
within the kidney are essential to an understanding
of dose-response relationships for long term renal
injury.
In order to obtain precise information on the in
situ renal localisation of this drug, autoradiography
was performed, following administration of Pt-
195m labelled cis-platin. BDF1 mice were given
10mgkg-1 cis-platin i.v., and at predetermined
times five animals per time point were sacrificed.
The kidneys were removed and fixed for auto-
radiography. Slides were dipped in ILFORD K5
emulsion and exposed for four days. Following
development the slides were stained with celestine
blue.
Microscopic examination showed widespread
distribution of label. Initially, high concentrations
were seen in the renal pelvis, however at later times
microdensitometric analysis showed retention of
more label within the cortex than in the medulla.
Autoradiographs were prepared at various times up
to 2 weeks after drug administration. These showed
that the label had virtually disappeared from the
glomerulus, but it was retained by the tubule epi-
thelium. There appeared to be no marked difference
in the retention of platinum along the tubule. This
is now being quantified in detail.
Lack of relationship between plasma and tumour
levels of thioTEPA and its metabolite tepa on the
response of murine tumours
R.M. Phillips', M.C. Bibby1, J.A. Double'
& B.J. McDermott2
1Clinical Oncology Unit, University ofBradford,
Bradford BD7 IDP and 2Department of
Therapeutics & Pharmacology, Queen's University,
Belfast, BT9 7BL, UK.
The cytotoxic drug ThioTEPA is being used
currently in the treatment of ovarian and breast
cancer (Turner, Int. Congr. Ser., Excerpta Med., 9,
1, 1981). Responses are variable and may correlate
with pharmacokinetic parameters. Objective assess-
ment of clinical response is lengthy and difficult but
can be easily accomplished in an experimental
system. Three mouse colon tumours of varying
growth characteristics and histology (MAC
tumours) and the P388, L1210 have been used to
examine the relationship between plasma and
tumour levels of drug and metabolite and sensi-
tivity. MAC 26, L1210 and P388 were the most
sensitive tumours with MAC 13 being moderately
responsive and the ascitic tumour MAC 1SA
showing no response, even when grown sub-
cutaneously. Plasma levels of drug and metabolite
determined by GC (McDermott et al., J. Chromatog.,
338, 335, 1985) 60min after treatment with
20mgkg-1 were similar in MAC 13 and MAC 26
but significantly higher in P388, L1210 and MAC
15A. Subcutaneous tumour concentrations of drug
and metabolite were similar in MAC 13, MAC 15A
and MAC 26 but significantly lower in the ascitic
MAC 15A and not detected in P388 and L1210.
Significant levels of both drug and metabolite in
peritoneal fluid from MAC 15A indicate inherent
resistance rather than availability may be
responsible for insensitivity. This observation has
been confirmed in vitro. These studies have indi-
cated the levels of drug and metabolite required to
achieve responses and that limited pharmacokinetic
studies alone are insufficient to predict response.
However in a corresponding clinical situation if it
were possible to determine in vitro sensitivity then a
knowledge of pharmacokinetic parameters would196 PROCEEDINGS OF BACR 27TH AGM
provide a valuable guide to predicting the outcome
of therapy.
Photodynamic therapy of cancer: Potential use of
phthalocyanines as tumour localising photosensitisers
W.-S. Chan, J. Marshall & I.R. Hart
ICRF Laboratories, Lincoln's Inn Fields, London
WC2A 3PX, UK.
The present study was undertaken to evaluate
the suitability of aluminium chloro-sulphonated
phthalocyanine (AlSPc) as a photosensitiser for use
in photodynamic therapy (PDT) of cancer. AlSPc
absorbs red light strongly, is taken up in vitro by
cells in a dose dependent fashion and the treated
cells remain viable following exposure to normal
room light. In contrast, exposure to red light
(- 600-700nm) for 30min produced 100% cyto-
toxicity in UV-2237 firbosarcoma cells as evaluated
3 days later. The uptake and retention of AlSPc has
been examined using three murine tumours of
different histological origin growing in the sub-
cutaneous flank regions of syngeneic hosts. At
various times after i.v. injection of the dye mice
were killed (3 per time point per tumour), organs
were recovered and weighed. Organ associated dye
was extracted and determined by measuring
fluorescence (excitation 603nm; emission 673nm)
and expressed as fluorescence unit per gram of
tissue. By 24-48h after i.v. injection all three
tumour types, the M5076 ofmacrophage origin, the
UV-2237 fibrosarcoma and the colorectal Colo 26,
showed significant retention of AlSPc compared to
many normal tissues. These preliminary results
suggest that the phthalocyanine compound AlSPc
has considerable potential for use as a
photosensitizer in PDT of cancer.
Evidence for the formation of a reactive
metabolite of the investigational antitumour drug
N-methylformamide
P. Kestell1, P.B. Farmer2, A. Gescherl,
A.P. Gledhill' & M.D. Threadgill'
1CRC Experimental Chemotherapy Group,
Pharmaceutical Sciences Institute, Aston University,
Birmingham and 2MRC Toxicology Unit,
Carshalton, UK.
Clinical trials and animal experiments have shown
that the investigational antitumour drug N-
methylformamide (NMF) is a hepatotoxin, but
completely lacks myelotoxic properties. NMF is
metabolised to a compound which is bound
covalently to hepatic proteins in vitro and in vivo
(Pearson, Harpur and Gescher, unpublished). NMF
also depletes hepatic glutathione (Gescher et al., Br.
J. Cancer, 45, 843, 1982). This indicates that an
electrophilic, possibly cytotoxic metabolite is
formed. We have investigated the metabolites of
NMF in the urine of patients who had received
NMF in a phase I clinical trial (McVie et al.,
Cancer Treat. Rep., 68, 607, 1984) in order to get
further evidence to support this hypothesis. After
freeze drying, a metabolite was isolated by
preparative TLC, which had acidic properties and
contained sulphur. Esterification with methanolic
hydrogen chloride afforded a compound which
gave the following fragments on chemical ionisation
mass spectrometry: m/z235 (M+ +H), 178, 136 and
60. The spectrum was identical with that of the
methyl ester of authentic S-(N-methylcarbamoyl)N-
acetylcysteine. This identification was supported by
high-field NMR spectroscopy. It is possible and
congruent with other evidence that this metabolite
is the product of the hepatic reaction of a reactive
NMF oxidation product, such as methylisocyanate,
and glutathione. Furthermore N-alkylmonothio-
carbamates such as this metabolite are electrophiles
and carbamoylating agents in their own right.
Pharmacokinetics of oral weekly Idarubicin
(4DMDNR)
D.B. Smith1, J. Margison2, P.M. Wilkinson2,
A. Howell' & G. Thomas'
'CRC Department ofMedical Oncology and
2Department ofClinical Pharmacology, Christie
Hospital & Holt Radium Institute, Manchester, and
3Farmitalia Ltd., UK.
Following oral or i.v. administration Idarubicin
(Ida) is rapidly metabolised to 13-OH 4DMDNR.
This metabolite is of equal antitumour activity to
the parent drug in animal systems and is still
present in the serum 7 days after dosing. The
purpose of this study was to determine whether the
pharmacokinetics of oral weekly Ida altered signifi-
cantly with prolonged administration. Ida and 13-
OH 4DMDNR concentrations were measured using
reverse phase HPLC with fluorescence detection
giving a sensitivity of 0.05ngml-'. Ida was
administered orally at a dose of 15mgm2 week-I to
26 patients with advanced breast cancer. Serum
profiles were measured at weeks 1, 4, 12 and 24 in
4 patients, at weeks 1 and 4 in 4 patients and atPROCEEDINGS OF BACR 27TH AGM 197
week 1 only in 3 patients. In an additional 5
patients the serum profile following an oral* dose
was compared with that following the same dose
i.v. Seven day 13-OH 4DMDNR levels were mea-
sured at each clinic visit in 26 parents. After an oral
dose of Ida 15mgm 2 the mean peak serum con-
centration was 3.33ngmlP-I +2.10 occurring
2.82h+ 1.53 following ingestion. The mean peak
13-OH 4DMDNR concentration was
7.69ngml1 +5.19 occurring 3.46h+ 1.84 after dos-
ing. Mean AUC (Ida) after i.v. administration was
248 ugI - 1h-1 +94.64 and after oral was
75.3 jug1-1 h-1+59.38 indicating oral availability of
26%. In patients studied for 24 weeks the mean
AUC for Ida was 50.75+7.59,ugI1- h- at the start
of treatment and 56.0+9.37 ugI 1 h - at 6 months.
The corresponding values of AUC for 13-OH
4DMDNR were 251.3 ig-1 h-1 + 117.2 and
274.3 igl-1 h-1 +34.8. The mean 7 day level of the
metabolite was 0.8ngml-1 +0.55 and there was no
indication of accumulation. The pharmacokinetics
of Ida do not appear to alter with continuous oral
weekly treatment.
Bioavailability and tolerance of oral ifosfamide in
patients with bronchial carcinoma
T. Cerny', J. Margison2, N. Thatcher'
& P.M. Wilkinson2
'Department ofMedical Oncology and 2Department
ofClinical Pharmacology, Christie Hospital,
Manchester M20 9BX, UK.
The aim of this study was to assess the bioavaila-
bility and tolerance of oral Ifosfamide (I) at
different dose levels. Pharmacokinetics of (I) were
determined in patients with bronchial carcinoma
following bolus dose administration of 1 g and 2g
p.o. and i.v. in 7 patients and 5g p.o. in 3 patients.
Serial serum and urine samples were collected
during the first 48h after administration and con-
centration of (I) were assayed by HPLC using a
method developed in this laboratory. The AUC
following 1 and 2g doses was the same for both i.v.
Bioavailability and T2 terminal of Ifosfamide
ig 2g
Sg
P.O. i.v. p.o. i.v. p.o.
AUC (pghl-1) 266.3 294.2 511.8 478.2 1,229.7
s.d. 12.0 29.8 83.9 34.8 156.2
s.e. 4.9 12.1 31.7 13.7 90.1
T- terminal
(h-1) 5.3 5.9 5.3 5.29 4.07
and oral treatment and increased linearly after 5g
oral (I) indicating a 100% bioavailability (Table).
The terminal half life was decreased with increasing
dose but drug clearance was similar. The side
effects of 1 and 2g oral (I) were mild (slight nausea
was noted in 4 of 26 courses and self limiting
episodes of vomiting in 2 of 26 courses) whereas 2
of 3 patients showed signs of CNS toxicity and
severe vomiting after 5g oral (I). We conclude that
1 and 2g oral (I) were well tolerated but 5 g oral (I)
may not be compatible with a simple oral
treatment.
A study of a combination of two hypoxic cell
radiosensitisers, Ro 03-8799 and SR 2508: Clinical
toxicity and pharmacology
H.F.V. Newman, N.M. Bleehen & P. Workman
MRC Clinical Oncology and Radiotherapeutics Unit,
MRC Centre, Hills Road, Cambridge, UK.
The hydrophilic hypoxic cell radiosensitiser SR2508
causes peripheral neuropathy at total doses of
>30gm 2. The basic analogue, Ro03-8799, pro-
duces a transient syndrome of sweating, dizziness
and affective changes, but no other toxicity. By
combining tolerable doses of each, it may be
possible to increase efficacy without increasing
toxicity. In an escalating single-dose study, the
drugs were infused together i.v. in 50ml saline over
10min, beginning at 0.5gm 2 of each agent, and
proceeding to 0.75 gm-2 RoO3-8799 with 0.5, 1.0,
1.5, 2.0 and 3gm-2 SR2508. Two patients were
treated at each dose level. Four patients experienced
the known Ro03-8799 associated syndrome, but
the severity did not vary with increasing dose of
SR2508, and no other toxicity was seen. Plasma
and urine pharmacokinetic studies showed that no
drug interaction occurred. Mean tBfl values were
5.15h and 5.36h for RoO3-8799 and SR2508
respectively. Subsequently, a 9 dose regimen over a
3 week period has been given to 8 patients, using
0.75gm 2 Ro03-8799 with escalating doses of
0.5, 1.0, 1.5 and 2.0gm-2 SR2508. All patients
exhibited mild to moderate toxicity from Ro 03-8799.
No other toxicity was seen. Plasma pharmaco-
kinetics showed no change between 1st and 9th
infusions. Biopsies of accessible tumours following
radiosensitiser administration were taken from I I
patients. Mean tumour concentrations showed over
the 30min following infusion were 30 and 72pgg-
for Ro03-8799 and SR2508 respectively. The
predicted single-dose sensitiser enhancement ratio
would be 1.5-1.6, representing a useful gain over
either agent used alone. Escalation of dose and
number ofdoses is now in progress.198 PROCEEDINGS OF BACR 27TH AGM
Bleomycin pulmonary toxicity
P. Goddard1, S. Goodman2 & J. Bell1
1Department ofRadiodiagnosis, Bristol Royal
Infirmary and 2Bristol Radiotherapy Centre, UK.
Twenty men with testicular tumours treated with
bleomycin underwent serial chest radiographs and
computed tomography (CT scans). These were then
analysed to look for changes in the lung due to
bleomycin.
The films were assessed by two radiologists. The
presence or absence of interstitial fibrosis, linear
pulmonary opacities, a sub-pleural line and pleural
opacities was noted.
CT showed changes with a much greater
sensitivity than chest radiographs. It showed inter-
stitial fibrosis in 12, only 3 of whom had plain
radiographic changes. In all but 1 changes were
maximal in the lower lobes. In 7 patients CT
showed a sub-pleural line. The other abnormalities
detected by CT were linear pulmonary opacities in
5 patients, pleural thickening or pleural plaques in
4 and pulmonary metastatic deposits in 2.
The non-metastatic CT changes were similar to
those seen in fibrosing alveolitis, rheumatoid lung
and asbestosis. Rapid progression was seen over a
series of CT scans in some cases.
CT changes occur in some cases before the
patient complains of any respiratory symptoms and
before plain radiographic changes are evident.
Of 4 patients so far scanned with gallium citrate
2 have had uptake in the lungs, indicating an active
inflammatory process.
Diagnostic imaging of post-irradiation changes in the
chest
J. Bell', J.A. Bullimore2, E.R. Davies1, J. Hill2
& P.R. Goddard1
'Department ofRadiodiagnosis, Bristol Royal
Infirmary and 2Bristol RTC, UK.
Chest radiographs and CT scans of 20 patients who
had undergone thoracic irradiation were reviewed.
A further 19 patients undergoing irradiation of the
thorax were studied prospectively with ventilation-
perfusion lung scanning with single photo emission
computed tomography (SPECT), in addition to
plain radiography and CT.
CT was more sensitive than plain radiography at
detecting post-irradiation changes in the lung. In
some cases it is also more specfic, showing areas of
pulmonary opacification to have a straight edge
corre,sponding to the edge of the irradiation field,
when such an edge is invisible on plain radiography
owing to its obliquity. Shrinkage of pulmonary
vessels in areas outside the irradiation field is also
seen.
Ventilation-perfusion scanning shows that defects
occur in long perfusion which may be partially
matched by ventilation defects. Defects occur both
within the irradiation field and outside it. SPECT
imaging of perfusion scans show defects with a
greater sensitivity than planar scans. Defects in the
irradiation field are matched by CT opacification,
those outside the field may be matched by areas of
vessel shrinkage. Perfusion defects outside the
irradiation field appear related to irradiation of the
hilum.
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Changes in mucus glycoprotein histochemistry have
been described in both human and rat colonic
cancer. However, limited biochemical information is
available concerning these carbohydrate changes.
Recently, alterations have been detected during
human colonic malignant transformation using
peanut lectin, reportedly specific for detection of
the 'T'-antigen (galactosyl-fl(I-3)N-acetyl-galactos-
amine), and polyclonal anti-'T' antibodies. Inter-
pretation of binding by these ligands is however
difficult. The use of mono-specific reagents towards
the 'T'-antigen and enzymic analysis ofits formation
and blocking may clarify these anomalies.
We have developed a methodology to evaluate
specific mucus carbohydrate changes during experi-
mental colonic carcinogenesis in rats. This involves
transfer of galactose, N-acetylglucosamine and
sialic acid to specific acceptors containing 'Tn'-
antigen (N-acetylgalactosamine-) or 'T'-antigen.
Total glycosyltransferase activity and the nature of
the products are determined using radioactive
nucleotide sugars and tritiated acceptors respec-
tively. Tritiated products are isolated after alkali
fl-elimination and characterised.
Parallel immunohistological studies using both
lectins (including peanut and Limax Flavus) and
monoclonal antibodies directed against 'Tn' and 'T'
antigens are also carried out.
This novel approach enables us to detect and
locate specific mucus glycoprotein changes during
colonic carcinogenesis and to determine the precise
nature of enzymic modifications. These studies are
continuing in human colonic cancer.